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ABSTRACT 
 
The development of nanoscale drug delivery systems is a rapidly growing field within 
the realm of nanomedicine, as it has the potential to improve therapeutic efficacy and 
minimize side effects of various drugs.  This dissertation focuses on the rational design, 
development and application of well-defined polymeric nanoparticles, capable of high 
loading of both hydrophobic and hydrophilic therapeutic agents, toward the effective 
treatment of lung diseases. 
In the first study, cisplatin was loaded into non-degradable poly(acrylic acid)-b-
polystyrene-based SCKs through the formation of coordination bonds between platinum 
and carboxylate groups in the nanoparticle shell domain.  The effects of crosslinking 
were investigated by comparing drug loading & release, in vitro cytotoxicities, and 
immunotoxicities.  In another study, degradable polyphosphoester-based polymeric 
micelles and SCKs, each derived from non-cytotoxic, amphiphilic block-graft 
terpolymers, were specifically designed and synthesized for anti-cancer drug paclitaxel 
(PTX) delivery toward the treatment of osteosarcoma lung metastases.  PTX could be 
encapsulated into either micelles or SCKs, with overall PTX concentration as high as 4.8 
mg/mL vs. the low solubility for free PTX in water of less than 2.0 µg/mL.  In vivo 
biodistribution indicated that both micelles & SCKs underwent extravasation from the 
lung in a controlled manner, while crosslinking slowed the rate of extravasation 
significantly.  Moreover, hydrophilic silver cations were also attached to the 
nanoparticles via the interaction between silver and alkyne as a potential treatment for 
    iii 
bacterial pulmonary infections.  The well-defined Ag-loaded nanoparticles released 
silver in a controlled and sustained manner over 5 days, and displayed enhanced in vitro 
antibacterial activities against cystic fibrosis-associated pathogens and decreased 
cytotoxicity to human bronchial epithelial cells, in comparison to silver acetate. 
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CHAPTER I  
 INTRODUCTION 
 
1.1 Nanomedicine 
In 1959, American physicist Richard Feynman first introduced the concept of 
nanotechnology in his prescient talk “There’s Plenty of Room at the Bottom”, where he 
talked about the manipulating and controlling things on the atomic and molecular level.1  
Nowadays, nanotechnology is a rapidly growing filed, with numerous applications in 
fields such as medicine, electronics, and materials.  The application of nanotechnology 
in medicine has led to a new field termed nanomedicine, where nanostructured materials 
are used to prevent, diagnose, and treat diseases.2,3  Within the realm of nanomedicine, 
the development of nanoscale drug delivery systems is a rapidly growing field, 
accounting for 76% scientific papers and 59% of the patents during 1984-2004.3  There 
are several advantages of using nanoscopic carriers for therapeutic agents.   
First, nanocarriers can improve drugs’ solubility and chemical stability.  For example, 
the aqueous concentration of paclitaxel (PTX) was increased from < 2 µg/mL to 4 
mg/mL in the micellar formulation Genexol-PM® (approved for breast cancer in South 
Korea in 2007), which was self-assembled from amphiphilic block copolymer 
poly(ethylene glycol)-b-poly(D,L-lactide).4  Additionally, it was found that PTX would 
undergo epimerization and hydrolysis into several species in aqueous solution.5  The 
chemical stability of PTX may be increased by encapsulation in the core of the micelles 
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via hydrophobic interaction, which limits its exposure to water.  These nanocarriers can 
also protect the drug from biodegradation by enzymes or inactivation by biological 
compounds such as protein.6 
Second, nanocarriers can release their payload in a controlled manner.7  Since the 
toxicities of drugs are usually dependent on their maximum plasma concentrations, slow 
and sustained drug release can partially alleviate their side effects.8,9  For example, 
cisplatin-incorporating polymeric micelles (NC-6004) formulation, which slowly 
released 50% cisplatin over 4 days, was shown to reduce the ototoxicity, nephrotoxicity 
and neurotoxicity of cisplatin in vivo.10,11  Further, carefully designed stimuli-sensitive 
nanocarriers could release drugs under environmental triggers, such as pH, temperature, 
enzyme, and light, which can limit premature drug release and thus minimize systemic 
exposure and reduce side effects.12,13 
Third, nanomedicine can improve the biodistribution and pharmacokinetics of drugs.  
Biodistribution and pharmacokinetics of free drugs, which are determined by their 
intrinsic physic-chemical properties, are usually not optimal and have issues such as 
rapid renal clearance, binding to plasma proteins and limited ability to penetrate into 
tumor tissues.12  On the other hand, nanosized drug delivery vehicles, especially those 
that were coated with poly(ethylene glycol) or poly(zwitterions)s, for instance, 
poly(carboxybetaine)s (PCBs), were reported to have decreased the nonspecific protein 
interactions and slower clearance from the bloodstream, which led to longer blood 
circulation time.14-18  Furthermore, drugs incorporated in nanocarriers can preferably 
accumulate in cancer tissues by passive targeting exploiting a mechanism known as the 
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enhanced permeability and retention (EPR) effect, and active targeting via attaching 
targeting ligands to the surface of nanocarriers.19   
The EPR effect was first described by Matsumura and Maeda in 1986 and was one of 
the greatest breakthroughs in targeted therapeutics delivery.20,21  Briefly, cancer tissues 
have higher vascular permeability but comprised lymphatic drainage system compared 
to normal tissues, which allows macromolecules and nanoparticles to enter the tumor’s 
interstitial spaces and remain there.20,22  On the other hand, molecules with low 
molecular weight will return to circulation by diffusion.20,22  Therefore, drugs loaded in 
nanocarriers are expected to selectively accumulate in cancer tissues, resulting in 
improved therapeutic efficacy and minimize side effects. 
In addition to passive targeting by the EPR effect, nanocarriers can also actively target 
the cancer tissues by attaching targeting ligands, such as antibodies, aptamers, peptides 
and some other small molecules, to the surface of nanocarriers.19  The targeting ligands 
can be selectively recognized by the receptors that are overexpressed on the surface of 
cancer cells, and thus facilitate the selective accumulation of nanocarriers in cancer 
tissues and subsequent internalization by cancer cells.23  For example, the 
overexpression of folate receptors is observed in varieties of human cancers.23  The 
folate conjugated liposomes, with doxorubicin loaded, were shown to have 45-fold 
higher cellular uptake of doxorubicin over non-targeted doxorubicin-loaded liposomes in 
KB cells.24  This targeted formulation was also found to be 86-fold higher cytotoxic 
compared to non-targeted formulations.24  The ligand-receptor interaction is much more 
selective and precise than passive targeting; hence, receptor-mediated nanomedicine is 
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expected to greatly enhance drug efficacy and reduce side effects.  However, most of 
actively targeted formulations have failed to demonstrate benefits in clinical testing, 
likely due to their intrinsic complexity and a number of anatomical and physiological 
barriers existing on their way from circulation to cancer cells.12,19,25 
1.2 Polymeric micelles 
Various types of nanoscopic carriers have been developed over the past decades, such 
as antibody drug conjugates (ADCs), polymer drug conjugates, liposomes, polymeric 
micelles, dendrimers, and inorganic nanoparticles.12  There are about 15 nanostructured 
formulations on the market today (two of the approved antibody drug conjugates have 
been withdrawn from market in 2010 and 2014).12  Among them, liposome-based 
formulations are one of the most successful nanocarriers, with 7 formulations currently 
on the market and more than 50 formulations in clinic trials.12  The inner aqueous 
environment of the liposome makes it especially suitable for water-soluble drugs with 
high loading capacity, such as doxorubicin hydrochloride (the active ingredient of 
Doxil®) and vincristine sulfate (the active ingredient of Marqibo®).12,26-28  Hydrophobic 
drugs could also be loaded into the lipid bilayer, but with generally low drug loading due 
to the limited space within the bilayer, for example, the liposome-entrapped paclitaxel 
easy-to-use (LEP-ETU) formulation had a drug content of 3.3% (w/w).29   
Recently, polymeric micelles, constructed via the self-assembly of amphiphilic block 
copolymers, have attracted extensive investigation due to their characteristic core-shell 
morphology, where hydrophobic cores are especially suitable for the incorporation of 
hydrophobic drugs, such as paclitaxel (PTX), camptothecin (CPT), and their derivatives, 
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while the hydrophilic shells provide water solubility and functionality for post-
modification such as crosslinking, dye labeling, PEGylation, and installation of targeting 
ligands.16,30-33  For example, the micellar formulation Genexol-PM®, self-assembled 
from amphiphilic block copolymer poly(ethylene glycol)-b-poly(D,L-lactide), were 
shown to have a drug loading around 20%.4,34  Hydrophilic drugs can also be loaded into 
the shell of micelle by various mechanisms, for example, electrostatic interactions or 
formation of silver acetylides for silver cations loading, and formation of coordination 
bonds for cisplatin loading.35-37  Furthermore, different sizes and morphologies, like 
spheres, cylinders, toroids, vesicles and helices, can be obtained by tuning the chemical 
structures of polymer, and the length & ratio of hydrophilic and hydrophobic building 
blocks.16,38-40  However, micelles cannot maintain their sizes and morphologies below 
the critical micelle concentration (CMC), and will dissociate into single polymer chains.  
Since micelles are dynamic systems, structure reorganization of micellar structure may 
lead to dissociation of their payload even at concentrations above the CMC. 
To overcome micellar dissociation, shell crosslinking is of significant importance to 
enhance structural stability, as well as to mediate stimuli-responsive drug release.16,41  
Shell crosslinked knedel-like nanoparticles (SCKs), were first introduced by Wooley and 
coworkers in 1990s.42  Over the past two decades, the incorporation of crosslinks within 
the shells of polymeric micelles has been shown to improve their structural stability, 
while retaining the tunability of size and shape, and enhancing the ability to perform 
chemical modifications throughout the shell of the nano-sized scaffold or within other 
selective domains.42-49  Besides improved stability in aqueous environments, shell 
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crosslinks serve as an additional physicochemical barrier to protect drugs in the 
hydrophobic core from hydrolysis or enzymatic degradation, as well as to mediate drug 
release.41  Moreover, by incorporating stimuli-responsive crosslinkers, SCKs can have 
accelerated drug release under external triggers, for instance, SCKs with a redox-
responsive disulfide crosslinker were shown to release PTX significantly faster in the 
presence of glutathione (GSH) compared to those without GSH.50  In addition, hollow 
nanocages can be obtained by removal of the core of SCKs, which may have higher 
loading capacity over their parent micelles.51 
Both degradable and non-degradable amphiphilic block copolymers have been used as 
the building units for drug delivery carriers.  Though non-degradable polymers, such as 
polyacrylic acids and polystyrene-based block copolymers, are investigated as potential 
drug delivery carriers due to facile synthesis, easy manipulation, and no complication 
with degradation products, biocompatible and biodegradable polymers have drawn more 
attention as they can be ultimately cleared from biological systems via intrinsically built-
in degradation pathways.16,36,52,53  Nowadays, a variety of biodegradable polymers, such 
as polyesters,15,54,55 polypeptides,56,57 polycarbonates,58-60 polyphosphoesters,61-63, 
polyketals,64 and others,65 could be obtained with relatively narrow polydispersity 
indices, due to significant progress made in polymerization techniques, especially living 
controlled polymerization.52  Among them, polyphosphoesters have been widely used in 
biomedical applications, such as drug delivery,66,67 gene delivery68,69 and tissue 
engineering,70,71 because of their biocompatibility, biodegradability and structural 
similarity to naturally occurring biomacromolecules, such as DNA and RNA.52,69,72-74  
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Since the phosphorous atom is pentavalent, reactive pendant groups, including hydroxyl, 
carboxyl, and alkynyl goups, may be introduced as side-chain functionalities, allowing 
polyphosphoesters to be structurally versatile.52,61,62   
1.3 Lung cancer and pulmonary infections 
Despite current significant advancements in modern medicine, lung cancer and 
pulmonary infections continue to pose great clinical challenges to successful medical 
treatment.  According to World Health Organization, cancer in total caused 8.2 million 
of deaths in the world in 2012, among which the lung cancer caused the most deaths 
comprising 1.6 million.75  On the other hand, lower respiratory infections were reported 
to kill more people worldwide compared to lung cancer, accounting for 3.1 million 
deaths in 2012.  In fact, both lung cancer and lower respiratory infections are among the 
top five leading causes of deaths worldwide in 2012.76  There is a pressing need to 
develop novel effective treatments for lung diseases. 
One of our target lung diseases is osteosarcoma lung metastases.  Osteosarcoma is the 
most common primary cancer of bone in children and adolescents, with a peak incidence 
at the ages of 10-14 years, and a high fatality rate (70% survival at 5 years for non-
metastatic patients, and < 30% for those presenting with metastasis).77,78  Osteosarcoma 
can occur in any bone, with femur as the most common site.4  The majority of 
osteosarcoma patients (80-90%) have microscopic metastasis at the time of diagnosis, 
though only < 20% patients with high-grade osteosarcoma have detectable 
metastasis.79,80  The most common site of metastasis is the lung, followed by other 
bones, with approximately 40% of patients presenting with overt metastasis.79,80  
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Osteosarcoma is often treated by complete surgical excision of the primary tumor, 
followed by chemotherapy, preferably with more than one therapeutics to prevent or 
eliminate micrometastatic disease.81,82  However, once micrometastases grow into 
recurrent, overt disease, tumors are often resistant to conventional chemotherapy, and 
unresectable recurrent disease is uniformly fatal.81,83  More effective treatment of 
osteosarcoma lung metastases is needed to improve cure rates and improve patient 
quality of life. 
Another target disease is pulmonary infections, especially those associated with cystic 
fibrosis (CF).  CF is an inherited disease of the secretory glands, affecting ~70k people 
worldwide, especially those of European descent.84  CF results from defects in a gene 
encoding the cystic fibrosis transmembrane conductance regulator (CFTR).84,85  Many 
organs are affected, including sinuses, lungs, skin, liver, pancreas, intestines, and 
reproductive organs.84  The abnormally thick and sticky mucus in the airways of lungs 
can cause obstructions that lead to severe problems with breathing, and provide an 
environment for bacterial infections to occur.  Indeed, the primary cause of death of 
patients with CF is respiratory failure from pulmonary infections caused by bacteria, 
especially Pseudomonas aeruginosa (PA).84  Pulmonary infections are becoming 
challenging for successful treatment, partly due to widespread antibiotic resistance, 
which enables antibiotic-resistant bacteria, such as Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas 
aeruginosa, and Enterobacter species (ESKAPE), to survive despite treatment with 
existing antibacterial drugs.86-88  The growing number of multi-drug resistant strains has 
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made imperative the development of new antibiotics and novel approaches to deliver 
existing agents.86,89-91 
The lungs have a large surface area for absorption of solutes with high permeability 
and low proteolytic activity, which makes them particularly suitable for direct drug 
delivery to the respiratory tract for lung diseases and systemic diseases as well.92  
Several small molecular drugs, for instance, tobramysin, amikacin and colistin, have 
been delivered to the lungs to treat respiratory diseases, such as asthma or cystic 
fibrosis.92,93  More recently, nanoparticle-based formulations have been explored 
extensively for the added benefit of controlled drug release.92  These formulations are 
most often delivered to the lungs through nebulization into micro-scale droplets with 1-5 
µm aerodynamic diameter.92,94  Larger sized particles mainly deposit in upper airways, 
while very small particles are more likely to remain suspended or be exhaled.92  The 
non-invasive aerosol delivery of drug-loaded nanoparticles has been reported to yield 
high pulmonary drug concentration, reduced systemic toxicity, and reduced dosage 
requirements, compared with parenteral and oral administration.35,95-97  Therefore, we 
intend to exploit the local delivery of high quantities of the therapeutic agents, PTX for 
osteosarcoma lung metastases and silver cations for pulmonary infections, with 
degradable polymer-based nanoparticles being able to overcome key challenges of 
packaging and transport of sufficient drug quantities directly to the site of the diseases, 
as well as extravasation of the delivery vehicle from the lungs and secondary organs. 
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1.4 Scope of the thesis 
This dissertation is focused on the design and development of polymeric 
nanoparticles for the delivery of therapeutics.  Well-defined nanoparticles were prepared 
by self-assembly of amphiphilic block copolymer, especially polyphosphoester-based 
degradable polymers, for targeted delivery of therapeutic agents, including, cisplatin and 
PTX for cancer therapy, and silver-based small molecules & other antibiotics for 
pulmonary infections.  These drugs are either physically entrapped or chemically 
conjugated to the nanocarriers. 
In Chapter II, we have investigated the effects of crosslinking on the incorporation of 
cisplatin into SCKs by forming polymer-metal complexes, where cisplatin was loaded 
into shells of these nanoparticles.  Nanosized particles with unimodal size distribution 
and low polydispersity were formed.  The nanoparticles imparted significant physical 
stability to the incorporated drug and allowed control over its release from the polymeric 
particles.  Crosslinking of polymeric micelles is often considered to be beneficial for 
improved stability against dilution.  Here, with Pt-complexation, Pt provides 
complexation-based crosslinks and additional covalent crosslinks diminish sites for Pt 
complexation, giving lower drug loading and higher in vitro immunotoxicity.  Therefore, 
any covalent crosslinking within future nanoparticle designs should be incorporated into 
an alternate region within the nanoparticle framework, to avoid consuming 
functionalities required for the drug-complexation.  More recently, nanoscopic delivery 
vehicles comprised of degradable polymers have been developed, where cisplatin was 
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loaded into either core or shell of these nanoparticles without additional covalent 
crosslinking (Appendix A). 
Nanomaterials have great potential to offer effective treatment against devastating 
diseases by providing sustained release of high concentrations of therapeutic agents 
locally, especially when the route of administration allows for direct access to the 
diseased tissues.  In Chapter III, biodegradable polyphosphoester-based polymeric 
micelles and SCKs have been designed from amphiphilic block-graft terpolymers, 
poly(2-ethylbutoxy phospholane)-block-poly(2-butynyl phospholane)-graft-
poly(ethylene glycol) (PEBP-b-PBYP-g-PEG), which effectively incorporate high 
concentrations of PTX.  Well-dispersed nanoparticles physically loaded with PTX were 
prepared, exhibiting desirable physiochemical characteristics.  Encapsulation of 10 wt% 
PTX, into either micelles or SCKs, allowed for aqueous suspension of PTX at 
concentrations up to 4.8 mg/mL, as compared to < 2.0 µg/mL for the aqueous solubility 
of the drug alone.  Drug release studies indicated that PTX released from these 
nanostructures was defined through a structure-function relationship, whereby the half-
life of sustained PTX release was doubled through crosslinking of the micellar structure 
to form SCKs.  In vitro, physically-loaded micellar and SCK nanotherapeutics 
demonstrated IC50 values against osteosarcoma cell lines, known to metastasize to the 
lungs (CCH-OS-O and SJSA), similar to the pharmaceutical Taxol® formulation.  
Evaluation of these materials in vivo has provided an understanding of the effects of 
nanoparticle structure-function relationships on intratracheal delivery and related 
biodistribution and pharmacokinetics.  In this study, we have demonstrated the potential 
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of these novel nanotherapeutics towards future sustained release treatments via 
administration directly to the sites of lung metastases of osteosarcoma.  More recently, 
PTX was also chemically conjugated to the polymer side chains.  The drug conjugates 
maintained the ability to physically encapsulate PTX to achieve a >15 mg/mL PTX total 
concentration in water (Appendix B). 
In Chapter IV, polymeric micelles constructed from PEBP-b-PBYP-g-PEG were 
utilized as the drug carrier for silver cations via formation of silver acetylides with 
different coordination geometries, towards the treatment of pulmonary infections 
associated with cystic fibrosis.  The amount of silver loaded into the micelles was 
quantified by inductively coupled plasma-mass spectrometry (ICP-MS) using rhodium 
as an internal standard.  Up to 15% (w/w) loading could be achieved, consuming most of 
the pendant alkyne groups along the backbone.  Raman spectroscopy of Ag-loaded 
micelles revealed that silver was loaded into the nanoparticles mainly by two 
coordination geometries at a molar feed ratio of 1:1 (alkyne : silver acetate).  A 
combination of DLS, TEM and AFM indicated that the nanoscopic polymer assemblies 
were well-defined, having a hydrodynamic diameter of ca. 11 nm, and that they 
underwent significant flattening upon adsorption onto substrates.  The co-localization of 
silver, oxygen and phosphorous, visualized by EDS elemental mapping, further 
confirmed that silver was loaded into the polymeric matrices.  Silver was found to 
release in a sustained and controlled manner over 5 days, with release half-life values of 
28 h in nanopure water and 16 h in 10 mM phosphate buffer containing 10 mM NaCl.  
The superior stability of silver cations when loaded into the micelles has the potential to 
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avoid the inactivation by anions and other biological compounds in the human body.  
Furthermore, these silver-loaded nanoparticles were measured to have higher 
antimicrobial activities against a series of cystic fibrosis pathogens and lower toxicities 
to human bronchial epithelial cells in vitro, as compared to the free drug (silver acetate), 
demonstrating advantageous features of this nanoscopic silver delivery platform.  
Evaluation of these silver-loaded nanoparticles as antimicrobial agents for pulmonary 
infections in vivo, as well as determination of their in vitro and in vivo degradation 
profiles, are currently under investigation.  Combination delivery of silver and other 
antibiotics is also currently under investigation (Appendix C). 
In addition, non-degradable poly(acrylic acid)35,40, polyphosphoesters,61,66,98-101 
polypeptides57,102-104 and polylactides15,105 based nanomaterials were also extensively 
investigated, and related co-authored publication were listed in Appendix D. 
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CHAPTER II 
 SHELL CROSSLINKED KNEDEL-LIKE NANOPARTICLES FOR DELIVERY 
OF CISPLATIN:  EFFECTS OF CROSSLINKING* 
 
2.1 Introduction 
 Cisplatin (cis-dichlorodiammineplatinum(II); CDDP) is one of the most potent 
anti-cancer drugs, and has been widely used for many malignancies, such as 
testicular, ovarian, bladder, and lung cancers.106  However, its clinical use is limited 
due to its severe side effects, including nausea, vomiting, auditory toxicity, 
neurotoxicity and nephrotoxicity.107  In recent years, numerous nanometer-sized drug 
delivery systems, including polymeric micelles, dendrimers, nanogels, liposomes and 
star polymers, have been exploited to minimize the side effects of CDDP and 
improve its antitumor efficacy.108-113  In particular, CDDP-loaded polymeric micelles 
via the formation of polymer-metal complexes have been showing promising 
results.114-118  For example, NC-6004 micellar formation, where CDDP was 
conjugated onto poly(ethylene glycol)-b-poly(glutamic acid) diblock copolymers via 
coordination bonds, reached a remarkable 39% (w/w) loading, and demonstrated 
significantly lower toxicity and superior anti-tumor activity than CDDP.11,109  
                                                 
* Reprinted (adapted) with permission from “Shell crosslinked knedel-like nanoparticles for 
delivery of cisplatin:  Effects of crosslinking” by Zhang, F.; Elsabahy, M.; Zhang, S.; Lin, L. Y.; 
Zou, J.; Wooley, K. L., Nanoscale, 2013, 5, 3220-3225.  
http://pubs.rsc.org/en/content/articlehtml/2013/nr/c3nr34320k.  Copyright 2013 The Royal 
Society of Chemistry (RSC). 
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Polymeric micelles, constructed via the self assembly of amphiphilic block 
copolymers, have long been investigated for drug delivery applications due to their 
distinctive core-shell morphology, where the hydrophobic cores serve as reservoirs for 
drugs while the hydrophilic shells provide water solubility.31,119  Over the past sixteen 
years, the incorporation of crosslinks within the shells of polymeric micelles, to afford 
shell crosslinked knedel-like nanoparticles (SCKs), has been shown to provide enhanced 
structural stability, while retaining tunability of size and shape, and enhancing the ability 
to perform chemical modifications throughout the shell of the nano-sized scaffold or 
within other selective domains.42-49  Recently, we have demonstrated that SCKs could 
load relatively large payloads of doxorubicin (DOX) and paclitaxel (PTX) 
chemotherapeutic agents, mainly into their hydrophobic cores.45,120  Herein, we explore 
the potential of SCKs as the delivery carriers for CDDP.  Towards this aim, we 
synthesized the amphiphilic block copolymer poly(acrylic acid)-b-polystyrene (PAA-b-
PS), which was then self assembled into polymeric micelles and subsequently 
transformed into SCKs by crosslinking the shell domain of the micelles via amidation 
chemistry.  These micelles and SCKs contained carboxyl groups in the shell region of 
the nanostructures, which provided sites for complexation with CDDP.114  The effects of 
crosslinking were studied by comparing the release kinetics of these CDDP-loaded 
micellar vs. SCK nanoparticles in PBS, in addition to their stabilities in aqueous milieu, 
in vitro cytotoxicities in OVCAR-3 ovarian cancer cells and RAW 264.7 mouse 
macrophages, and in vitro immunotoxicities in RAW 264.7 mouse macrophages. 
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2.2 Materials and methods 
2.2.1. Materials   
 Cisplatin was purchased from Strem Chemicals, Inc. (Newburyport, MA).  All 
other chemicals were purchased from Aldrich Chemical Co. (St. Louis, MO) and 
used without further purification unless otherwise noted.  Slide-A-Lyzer dialysis 
cassettes (10 kDa molecular weight cut-off, MWCO) were purchased from Pierce 
Biotech. (Rockford, IL).  The Spectra/Por Dialysis Membranes (MWCO 6-8 kDa) 
were purchased from Spectrum Laboratories, Inc (Rancho Dominguez, CA).  
Nanopure water (18 MΩ•cm) was acquired by means of a Milli-Q water filtration 
system, Millipore Corp. (Bedford, MA).   
2.2.2 Instrumentation 
1H NMR and 13C NMR spectra were recorded on Inova 300 or Mercury 300 
spectrometer interfaced to a UNIX computer using VnmrJ software.  Chemical shifts 
were referenced to the solvent residual signals. 
FTIR spectra were recorded on an IR Prestige 21 system using a diamond ATR lens 
(Shimadzu Corp., Japan) and analyzed using IRsolution v. 1.40 software. 
Gel permeation chromatography (GPC) was performed on a Waters Chromatography, 
Inc., 1515 isocratic HPLC pump equipped with an inline degasser, a model 2414 
differential refractometer (Waters, Inc.), and four PLgel polystyrene-co-divinylbenzene 
gel columns (Polymer Laboratories, Inc.) connected in series: 5 μm Guard (50×7.5 mm), 
5 μm Mixed C (300×7.5 mm), 5 μm 104 (300×7.5 mm), and 5 μm 500 Å (300×7.5 mm).  
The instrument was operated at 40 °C with tetrahydrofuran (THF) as eluent (flow rate 
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set to 1.0 mL/min).  Polymer solutions were prepared at a known concentration (ca. 3 
mg/mL) and an injection volume of 200 μL was used.  Data collection and analysis was 
performed with the Breeze (version 3.30, Waters, Inc.) software.  The system was 
calibrated with polystyrene standards (Polymer Laboratories, Amherst, MA). 
Dynamic light scattering (DLS) measurements were conducted using Delsa Nano C 
(Beckman Coulter, Inc., Fullerton, CA) equipped with a laser diode operating at 658 nm.  
Size measurements were made in nanopure water (n = 1.3329, η = 0.890 cP at 25 ± 1 
°C).  Scattered light was detected at 165° angle and analyzed using a log correlator over 
70 accumulations for a 3.0 mL sample in a glass sizing cell (4.0 mL capacity).  The 
photomultiplier aperture and the attenuator were automatically adjusted to obtain a 
photon counting rate of ca. 10 kcps. Calculation of the particle size distribution and 
distribution averages was performed using CONTIN particle size distribution analysis 
routines.  The peak averages of histograms from number distributions out of 70 
accumulations were reported as the average diameters of the particles. 
Glass transition temperatures (Tg) were measured by differential scanning calorimetry 
on a Mettler-Toledo DSC822® (Mettler-Toledo, Inc., Columbus, OH), with a heating 
rate of 10 °C/min.  Measurements were analyzed using Mettler-Toledo Stare v. 7.01 
software.  The Tg was taken as the midpoint of the inflection tangent, upon the third 
heating scan.  Thermogravimetric analysis was performed under N2 atmosphere using a 
Mettler-Toledo model TGA/SDTA851e, with a heating rate of 10 °C /min.  
Measurements were analyzed by using Mettler-Toledo Stare v. 7.01 software. 
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Transmission electron microscopy (TEM) images were collected on a JEOL 1200EX 
operating at 100 kV and micrographs were recorded at calibrated magnifications using a 
SIA-15C CCD camera.  A FEI Tecnai G2 F20 ST operated at 200 kV was also adopted 
to obtain high resolution TEM (HR-TEM) image, as well as the high-angle annular dark 
field imaging in the scanning TEM mode (HAADF-STEM).  The samples as aqueous 
solutions (4 μL) were deposited onto carbon-coated copper grids, which were pre-treated 
by a glow discharge on a PELCO easiGlow™ to increase the surface hydrophilicity.  
Excess sample was wicked off using filter paper and the grids were allowed to dry in air 
overnight.  For samples without platinum loading, a drop of 1% phosphotungstic acid 
(PTA) stain was then added, and allowed to stand for 30 seconds before excess stain was 
wicked away. 
The concentration of platinum was measured by inductively coupled plasma-mass 
spectrometry (ICP-MS) on Perkin Elmer DRCII ICP-MS.  The element/mass detected 
was 195Pt and the internal standard used was 193Hf. 
2.2.3. Experimental procedures 
Preparation of poly(tert-butyl acrylate), PtBA90.  A flame-dried 100-mL Schlenk 
flask equipped with a magnetic stir bar was charged with S-dodecyl-S′-(α,α′-dimethyl-
α″-acetic acid) trithiocarbonate (DDMAT, 0.547 g, 1 eq.), tert-butyl acrylate (t-BA, 57.7 
g, 300 eq.), azobisisobutyronitrile (AIBN, 12.3 mg, 0.05 eq.), and 2-butanone (27 mL).  
The flask was sealed with a rubber septum and allowed to stir for 10 min at room 
temperature to ensure homogeneous mixing.  The reaction mixture was degassed by 
several freeze-pump-thaw cycles (N>3), after which the flask was allowed to return to 
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room temperature and was allowed to stir for an additional 10 min.  The flask was then 
immersed into a pre-heated oil bath at 52 °C to start the polymerization.  The 
polymerization was monitored by analyzing aliquots collected at pre-determined times 
by 1H-NMR spectroscopy.  As the expected monomer conversion was reached, after ca. 
3 h depending on the desired block chain lengths, the polymerization was quenched by 
quick immersion of the reaction flask into liquid N2 and opening to air.  THF (20 mL) 
was added to the reaction flask and the polymer was purified by precipitation into 2 L of 
a methanol/ice (1:1) mixture four times.  The precipitants were collected and dried under 
vacuum overnight to afford the final product as a yellow powder (13.6 g, 31.3% 
conversion, 73% yield).  GPC: Mn = 12400 Da, PDI = 1.11.  IR: 3026–2885, 1720, 1450, 
1365, 1250, 1142, 841, 749 cm-1.  1H NMR (CDCl3, 300 MHz): δ 0.86 (t, J = 6 Hz, 
CH3CH2–), 1.13–1.90 (br, –CHCH2– of the polymer backbone, alkyl chain of initiator, 
and HOOCC(CH3)2–), 1.28–1.58 (br, CH3C), 2.12–2.38 (br, –CHCH2– of the polymer 
backbone), 3.31 (t, J = 2 Hz, –SCSCH2–), 4.62–4.72 (br, –CH2CHS) ppm.  13C NMR 
(CDCl3, 75 MHz): δ 28.2, 34.0–38.5, 41.1–42.9, 80.1–81.0, 173.6–174.6 ppm.  DSC: Tg 
= 47 °C.  TGA in N2: 200–260 °C, 47% mass loss; 260–480 °C, 41% mass loss, 12 % 
mass remaining above 480 °C.   
Preparation of poly(tert-butyl acrylate)-b-polystyrene, PtBA90-b-PS120.  To a 
flame-dried 50 mL Schlenk flask equipped with a magnetic stir bar, PtBA90 (2.48 g, 1 
eq.), styrene (16.6 g, 798 eq. based on desired polymer chains), AIBN (1.6 mg, 0.05 eq.) 
and 1,4-dioxane (4.2 mL) were added.  The flask was sealed with a rubber septum and 
allowed to stir for 10 min.  The reaction mixture was then degassed by several freeze-
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pump-thaw cycles (N>3).  After allowing the flask to return to room temperature, it was 
allowed to stir in a pre-heated oil bath at 60 °C to start the polymerization.  The 
polymerization was monitored by analysis of aliquots taken at various times by 1H-NMR 
spectroscopy.  The polymerization was quenched at ca. 50 h (depending on desired 
block chain lengths) by immersing the flask in liquid nitrogen and opening to air.  The 
product was purified by precipitation into methanol/water (5:1) mixture three times and 
dried under vacuum overnight to yield a pale yellow powdery product (4.85 g, 16.7% 
conversion, 92% yield).  GPC: Mn = 25300 Da, PDI = 1.13.  IR: 3109–2792, 1728, 1489, 
1450, 1365, 1250, 1149, 848, 756 cm−1.  1H NMR (CD2Cl2, 300 MHz): δ 0.89 (t, J = 6 
Hz, CH3CH2–), 1.15–2.13 (br, –CHCH2– of the polymer backbone, alkyl chain of 
initiator, and HOOCC(CH3)2-), 1.12–1.64 (br, CH3C), 2.12–2.36 (br, C5H5CHCH2– of 
the polymer backbone), 3.20–3.32 (br, -SCSCH2–), 6.34–7.56 (br, Ar–H) ppm.  13C 
NMR (CD2Cl2, 75 MHz): δ 28.4, 36.1–38.2, 40.6–43.0, 80.9, 125.8–129.4, 145.2-147.0, 
174.4–175.2 ppm.  DSC: (Tg)1 = 48 °C, (Tg)2 = 102 °C.  TGA in N2: 190–270 °C, 16% 
mass loss; 270–470 °C, 54% mass loss, 30 % mass remaining above 470 °C.   
Preparation of poly(acrylic acid)-b-polystyrene, PAA90-b-PS120.  A flame-dried 100 
mL round bottom flask equipped with a magnetic stir bar was charged with PtBA90-b-
PS120 (1.00 g) and dichloromethane (4 mL).  Trifluoroacetic acid (TFA, 47 mL, 162 eq.) 
was added to the stirring solution and the reaction was allowed to stir 24 h at room 
temperature, after which the solvent was removed under vacuum.  The crude product 
was resuspended in 20 mL of THF and transferred to a pre-soaked dialysis tubing 
(MWCO ca. 6–8 kDa), and dialyzed against nanopure water for 3 days.  The solution 
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was then lyophilized to yield a yellowish solid (0.791 g, 95% yield).  IR: 3600–2400, 
1708, 1492, 1451, 1238, 1177, 1067, 1029, 754, 696 cm−1.  1H NMR (DMSO-d6, 300 
MHz): δ 1.02-1.08 (m, CH3CH2–), 1.00–2.02 (br, –CHCH2– of the polymer backbone, 
alkyl chain of initiator, and HOOCC(CH3)2-), 2.09–2.39 (br, C5H5CHCH2– of the 
polymer backbone), 2.71–2.73 (br, –SCSCH2–), 6.29–7.39 (br, Ar–H) ppm.  13C NMR 
(DMSO-d6, 75 MHz): δ 34.2–36.8, 40.1–41.6, 124.7–128.6, 144.8-145.8, 175.5-176.0 
ppm.  DSC: (Tg)1 = 103 °C, (Tg)2 = 145 °C.  TGA in N2: 190–290 °C, 5% mass loss; 
290–490 °C, 69% mass loss 26 % mass remaining above 490 °C.   
Preparation of micelles and shell crosslinked knedel-like (SCK) nanoparticles.  
Micelles:  PAA90-b-PS120 (ca. 25 mg) was dissolved in DMF (25 mL) in a 100 mL round 
bottom flask and allowed to stir for 30 min at room temperature.  To this solution, an 
equal volume of nanopure water was added dropwise via a syringe pump over a period 
of 2 h.  The reaction mixture was allowed to stir overnight at room temperature and 
dialyzed against nanopure water for 2 days in a presoaked dialysis tubing (MWCO ca. 
6–8 kDa) to afford a micelle solution with a final polymer concentration of ca. 0.22 
mg/mL. 
SCKs:  To the micelle solution of PAA-b-PS was added a solution of 
2,2′-(ethylenedioxy)diethylamine (EDDA) in nanopure water (ca. 2 mg/mL, 0.05 or 0.15 
eq., with respect to acid residues, nominal 10% or 30% crosslinking, respectively) 
dropwise, and the solution was allowed to stir for 2 h.  To this solution, 1-[3´-
(dimethylamino)propyl]-3-ethyl-carbodiimide methiodide (EDCI) in nanopure water (ca. 
1 mg/mL, 0.15 or 0.30 eq., with respect to acid residues) was added dropwise over 20 
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min and the resulting mixture was allowed to stir overnight before dialysis against 
nanopure water for 2 days in presoaked dialysis tubing (MWCO ca. 6–8 kDa) to afford 
SCK solutions with a final polymer concentration of ca. 0.22 mg/mL. 
Loading cisplatin into micelles and SCK nanoparticles.  In a typical experiment, to 
a vial containing a magnetic stir bar and micelle or SCK solution (10 mL, polymer 
PAA90-b-PS120 concentration 0.22 mg/mL, acid residues had been neutralized by 
addition of 0.1 M NaOH(aq)), a solution of cisplatin (1.0 mg/mL in water, 0.5 molar ratio 
with respect to the PAA carboxylate residues) was added dropwise.  The solution was 
stirred for three days and then dialyzed against nanopure water at room temperature to 
remove free cisplatin.  Dynamic light scattering (DLS), transmission electron 
microscopy and inductively coupled plasma mass spectrometry (ICP-MS) were used to 
measure the particle dimensions and platinum concentrations, respectively. 
Release studies of cisplatin-loaded micelles and SCK nanoparticles.  In a typical 
procedure, a solution of CDDP-loaded micelles or SCKs (0.9 mL) was transferred into a 
presoaked dialysis cassette (Slide-A-Lyzer, 10 kDa MWCO, Pierce Biotechnology, 
Rockford IL).  The cassette was allowed to stir in a beaker containing PBS (180 mL, 10 
mM phosphate, 137 mM NaCl, pH 7.4 at 37 oC), and samples (2 mL) were collected 
from the dialysate at pre-determined times and analyzed by ICP-MS, with fresh PBS (2 
mL) added back into the beaker. 
In vitro cytotoxicity assays.  OVCAR-3 (5x103 cells/well) or RAW 264.7 (2x104 
cells/well) cells were plated in a 96-well plate in RPMI media and Dulbecco's Modified 
Eagle Medium (DMEM) (20% and 10% fetal bovine serum, for the OVCAR-3 and 
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RAW 264.7, respectively, and 1% penicillin/streptomycin).  Cells were incubated at 37 
C in a humidified atmosphere containing 5% CO2 for 24 h to adhere.  Then, the 
medium was replaced with a fresh media 1 h prior to the addition of the various 
formulations at concentrations that ranged from 7x10-4 to 150 M of cisplatin.  For each 
well, 20 L of the formulations was added to 100 L of the medium.  The cells were 
incubated with the formulations for 72 h and washed once with PBS and 100 μL of the 
complete media was added to the cells.  MTS combined reagent (20 μL) was added to 
each well (Cell Titer 96® Aqueous Non-Radioactive Cell Proliferation Assay, Promega 
Co., Madison, WI).  The cells were incubated with the reagent for 2 h at 37 C in a 
humidified atmosphere containing 5% CO2 protected from light.  Absorbance was 
measured at 490 nm using SpectraMax M5 (Molecular Devices Co., Sunnyvale, CA).  
The cell viability was calculated based on the relative absorbance to the control 
untreated cells.  The IC50 values were calculated using GraphPad Prism four-parameter 
fit, considering the 0% and 100% viabilities are for media control (no cells) and cells 
with no treatment, respectively.   
Multiplex assay.  RAW 264.7 (2x104 cells/well) cells were plated in a 96-well plate in 
DMEM, as described in the previous section.  Cells were incubated at 37 C in a 
humidified atmosphere containing 5% CO2 for 24 h to adhere.  Then, the medium was 
replaced with a fresh media 1 h prior to the treatment with medium (control), micelles 
and SCKs of varying degrees of crosslinking (10 and 30%) at concentrations of 32 
µg/mL.  The supernatants were then collected and centrifuged for 10 min at 13,000 rpm.  
Serial dilutions of standards of cytokines were also prepared in the same diluent utilized 
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for the samples (i.e. cell-culture medium).  Control, standards and nanoparticle-treated 
samples (50 µL) were incubated with antibody-conjugated magnetic beads for 30 min in 
the dark.  After washing, the detection antibody was added to the wells and incubated in 
the dark for 30 min under continuous shaking (300 rpm).  After washing, streptavidin-
phycoerythrin was added to every well and incubated while protected from light for 10 
min under the same shaking conditions.  Finally, after several washings and re-
suspension in the assay buffer and shaking, the expression of the mouse cytokines, 
interleukin (IL)-1, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (P40), IL-12 
(P70), IL-13, IL-17, Eotaxin, granulocyte-colony-stimulating factor (G-CSF), 
granulocyte macrophage-colony-stimulating factor (GM-CSF), interferon- (IFN-), 
keratinocyte-derived chemokine (KC), monocyte chemotactic protein (MCP)-1, 
macrophage inflammatory protein (MIP)-1, MIP-1β, regulated upon activation normal 
T-cell expressed and presumably secreted (RANTES) and tumor necrosis factor-α (TNF-
α) was measured immediately using Bio-plex 200 system with HTF and Pro II Wash 
station and the data were analyzed using the Bio-plex Data Pro software (Bio-Rad 
Laboratories, Inc., Hercules, CA).. 
2.3 Results and discussions 
The amphiphilic block copolymer poly(acrylic acid)-b-polystyrene (PAA90-b-PS120) 
was synthesized according to the previously reported method (Figure 2.1a).45  Reversible 
addition−fragmentation chain transfer (RAFT) polymerization, a well-studied controlled 
radical polymerization technique that can be used to generate complex polymer 
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structures, was employed to prepare the amphiphilic block copolymer precursor.121  
Briefly, poly(tert-butyl acrylate)90 (PtBA90) was synthesized by polymerization of tert-
butyl acrylate (t-BA), using S-1-dodecyl-S′-(α,α′-dimethyl-α″-acetic acid) 
trithiocarbonate (DDMAT) as the chain transfer agent and azobisisobutyronitrile (AIBN) 
as the initiator.  Chain extension with styrene from the macrotransfer agent PtBA90 was 
conducted to afford the diblock copolymer poly(tert-butyl acrylate)-b-polystyrene 
(PtBA90-b-PS120).  Gel permeation chromatographic (GPC) analysis showed that both 
PtBA90 and PtBA90-b-PS120 exhibited mono-modal molecular weight distributions with 
low polydispersity indices (1.11 and 1.13, respectively, Figure 2.1b).  The decreased 
retention time of PtBA90-b-PS120, relative to PtBA90, demonstrated the increase of 
apparent molecular weight.  The degrees of polymerization of these polymers were 
finally confirmed by 1H NMR spectroscopy, which were in agreement with the GPC  
 
 
Figure 2.1.  (a) Synthesis of PAA-b-PS copolymer via sequential RAFT polymerizations of tert-
butyl acrylate and styrene, followed by the removal of the tert-butyl protecting groups.  (b) Gel 
permeation chromatography traces of PtBA90 homopolymer (solid line) and PtBA90-b-PS120 
diblock copolymer (dashed line). 
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analysis.  The removal of tert-butyl protecting groups of the PtBA90-b-PS120 by using 
trifluoroacetic acid generated the final polymer PAA90-b-PS120. 
The SCKs were prepared by supramolecular assembly of PAA90-b-PS120 into micelles, 
followed by amidation-based shell crosslinking (Figure 2.2).  N,N-dimethylformamide 
(DMF) is a good solvent for both the PAA and the PS blocks, and was chosen to 
dissolve the diblock polymer.  Subsequent addition of water directed the hydrophobic PS 
segments to aggregate and form the core domains of the micelles, while the hydrophilic 
PAA blocks formed the shell domains.  The SCKs were then constructed by crosslinking  
 
 
Figure 2.2.  Preparation of SCKs via self assembly of amphiphilic block copolymer 
PAA90-b-PS120 followed by crosslinking.  Cisplatin incorporation into each of the 
micelles and SCKs was conducted via polymer-metal complex formation. 
 
the shell region of these micelles with 2,2′-(ethylenedioxy)diethylamine (EDDA) in the 
presence of 1-[3´-(dimethylamino) propyl]-3-ethyl-carbodiimide methiodide (EDCI).  
SCKs having nominally 10 and 30% crosslinking were prepared by employing 5 and 15 
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mol% of the diamine, respectively, relative to the acrylic acid residues of the PAA chain 
segments. 
Loading of the micelles and SCKs with CDDP was then performed to investigate the 
influence of shell crosslinking on the loading capacities and release kinetics.  The 
coordination bonds between chloride ligands and platinum are usually labile and subject 
to ligand substitution reactions, therefore, in this study, the carboxylic acid residues from 
the PAA regions of the micelles and SCKs were first deprotonated by reacting with 
equal molar amounts of sodium hydroxide to expedite the substitution process.114  CDDP 
in water was then added to the aqueous solutions of micelles or SCKS, which allowed 
for the CDDP chloride ligands to undergo displacement by carboxylate groups in the 
nanoparticle shell domains and also with water, to coordinate Pt within the micelle and 
SCK shells while also generating various aqua derivatives in the aqueous 
environment.115  Since CDDP has two available sites for substitutions, it may crosslink 
two polymer chains or form an intramolecular loop (Figure 2.2).  After removal of 
excess CDDP by dialysis, the loaded amount of CDDP was determined by inductively-
coupled plasma mass spectrometry (ICP-MS) (Table 2.1).  For micelles, the loading was 
as high as 48% (w/w, relative to the mass of PAA90-b-PS120 block copolymer 
precursors), while a lower loading was found with SCKs.  Moreover, the loading 
decreased with increasing the degree of crosslinking, for example, SCKs with 10% 
crosslinking (SCKs-10) had a 32% (w/w) loading, which was higher than that of SCKs 
with 30% crosslinking (SCK-30, 26% loading, w/w), but lower than that of micelles.  
This trend can be explained by the decrease in the concentration of carboxylate binding 
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sites available for ligand substitution, caused by their consumption during crosslinking; 
the higher the crosslinking degree, the fewer carboxylate groups remaining for ligand 
substitution. 
 
Table 2.1.  CDDP loading into micelles and SCKs. 
Nanoparticles 
Degree of 
crosslinking 
CDDP conc. 
(mg/mL) 
Polymer 
conc.(mg/mL) 
CDDP 
loading 
(wt %) 
Micelles 0 0.11 0.23 48 
SCKs-10 10 0.070 0.22 32 
SCKs-30 30 0.055 0.21 26 
 
 The sizes and size distributions of these micelles and SCKs were characterized by 
dynamic light scattering (DLS) and transmission electron microscopy (TEM).  As 
indicated by DLS histograms, all particles showed mono-modal and narrow 
hydrodynamic diameter distributions (Figure 2.3).  The number-averaged 
hydrodynamic diameters of micelles, SCKs-10, SCKs-30, micelles-CDDP, SCKs-10-
CDDP and SCKs-30-CDDP were 27 ± 8 nm, 23 ± 7 nm, 24 ± 7 nm, 17 ± 5 nm, 18 ± 
5 nm, and 23 ± 6 nm, respectively.  Bright-field TEM images of these nanoparticles 
were uniform with diameters of approximately 20 nm (Figure 2.4).  Since CDDP was 
introduced to these nanoparticles by ligand exchange with carboxylate groups, 
platinum predominantly bonded to the shell regions, which was clearly observed in 
the TEM analysis.  In the images of Figure 2.3d, 3e, 3f and especially the image with 
the high-magnification 2.3g, the peripheral regions of these nanoparticles were 
darker than their cores, indicating higher concentrations of platinum in the shell 
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regions, since no staining solutions were used in the TEM sample preparation.  In 
addition, some elemental platinum was observed as <2 nm nanoparticles surrounding 
the micelles or SCKs, which was measured to have metallic Pt lattice spacing dPt(111) 
= 2.3 Å (Figure 2.4g), indicating some Pt(II) had been reduced in the polymeric 
nanoparticle matrices.122-124  Figure 2h is an image obtained in the high-angle annular 
dark field imaging in the scanning TEM mode (HAADF-STEM), where bright round 
rings were observed, serving as further evidence of shell loading of cisplatin.  
 
 
Figure 2.3.  Characterization of nanoparticles by DLS.  DLS histograms of intensity-
averaged (Dh(intensity)), volume-averaged (Dh(volume)), number-averaged 
hydrodynamic diameters (Dh(number)): (a) micelles, (b) SCKs-10, (c) SCKs-30, (d) 
CDDP-loaded micelles, (e) CDDP-loaded SCKs-10, and (f) CDDP-loaded SCKs-30, 
each in nanopure water. 
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Figure 2.4.  Transmission electron microscopy (TEM) images of (a) micelles, Dav =19 ± 
3 nm, (b) SCKs-10, Dav =20 ± 3 nm, (c) SCKs-30, Dav =20 ± 3 nm, (d) CDDP-loaded 
micelles, Dav =19 ± 3 nm, (e) CDDP-loaded SCK-10, Dav =19 ± 2 nm, (f) CDDP-loaded 
SCKs-30, Dav =17 ± 3 nm, and (g) CDDP-loaded SCKs-10 (high magnification).  (h) 
Scanning TEM image of CDDP-loaded SCKs.  Samples a, b, c were stained by 
phosphotungstic acid, and the remaining samples were not stained.  The average 
diameters were calculated after measuring more than 100 particles. 
 
 Release of platinum from micelles and SCKs was evaluated by monitoring the 
increase of platinum concentration in PBS at pH 7.4, after escaping from dialysis 
cassettes (Figure 2.5).  The high concentration of chloride anions in PBS is necessary for 
the effective release of platinum, whereby carboxylate ligands are substituted by 
chloride anions via ligand exchange reactions.109,117  Regardless of crosslinking degrees, 
all CDDP-loaded nanoparticles released the platinum in a sustained and slow manner 
over 5 days.  Previously, we had observed that shell crosslinks inhibited drug transport 
through the shell, giving slower release of doxorubicin from PAA-b-PS based SCKs 
compared to the corresponding micelle precursors.41,45  Interestingly, there was no 
noteworthy difference in CDDP release kinetics among micelles and SCKs, probably 
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because CDDP was incorporated in the shell and served as additional crosslinkers within 
either type of nanoparticles.  As a control experiment, the release of free CDDP from the 
dialysis cassette, for solutions with similar Pt concentration as the nanoparticle loaded 
systems, was found to be complete within 2 h. 
 
 
Figure 2.5.  Release of CDDP that was either free or loaded into micelles and SCKs 
(PBS, pH 7.4, 37 ºC), measured by ICP-MS of aliquots collected from the dialysate over 
five days. 
 
 The apparent stability of free CDDP and CDDP-loaded micelles and SCKs was 
qualitatively determined by incubating the aqueous solutions at room temperature while 
being stirred in the dark.  After 5 days, there were many black precipitates on the stir bar 
in the sample for which free CDDP was dissolved in nanopure water (Figure 4c), while 
almost none were observed in the CDDP-loaded micelle (Figure 4a) and SCK samples 
(Figure 4b).  When CDDP was dissolved in water, it converted into various aqua 
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derivatives, among which hydroxide-bridged diplatinum complexes could be responsible 
for formation of the irreversible black precipitates.115,125  On the other hand, the CDDP-
loaded polymer-metal complexes were stable in nanopure water, and only minor 
amounts of platinum species were released and underwent decomposition. 
 
 
Figure 2.6.  Apparent physical stability of the CDDP-loaded (a) micelles (0.11 mg/mL) 
and (b) SCKs-10 (0.07 mg/mL), as compared to (c) the free CDDP (0.10 mg/mL).  All 
samples were incubated at room temperature and protected from light for 5 days.  All 
concentrations correspond to the cisplatin concentrations in solutions in nanopure water. 
 
 The cytotoxicities of CDDP and CDDP-loaded nanoparticles were determined in 
vitro by using OVCAR-3 ovarian cancer cells and RAW 264.7 mouse macrophages 
(Table 2.2).  Both the CDDP-loaded micelles and SCKs showed higher IC50 values 
than that measured for free CDDP against both cell lines, which was consistent with 
results of other reported CDDP-loaded polymeric micelle systems.11,115,118  The 
obvious reason is the slow release of platinum.  As shown in Figure 2.5, only ca. 
20% of platinum was released after 72 h, in other words, the actual available 
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platinum was far less than the amount available with the free CDDP solution.  Worth 
noting, the CDDP-loaded SCKs-10 showed higher cytotoxicity compared to micelles, 
which may result from the possible higher cellular uptake induced by crosslinking. 117  
However, the advantage of crosslinking in this case should be treated cautiously, 
since the crosslinking also decreased the loading capacity of the nanoparticles, for 
instance, the SCKs-10 only had ca. 60% loading capacity, in comparison to the 
micelles.  In addition, the RAW 264.7 mouse macrophages seemed to be more 
sensitive to platinum-based formulations than were the OVCAR-3 cancer cells.  The 
polymers themselves did not induce any toxicity on both cell lines at the tested 
concentrations. 
 
Table 2.2.  IC50 values for free CDDP vs. CDDP-loaded micelles and SCK 
nanoparticles, measured against two cell lines. 
Formulation 
IC50 (µM) 
OVCAR-3 RAW 264.7 
CDDP 0 0.11 
Micelles 10 0.070 
SCKs-10 30 0.055 
 
 The immunotoxicities of nanoparticles were evaluated by a multiplex assay, as 
described previously.126  Briefly, the expression levels of 23 cytokines were measured 
upon treatment of RAW 264.7 mouse macrophages for 24 h with the micelles and SCKs 
of 10% and 30% crosslinking at concentrations of 32 µg/mL.  The CDDP-loaded 
nanoparticles also were tested but at non-cytotoxic concentrations (0.6 µM CDDP and 
0.08 µg/mL of nanoparticles).  As expected, the nanoparticles, either free or loaded with  
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Figure 2.7.  Heat map of the relative expression of the following mouse cytokines, 
interleukin (IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (P40), IL-12 
(P70), IL-13, IL-17, Eotaxin, granulocyte-colony-stimulating factor (G-CSF), 
granulocyte macrophage-colony-stimulating factor (GM-CSF), interferon-γ (IFN-γ), 
keratinocyte-derived chemokine (KC), monocyte chemotactic protein (MCP)-1, 
macrophage inflammatory protein (MIP)-1α, MIP-1β, RANTES (regulated upon 
activation normal T-cell expressed and presumably secreted) and tumor necrosis factor-α 
(TNF-α), following the treatment of RAW 264.7 cells with medium (control), micelles 
and SCKs of varying degrees of crosslinking (10 and 30%) at 32 µg/mL. 
 
CDDP, were not immunotoxic at these low concentrations.  The micelles and SCKs led 
to higher secretion of cytokines at 32 µg/mL.  The expression of the following mouse 
cytokines, GM-CSF, IL-3, IL-10, IL-12 (P40), IL-12 (P70), IL-13, IL-1α, IL-1β, KC, 
MCP-1, MIP-1β and RANTES were significantly higher for cells treated with micelles 
and SCKs, as compared to the control-untreated cells.  Consistently, there was an 
enhancement in the secretion of cytokines upon increasing the degree of crosslinking 
(Figure 2.7 and 2.8).  The SCKs with 30% crosslinking induced higher release of IL-10 
(p = 0.001), IL-12 (P70) (p = 0.007), IL-13 (p = 0.008), IL-1α (p = 0.02) and IL-3 (p = 
0.04) than the non-crosslinked micelles.  The latter induced higher secretion than the 
SCKs for only one cytokine (RANTES, p = 0.007).  The higher immunotoxicity of the 
crosslinked nanoparticles may be, in part, due to the amine residues from incomplete 
crosslinking via the amidation chemistry.126,127   
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Figure 2.8.  The expression of the mouse cytokines, GM-CSF, IL-3, IL-10, IL-12 (P40), 
IL-12 (P70), IL-13, IL-1α, IL-1β, KC, MCP-1, MIP-1β and RANTES following the 
treatment of RAW 264.7 cells with media (control), micelles and SCKs of varying 
degrees of crosslinking (10 and 30%) at 32 µg/mL.   
 
2.4 Conclusions 
 In this study, we have demonstrated the feasibility of incorporation of CDDP into 
the shells of micelles and SCKs by forming polymer-metal complexes with ultra-high 
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loading, which was decreased upon increasing the degree of crosslinking.  Nanosized 
particles with unimodal size distribution and low polydispersity were formed.  The 
nanoparticles imparted significant physical stability to the incorporated drug and 
allowed control over its release from the polymeric particles.  Since the toxicities of 
CDDP are related to the maximum plasma concentration of free drug, the slow and 
sustained release of CDDP can possibly reduce its systemic toxicity.112  These 
CDDP-loaded nanoparticles exhibited cell killing abilities in vitro that are 
comparable with reported micellar formulations.  Crosslinking of polymer micelles 
are often considered to be beneficial for improved stability against dilution.  Here, 
with Pt-complexation, Pt provides complexation-based crosslinks and additional 
covalent crosslinks diminish sites for Pt complexation, giving lower wt% loading of 
drug.  Although cytotoxicity increased with covalent crosslinking, the lower drug 
loading counterbalances the overall effect.  In addition, upon incubating the micellar 
and crosslinked nanoparticles with the mouse macrophages, the crosslinked 
nanoparticles resulted in higher in vitro immunotoxicity.  Therefore, any covalent 
crosslinking within future nanoparticle designs should be incorporated into an 
alternate region within the nanoparticle framework, to avoid consuming 
functionalities required for the drug-complexation.  
 Though CDDP-loaded micelles and SCKs showed decreased cytotoxicity in vitro 
mainly due to the slow release kinetics, they may provide superior efficacy than free 
CDDP in vivo by enhancing the accumulation of the drug in tumor tissues via the 
enhanced permeability and retention effect.20  In addition, the nanostructures allow 
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an opportunity for active targeting by decorating their surfaces with active targeting 
ligands, such as folic acid or an aptamer.128-130  Also, it is expected that CDDP-
loaded nanoparticles prepared in this study may show reduced side effects  including 
nephrotoxicity, neurotoxicity, and ototoxicity, as compared to the free drug.10,11  In 
addition, in this work, the CDDP was loaded in the shell, and thus the core of the 
nanoparticles remains available for incorporation of other hydrophobic drugs, which 
could be utilized for combinational therapy.  For instance, our previous results have 
demonstrated that DOX and PTX can be loaded at the core-shell interface or into the 
core of SCKs effectively.45,120  Therefore, the co-delivery of drugs that operate by 
different cellular mechanisms within one nanoparticle is possible, which is a 
promising approach for future cancer therapy that has the potential to exert 
synergistic efficacy and reduce side effects.125,131,132 
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CHAPTER III 
 IMPROVING PACLITAXEL DELIVERY:  IN VITRO AND IN VIVO 
CHARACTERI-ZATION OF PEGYLATED POLYPHOSPHOESTER-BASED 
NANOCARRIERS* 
 
3.1 Introduction 
Nanomedicines have great potential to provide effective treatment against devastating 
diseases, by providing sustained release of significant quantities of therapeutic agents 
locally, especially when the route of administration allows for direct access to the 
diseased tissues.  Our interest focuses on the design of polymer-based nanotherapeutics 
towards the treatment of osteosarcoma lung metastases.  Osteosarcoma is the most 
common primary cancer of bone in children and adolescents, with a peak incidence in 
adolescence (age range: <5 to ~40 years), no proven etiology and a high fatality rate 
(70% survival at 5 years for non-metastatic patients, and <30% for those presenting with 
metastasis).77,78  The most common site of metastasis is the lung, followed by other 
bones, with approximately 40% of patients presenting with overt metastasis, and 90% 
estimated to have micrometastatic disease at diagnosis.79,80  Osteosarcoma is treated with 
                                                 
* Reprinted (adapted) with permission from “Improving paclitaxel delivery:  In vitro and in vivo 
characterization of PEGylated polyphosphoester-based nanocarriers” by Zhang, F.; Zhang, S.; 
Pollack, S. F.; Li, R.; Gonzalez, A. M.; Fan, J.; Zou, J.; Leininger, S. E.; Pavía-Sanders, A.; 
Johnson, R.; Nelson, L. D.; Raymond, J. E.; Elsabahy, M.; Hughes, D. M. P.; Lenox, M. W.; 
Gustafson, T. P.; Wooley, K. L., J. Am. Chem. Soc. 2015, 137, 2056-2066.  Copyright 2015 
American Chemical Society. 
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combination chemotherapy (believed essential to eliminate micrometastatic disease) and 
complete surgical excision of the primary tumor (either amputation or limb salvage).81,82  
Once micrometastases grow into recurrent, overt disease, tumors are often resistant to 
conventional chemotherapy, and unresectable recurrent disease is uniformly fatal.81,83   
It has been demonstrated that drugs delivered to the respiratory tract in liposomal 
formulation resulted in high pulmonary drug concentration, reduced systemic toxicity, 
and reduced dosage requirements compared with parenteral and oral administration.95-97  
Standard delivery formulations for paclitaxel (PTX) are generally administered 
intravenously, resulting in rapid elimination of PTX and multiple undesirable side 
effects.133  Further, the poor solubility of this drug, together with the need to dissolve it 
in toxic carriers prior to delivery, limits the ability to deliver maximally effective doses 
to patients.  To improve efficacy while minimizing systemic toxicity and harmful side 
effects, it has been suggested that targeting of PTX to the site of disease via aerosol-
based delivery would be desirable, and may hold great potential.  Unfortunately, the 
unmodified drug’s solubility and overall stability at the high concentrations necessary 
for such administration remains a hurdle to the success of such delivery methods.134  Our 
hypothesis is that local inhalation-based delivery of high quantities of the 
chemotherapeutic agent PTX will be effective in the treatment of lung tumors, with 
degradable polymer-based nanoparticles being able to overcome key challenges of 
packaging and transport of sufficient drug quantities directly to the site of the metastatic 
disease, as well as extravasation of the delivery vehicle from the lungs and secondary 
organs.  Therefore, this study is a first step toward the development of a PTX 
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formulation containing high PTX concentrations within well-defined, degradable 
nanoparticles for the treatment of lung metastasis of osteosarcoma and other cancers that 
occur in the lung. 
PTX, a mitotic inhibitor originally isolated from the bark of the Paciﬁc yew Taxus 
brevifolia, is a potent chemotherapeutic agent for the treatment of a variety of cancers, 
including ovarian, breast and lung cancers.135,136  Due to its poor solubility in aqueous 
solutions, PTX is currently formulated with 1:1 blend of Cremophor EL 
(polyoxyethylated castor oil) and ethanol, under the trademark of Taxol®.137  However, 
the intrinsic toxicity of Cremophor EL has caused serious side effects, such as 
hypersensitivity reactions, nephrotoxicity, neurotoxicity and myelosuppression.135,138-140  
To avoid these side effects, alternative formulations141-143 are under development to 
improve PTX water solubility and biocompatibility, including Cremophor-free, albumin-
bound PTX (Abraxane®, PTX water solubility 5 mg/mL) as a protein-drug 
suspension.141,144-146  By taking advantage of the natural tumor uptake of nanosized 
albumin in the human body, Abraxane® has demonstrated increased antitumor activity 
and reduced toxicity, relative to Taxol®.141,144  Although the packaging of PTX within a 
prevalent natural protein is an attractive strategy, there are questions as to how to 
achieve high drug loading without alteration of the protein while maintaining control 
over protein assembly.141  Alternatively, synthetic nanoparticles have the potential for 
greater control over their compositions, structures and properties, while also allowing for 
selective domains into which the drug molecules can be packaged.16   
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Recently, an increasing number of polymeric nanoscopic platforms, including 
polymeric micelles,142,147 dendrimers,148 nanogels,149 brush polymers,150,151 and 
liposomes,95,96,152 have been developed for the delivery of PTX and other 
chemotherapeutics.153-155  In particular, polymeric micelles have been rigorously 
investigated due to their characteristic core-shell morphology, where hydrophobic cores 
are utilized for incorporation of hydrophobic drugs (herein PTX) while the hydrophilic 
shells provide water solubility and prolonged systemic circulation.16,31,36  For example, 
NK105, is a micellar nanoparticle formulation currently in clinical trials, where PTX is 
incorporated in the core of polymeric micelles constructed from an amphiphilic block 
copolymer comprised of poly(ethylene glycol) (PEG) and polyaspartate segments.142,156  
By utilizing the enhanced permeability and retention (EPR) effect, NK105 demonstrated 
improved efficacy with reduced toxicity.30,156,157  However, dissociation of polymeric 
micelles upon administration in vivo may cause premature release of therapeutics with 
loss in the control of delivery.16,158-160   
To overcome micellar dissociation, shell crosslinking is of significant importance to 
enhance structural stability, as well as to mediate stimuli-responsive drug release.16,41  
We have previously demonstrated that shell crosslinked knedel-like nanoparticles 
(SCKs) display improved structural stability while retaining the tunability of size, shape 
and surface properties.16,161,162  Recently, we have demonstrated that PTX could be 
loaded into the hydrophobic cores of SCKs, increasing the water solubility of PTX while 
maintaining comparable cytotoxicities to free PTX against several cancer cell lines.50  
However, these initial nanotherapeutics suffered from relatively low drug loading 
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percentages and their solubility limits led to fairly low overall PTX concentrations (< 30 
µg/mL), making them undesirable for clinical applications.  To improve upon these 
systems, we aimed to design biocompatible and fully degradable drug delivery carriers 
capable of effective incorporation of PTX at high concentrations in water.  Such systems 
are of high interest due to their increased potential to effectively deliver 
chemotherapeutics and to be cleared from biological systems via intrinsically built-in 
degradation pathways.52   
Polyphosphoesters have been receiving attention due to their biocompatibility, 
biodegradability and structural similarity to naturally-occurring biomacromolecules, 
such as DNA and RNA.52,69,72-74  Since the phosphorous atom is pentavalent, reactive 
pendant groups, including hydroxyl, carboxyl, and alkynyl, may be introduced as side 
chain functionalities, allowing polyphosphoesters to be structurally versatile.52,61,62  
Recently, our lab developed a hydrophobic-functional AB diblock copolymer via rapid 
sequential organocatalyzed ring-opening polymerizations of hydrophobic alkyl- and 
reactive alkynyl-functionalized cyclic phosphotriesters monomers in a stepwise one-pot 
manner.61  By taking advantage of radical-mediated thiol-yne reactions on the clickable 
alkynyl groups of the B block, this diblock copolymer could be transformed into a 
variety of amphiphilic block copolymers and assembled into functional nanoparticles 
tailored for biomedical applications.61  In this study, we made use of this structurally-
versatile platform to develop a drug carrier via copper(I)-catalyzed azide-alkyne 
cycloaddition (CuAAC) for transformation to an amphiphilic labeled polymer, capable 
of supramolecular assembly into PTX-loaded nanoparticles.  Our results demonstrate 
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that these new nanotherapeutic delivery vehicles show potential towards future sustained 
release treatments via administration directly to the site of lung metastasis of 
osteosarcoma, whereby shell crosslinking reduced the rate of drug release and increased 
the lung retention time 
3.2 Materials and methods 
3.2.1. Materials 
Paclitaxel was purchased from Alfa Aesar, Co. (Ward Hill, MA).  2-chloro-2-oxo-
1,3,2-dioxaphospholane (95%) was used as received from Thermo Fisher Scientific Inc 
(Pittsburgh, PA).  Chelex® 100 resin was used as received from Bio-Rad Laboratories 
(Hercules, CA).  Tetrahydrofuran (THF) and dichloromethane (DCM) were dried 
through solvent purification system (J. C. Meyer Solvent Systems, Inc., Laguna Beach, 
CA).  ɑ-Methoxy-ω-azido PEG2k (Mn = 1,950 kDa, Mw/Mn = 1.03) was purchased from 
RAPP POLYMERE (Tuebingen, Germany).  IRDye® 800CW near infrared dye 
(IR800CW) was purchased from LI-COR® Biosciences (Lincoln, NE).  All other 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and used without further 
purification unless otherwise noted.  Slide-A-Lyzer dialysis cassettes (10 kDa molecular 
weight cut-off, MWCO) were purchased from Pierce Biotech. (Rockford, IL).  The 
Spectra/Por dialysis membranes (MWCO 12-14 kDa) were purchased from Spectrum 
Laboratories, Inc. (Rancho Dominguez, CA).  Nanopure water (18 MΩ·cm) was 
acquired by means of a Milli-Q water filtration system, Millipore Corp. (Bedford, MA). 
CCH-OS-O and SJSA cell lines were obtained from the laboratory of Dr. Dennis 
Hughes, The University of Texas MD Anderson Cancer Center, Houston, TX.  RAW 
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264.7 and OVCAR-3 cell lines, as well as RPMI and DMEM media were obtained from 
the American Type Culture Collection (Manassas, VA).  Media additives (fetal bovine 
serum, penicillin/streptomycin) were obtained from Sigma-Aldrich (St. Louis, MO).  
Cell culture 96-well round bottom plates were purchased from Corning Costar Co. 
(Corning, NY).  The CellTiter 96 non-radioactive cell proliferation assay was obtained 
from Promega Co. (Madison, WI).   
3.2.2 Instrumentation 
1H NMR and 13C NMR spectra were recorded on a Varian Inova 300 or Mercury 300 
spectrometer interfaced to a UNIX computer using VnmrJ software.  Chemical shifts 
were referenced to the solvent residual signals.  FTIR spectra were recorded on an IR 
Prestige 21 system using a diamond ATR lens (Shimadzu Corp., Japan) and analyzed 
using IRsolution v. 1.40 software.  The DMF gel permeation chromatography (GPC) 
was conducted on a Waters Chromatography, Inc. (Milford, MA) system equipped with 
an isocratic pump model 1515, a differential refractometer model 2414, and a three-
column set of Styragel HR 4 5 μm DMF (300 × 7.5 mm), Styragel HR 4E 5 μm DMF 
(300 × 7.5 mm), and Styragel HR 2 5 μm DMF (300 × 7.5 mm).  The system was 
equilibrated at 70 °C in pre-filtered DMF containing 0.05 M LiBr, which served as 
polymer solvent and eluent (flow rate set to 1.00 mL/min).  Polymer solutions were 
prepared at a concentration of ca. 3 mg/mL and an injection volume of 200 μL was used.  
Data collection and analysis were performed with Empower 2 v. 6.10.01.00 software 
(Waters, Inc.).  The system was calibrated with polystyrene standards (Polymer 
Laboratories, Amherst, MA) ranging from 615 to 442,800 Da.   
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All steady-state emission, excitation, and anisotropy spectra were obtained with a 
Horiba FluoroMax4 with automatic polarizers.  Steady-state spectra were analyzed in 
FluorEssence (Horiba, Kyoto, Japan) and in Origin 9.0 Pro (Origin Lab, Northampton, 
MA).  Time-correlated single-photon counting (TCSPC) was employed to obtain all 
fluorescence lifetime and fluorescence anisotropy decay spectra. Measurements were 
achieved via a Fluorotime 100 fluorometer with a 640 nm solid-state picoseconds diode 
laser source (PicoQuant, West Springfield, MA) in matched quartz 0.7 mL cells 
(NSGPrecision Cells, Farmingdale, NY).  Instrument response functions (IRF) were 
determined from the scattering signal with a solution of Ludox HS-40 colloidal silica 
(0.01% w/w particles in water).  TCSPC analysis was performed on Fluorofit 
(PicoQuant) software and confirmed by tail-fitting in Origin 9 Pro.  All fluorescence 
confocal microscopy was carried out on a FV1000 confocal microscope with an IX-81 
inverted base (Olympus, Center Valley, PA) and PMT detectors.   
Dynamic light scattering (DLS) measurements were conducted using a Delsa Nano C 
(Beckman Coulter, Fullerton, CA) instrument equipped with a laser diode operating at 
658 nm.  Size measurements were made in nanopure water (n = 1.3329,  = 0.890 cP at 
25 ± 1 °C).  Scattered light was detected at a 165° angle and analyzed using a log 
correlator over 70 accumulations for a 3.0 mL sample in a glass sizing cell (4.0 mL 
capacity).  The photomultiplier aperture and the attenuator were automatically adjusted 
to obtain a photon counting rate of ca. 10 kcps.  Calculations of the particle size 
distribution and distribution averages were performed using CONTIN particle size 
distribution analysis routines.  The peak averages of histograms from number 
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distributions out of 70 accumulations were reported as the average diameters of the 
particles.  The particle zeta-potential values were determined by a Delsa Nano C particle 
analyzer equipped with a 30 mW dual laser diode (658 nm).  The ζ-potential of the 
particles in suspension was obtained by measuring the electrophoretic movement of 
charged particles under an applied electric field.  Scattered light was detected at a 15° 
angle at 25 °C. The zeta-potential was measured at five regions in the flow cell, and a 
weighted mean was calculated.  These five measurements were used to correct for 
electro-osmotic flow that was induced in the cell due to the surface charge of the cell 
wall.  All determinations were repeated five times. 
Glass transition temperatures (Tg) were measured by differential scanning calorimetry 
on a Mettler-Toledo DSC822® (Mettler-Toledo, Inc., Columbus, OH), with a heating 
rate of 10 °C/min.  Measurements were analyzed using Mettler-Toledo Stare v. 7.01 
software.  The Tg was taken as the midpoint of the inflection tangent, upon the third 
heating scan.  Thermogravimetric analysis was performed under N2 atmosphere using a 
Mettler-Toledo model TGA/SDTA851e, with a heating rate of 10 °C/min.  
Measurements were analyzed by using Mettler-Toledo Stare v. 7.01 software. 
Transmission electron microscopy (TEM) images were collected on a JEOL 1200EX 
operating at 100 kV and micrographs were recorded at calibrated magnifications using a 
SIA-15C CCD camera.  The samples as aqueous solutions (4 μL) were deposited onto 
carbon-coated copper grids, and after 1 min, the excess of the solution was quickly 
wicked away by a piece of filter paper.  A drop of 1 wt% uranyl acetate was then added, 
and allowed to stand for 30 seconds before excess stain was wicked away.  The grids 
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were allowed to dry in air overnight.  Cryo-TEM images were taken with an FEI Tecnai 
G2 F20 (FEI, Hillsboro, OR) operated at 200 kV and equipped with cryogenic 
accessories.  Specimens were prepared on CFLAT holey carbon ﬁlm TEM grids which 
were pretreated with glow discharge plasma for 30 s to improve the wetting of the 
hydrophobic grids.  The samples were frozen in liquid ethane using an FEI Vitrobot 
apparatus and submerged in liquid nitrogen, where it was kept until imaging.  
3.2.3. Experimental procedures 
Synthesis of EBP and BYP monomers.  2-(but-3-yn-1-yloxy)-2-oxo-1,3,2-
dioxaphospholane (BYP) and  2-(2-ethylbutoxy)-1,3,2-dioxaphospholane (EBP) were 
synthesized as previously described.61 
Synthesis of PEBP-b-PBYP diblock copolymer.  A solution of EBP (1.5 g, 7.2 
mmol) and benzyl alcohol (15.6 mg, 0.14 mmol) in 2.1 mL anhydrous dichloromethane 
was transferred via syringe into a flame-dried vial equipped with a stir bar and rubber 
septum, under N2, in an water/ice bath.  A solution of 1,5,7-triazabicyclo[4.4.0]dec-5-
ene (TBD) (40.2 mg, 0.29 mmol) in 0.3 mL anhydrous dichloromethane was injected 
quickly into the vial.  After being stirred for 2.5 min, another 2.4 mL of anhydrous 
dichloromethane was injected into the vial to dilute the reaction mixture, and the vial 
was transferred to a cooling bath composed of equal amounts of ice/water and sodium 
chloride at -10 °C.  Less than 0.1 mL of the reaction mixture was withdrawn and diluted 
with CDCl3 to determine the EBP conversion by 
31P NMR.  After being stirred for 
another 3 min, to the reaction mixture was added a solution of BYP (1.27 g, 7.2 mmol) 
in 2.4 mL anhydrous dichloromethane via syringe.  The reaction was quenched by 
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adding an excess amount of acetic acid dissolved in DCM after another 3 min, and an 
aliquot of the mixture was used to determine the conversion of BYP by 31P NMR.  The 
PEBP-b-PBYP was purified by precipitation from acetone into a pentane/diethyl ether 
mixture (3:1 volume ratio) three times and then dried under vacuum.  1H NMR (300 
MHz, CDCl3, ppm):  δ 0.90 (t, J = 7.4 Hz, POCH2CH(CH2CH3)2), 1.37 (m, 
POCH2CH(CH2CH3)2), 1.51 (m, POCH2CH), 2.11 (s, POCH2CH2CCH), 2.61 (m, 
POCH2CH2CCH), 4.00 (m, POCH2CH), 4.12–4.39 (m, POCH2CH2OP, POCH2CH2), 
5.08 (d, J = 8.3 Hz OCH2Ar), 7.31–7.40 (m, Ar-H); 13C NMR (75 MHz, CDCl3, ppm):  
δ 10.99, 20.69, 22.75, 41.55, 65.52-67.11, 70.08, 70.88, 79.59;  31P NMR (121 MHz, 
CDCl3, ppm):  δ -1.25, -1.81.  GPC:  Mn = 18900 g/mol, PDI = 1.24.  DSC:  Tg = - 58 
°C.  TGA in N2:  170–270 °C, 50% mass loss;  270–360 °C, 9.2% mass loss, 360–600 
°C, 11% mass loss, 30 % mass remaining above 600 °C.  IR (cm-1):  3700-3100, 3020-
2820, 1640, 1460, 1380, 1267, 1010, 965, 866, 805. 
Azide-alkyne Huisgen cycloaddition of PEBP-b-PBYP with α-methoxy--azido 
PEG (CH3O-PEG2k-azido).  In a typical experiment, an oven dried vial containing a 
magnetic stir bar was charged with PEBP-b-PBYP (0.89 g, 46 µmol, 1 eq.), α-methoxy-
-azido PEG (0.36 g, 180 µmol, 4 eq.), N,N,N,N,N-pentamethyldiethylenetriamine 
(PMDETA, 13 mg, 74 µmol, 1.6 eq.) and 7 mL of DMF.  The reaction mixture was 
degassed by several freeze-pump-thaw cycles (N>3), during which copper(I) bromide 
(5.3 mg, 37 µmol, 0.8 eq.) was added.  The flask was allowed to return to room 
temperature after the final cycle and stirred for another 3 h under N2.  The solution was 
subsequently filtered through a neutral alumina column and dialyzed against Chelex® 
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100 resin in nanopure water in presoaked dialysis tubing (MWCO ca. 12–14 kDa) for 2 
d to remove copper ions, followed by lyophilization to yield a white powder with a 72 % 
yield.  Inductively coupled plasma-mass spectrometry (ICP-MS) confirmed that ca. 10 
ppm of copper was present in the polymer.  1H NMR (300 Hz, CDCl3, ppm): δ 0.89 (t, J 
= 7.4 Hz, POCH2CH(CH2CH3)2), 1.36 (m, POCH2CH(CH2CH3)2), 1.50 (m, POCH2CH), 
2.05-2.24 (b, POCH2CH2CCH), 2.56-2.65 (b, POCH2CH2CCH), 3.12 (m, NCH2CH2), 
3.37 (s, OCH3), 3.63 (s, OCH2CH2), 4.00 (m, POCH2CH), 4.14-4.39 (m, POCH2CH2, 
POCH2CH2OP), 5.07 (d, J = 8.3 Hz, OCH2Ar), 7.31-7.40 (m, Ar-H), 7.63 (m, 
CH2CH2CCHNCH2).  
13C NMR (75 MHz, CDCl3, ppm):  δ 11.03, 20.72, 22.79, 41.60, 
65.52-67.15, 70.13, 70.68, 70.95, 79.72, 128.06, 128.73.  31P NMR (121 MHz, CDCl3, 
ppm): δ -0.99, -1.64.  GPC: Mn = 21800 g/mol, PDI = 1.24.  DSC:  Tg = - 51 °C; Tm = 46 
°C.  TGA in N2:  140–270 °C, 40% mass loss; 270–360 °C, 35% mass loss, 360–600 °C, 
3% mass loss, 22 % mass remaining above 600 °C.  IR (cm-1): 3700-3100, 3050-2800, 
166, 1465, 1342, 1275, 1109, 1016, 962, 841, 808. 
Determination of critical micelle concentrations (CMCs) for PEBP-b-PBYP-g-
PEG.  The CMC for the terpolymers PEBP-b-PBYP-g-PEG in nanopure water was 
determined by using pyrene as the fluorescent probe.  The sample solutions were 
prepared by adding 75 μL pyrene aqueous stock solution (6.0  10-7 mol/L) and from 
0.25 to 0.001 mg of polymer from an aqueous 1 mg/mL stock solution into a 5 mL vial, 
and the final volumes were adjusted to 1.0 mL by addition of nanopure water.  All the 
sample solutions were then stirred at 4 °C for 24 h to allow for equilibration of pyrene 
into the micelles.  The fluorescence measurements were conducted at room temperature, 
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pyrene was excited at 334 nm and its emission spectrum was recorded from 360 to 460 
nm.  The experiment was repeated three times and the ratios of intensities at 369 and 382 
nm, corresponding to the first and third pyrene vibrational peaks respectively, were 
plotted against the polymer concentrations in the sample solutions.  The CMC was taken 
as the intersection of the tangent to the curve at the inflection with tangent through the 
points at low polymer concentration. The CMC of the amphiphilic terpolymer was 
measured to be 0.018 ± 0.009 mg/mL. 
Preparation of shell crosslinked (SCK) nanoparticles from PEBP-b-PBYP-g-
PEG.  In a typical experiment, 30.0 mg PEBP-b-PBYP-g-PEG was dissolved in 15.0 mL 
methanol in a 100 mL flask and allowed to stir for 30 min at room temperature.  To this 
solution, 15.0 mL nanopure water was added dropwise via a syringe pump over a period 
of 4 min.  The mixture was allowed to stir another 30 min at room temperature and 
bubbled with nitrogen.  To the micelle solution was added a solution of hexa(ethylene 
glycol) dithiol (3.5 mg, 0.2 eq., with respect to alkyne, nominally 20% crosslinking) in 
1:1 methanol/nanopure water mixture, 2,2-dimethoxy-2-phenylacetophenone in 
methanol (DMPA, 2.9 mg, 0.2 eq., with respect to alkyne residues).  The resulting 
mixture was placed under an UV lamp and irradiated at 365 nm for 3 h, dialyzed against 
nanopure water for 2 d in presoaked dialysis tubing (MWCO ca. 12–14 kDa), and then 
lyophilized to yield a yellowish powder with a 87% yield.  Hydrodynamic diameters of 
SCKs in nanopure water as measured by DLS:  Dh(intensity) = 407 ± 475 nm, Dh(volume) = 19 
± 11 nm, Dh(number) = 14 ± 3 nm;  ζ-potential in nanopure water:  - 34 ± 2 mV;  Diameter 
as measured by TEM:  23 ± 3 nm. 
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NIR-labeling of micelles and SCKs.  In a typical experiment, an oven-dried vial 
containing a magnetic stir bar was charged with micelles or SCKs (PEBP-b-PBYP-g-
PEG, 88 mg, 3.2 µmol, 1 eq.), IR800CW (2.1 mg from a 1 mg/mL stock solution in 
DMSO, 1.6 µmol, 0.5 eq.), copper(II) sulfate pentahydrate (0.8 mg, 3.2 µmol, 1 eq.), 
sodium ascorbate (6.4 mg, 32 µmol, 10 eq.) and 9.0 mL nanopure water.  The reaction 
mixture was degassed for 10 min via nitrogen bubbling, wrapped with aluminum foil 
and stirred for another 24 h at 37 °C.  The solution was subsequently passed through a 
Sephadex G-25 desalting column and dialyzed against Chelex® 100 resin in nanopure 
water in presoaked dialysis tubing (MWCO ca. 12–14 kDa) for 2 d, to remove copper 
ions and unreacted IR800CW, followed by lyophilization to yield green powder. 
Dye-labeled micelles:  91% yield with a conjugation efficiency of 64%.  
Hydrodynamic diameters of micelles in nanopure water as measured by DLS:  Dh(intensity) 
= 36 ± 23 nm, Dh(volume) = 16 ± 8 nm, Dh(number) = 11 ± 3 nm;  ζ-potential in nanopure 
water:  - 36 ± 1 mV;  Diameter as measured by TEM:  36 ± 4 nm. 
Dye-labeled SCKs:  90% yield with a conjugation efficiency of 63%.  Hydrodynamic 
diameters of micelles in nanopure water as measured by DLS:  Dh(intensity) = 129 ± 155 
nm, Dh(volume) = 16 ± 10 nm, Dh(number) = 11 ± 3 nm;  ζ-potential in nanopure water:  - 36 
± 1 mV;  Diameter as measured by TEM:  24 ± 4 nm. 
PTX loading into PEBP-b-PBYP-g-PEG micelles and SCKs.  In a typical 
experiment, to a vial containing 4.5 mL of polymer or SCK solution in ethanol (polymer 
or SCK concentration: 4.0 mg/mL), PTX  at 2.0 mg/mL in ethanol, 10 wt% was added.  
The vial was shaken vigorously to mix the solution, and then ethanol was completely 
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removed in vacuo.  Subsequently, the micelles/SCKs with PTX were resuspended in 2.0 
mL of nanopure water.  After sonication for 5 min, a well dispersed nanoparticle 
suspension was obtained.  DLS and TEM were used to characterize these PTX-loaded 
nanoparticles, and HPLC was used to confirm the actual loading amount of PTX.   
PTX-loaded micelles:  hydrodynamic diameters in nanopure water as measured by 
DLS:  Dh(intensity) = 38 ± 20 nm, Dh(volume) = 19 ± 9 nm, Dh(number) = 14 ± 4 nm;  ζ-potential 
in nanopure water:  - 39 ± 4 mV;  Diameter as measured by TEM:  42 ± 5 nm 
PTX-loaded SCKs:  hydrodynamic diameters in nanopure water as measured by DLS:  
Dh(intensity) = 70 ± 43 nm, Dh(volume) = 32 ± 15 nm, Dh(number) = 24 ± 6 nm;  ζ-potential in 
nanopure water:  - 43 ± 2 mV;  Diameter as measured by TEM:  24 ± 4 nm 
PTX-loaded dye-labeled micelles:  hydrodynamic diameters in nanopure water as 
measured by DLS:  Dh(intensity) = 70 ± 55 nm, Dh(volume) = 21 ± 12 nm, Dh(number) = 14 ± 4 
nm;  ζ-potential in nanopure water:  - 45 ± 5 mV;  Diameter as measured by TEM:  38 ± 
4 nm 
PTX-loaded dye-labeled SCKs:  hydrodynamic diameters in nanopure water as 
measured by DLS:  Dh(intensity) = 77 ± 59 nm, Dh(volume) = 23 ± 13 nm, Dh(number) = 16 ± 5 
nm;  ζ-potential in nanopure water:  - 24 ± 3 mV;  Diameter as measured by TEM:  25 ± 
3 nm 
Release of PTX from PTX-loaded micelles and SCKs.  The release profiles of the 
PTX-loaded micelles and SCKs were studied by monitoring the decrease of PTX 
concentration over time in dialysis cassettes by high-performance liquid chromatography 
(HPLC) using a UV detector at 228 nm.  In a typical procedure, PTX-loaded 
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nanoparticles were diluted with phosphate buffered saline (PBS), yielding a 
concentration of 50 μg/mL.  A portion of the PTX-loaded micelles or SCKs solution (3.0 
mL) was transferred into a presoaked dialysis cassette (Slide-A-Lyzer, 10 kDa MWCO, 
Pierce Biotechnology, Rockford IL).  The cassette was allowed to stir in a beaker 
containing 3000 mL PBS (pH 7.4 at 37 °C).  Aliquots (0.1 mL) were taken at pre-
determined times and analyzed by HPLC.  The release was evaluated in triplicate. 
Sample preparation for steady-state anisotropy and fluorescence lifetime.  
(1)IRDye 800CW azide was dissolved in DMSO at a concentration of 1.0 mg/mL and 
diluted with water or PBS to achieve a final concentration of ca. 1.3 µg/mL with an 
absorption of ca. 0.25.  (2)IRDye 800CW labeled micelles or SCKs were dissolved at a 
concentration of 9.8 mg/mL in water and diluted with water or PBS to achieve a final 
concentration of ca. 320 µg/mL with an absorption of ca. 0.25.  (3)Physical mixtures 
were prepared by mixing IRDye 800CW azide and micelle or SCKs at the same ratio as 
dye conjugates and diluted with water or PBS to achieve a final concentration of ca. 320 
µg/mL polymer concentration with an absorption of ca.0.25. 
Cytotoxicity assays.  Human ovarian adenocarcinoma cells (OVCAR-3) (5  103 
cells/well), RAW 264.7 mouse macrophages (2  104 cells/well), CCH-OS-O (5  103 
cells/well) and SJSA (5  103 cells/well) were plated in 96-well plates in RPMI-1640 
medium (OVCAR-3) and Dulbecco's Modified Eagle's Medium (DMEM) (20% fetal 
bovine serum for the OVCAR-3, 10% fetal bovine serum for RAW 264.7, CCH-OS-O 
and SJSA, and 1% penicillin/streptomycin).  Cells were incubated at 37 °C in a 
humidified atmosphere containing 5% CO2.  The medium was replaced with fresh 
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medium 24 h after seeding.  Formulations of PTX-loaded micelles and SCKs dissolved 
in PBS were prepared at concentrations that ranged from 1.0  10-4 to 6.6 M.  For each 
well, 20 L of every formulation was added to 100 L of the medium.  Negative 
controls were created by addition of 20 L of PBS to wells containing cells and 100 L 
of the medium.  The cells were incubated for 72 h, and after this period, the medium was 
replaced with 100 μL of the fresh medium.  Then, 20 μL of the MTS combined reagent 
was added to each well (Cell Titer 96® Aqueous Non-Radioactive Cell Proliferation 
Assay, Promega Co., Madison, WI).  The cells were incubated with the reagent for 3 h at 
37 °C in a humidified atmosphere containing 5% CO2, and protected from light.  
Absorbance was measured at 490 nm using SpectraMax M5 (Molecular Devices Co., 
Sunnyvale, CA).  The cell viability was calculated based on the relative absorbance to 
the control untreated cells. The calculation of the IC50 values and the statistical analysis 
were performed using GraphPad Prism four-parameter fit, the 0% and 100% viabilities 
are for media control (no cells) and cells with no treatment, respectively. 
Preparation of cells for confocal microscopy.  CCH-OS-O cells were trypsinized 
and counted with a hemocytometer.  The cell pellet was dissolved in phosphate buffered 
solution (PBS pH = 7.0) to a final concentration of 2x105 cells/mL.  To a glass bottom 6-
well plate (No.0 Uncoated y-irradiated, MatTek Corporation) 0.5 mL of the cell solution 
was added to each well by placing 0.1 mL spots in a star pattern around the glass surface 
of the well to promote localization of cells.  Dulbecco’s Modfied Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) was added to each well to 
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achieve a final volume of 2.0 mL. Plates were incubated for 24 h in a humidified 
atmosphere with 5% CO2  
Preparation of polymer solutions for cellular uptake.  Lyophilized micelles and 
SCKs physically loaded with PTX were dissolved in PBS (pH = 7.0) to a final 
concentration of 9.8 mg/mL of polymer (33 μM IR800CW dye, 1270 μM PTX).  
IR800CW labeled micelles and SCKs without PTX were prepared under the same 
conditions to a concentration of 9.8 mg/mL of polymer.  
Addition of formulations to measure cellular uptake.  One of the formulations 
described above (micelles or SCKs) was added to each well by removing 500 μL of the 
well’s media, and mixing 400 μL of media with 100 μL of the prepared formulations.  
The resulting mixture was then added back to the well so that the total volume of media 
did not change.  The final concentration of polymer, IR800CW and PTX were ca. 2 
mg/mL, 20 μM and 254 μM respectively.  Formulations were added 2 h prior to 
imaging.  After 1.5 h, Hoechst 33345  was added to each well to stain the nucleus 
(1ug/mL, Life Technologies) and incubated for 15 min. The wells were washed twice 
with Opti-MEM medium (Gibco) and imaged live.  
Confocal microscopy of live CCH-OS-O cells for measuring cellular uptake.  A 
FV1000 confocal microscope with an IX-81 inverted base and PMT detectors was used 
for all confocal microscopy.  For excitation of the Hoechst-33342 nuclear stain, a 405 
nm diode laser was used, and emission was collected from 420-450 nm.  The NIR dye 
IR800CW (conjugated to the nanomaterials) was excited using a 635 nm solid-state 
laser, and emission was collected using a 775 nm long pass filter.  To confirm for the 
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lack of autofluorescence, samples of cells lacking nuclear stain and without polymer 
were imaged as a control.  Preliminary studies of unlabeled polymers also showed lack 
of autofluorescence.  A 20x UPlanSApo lens (na 0.75 infinity corrected) was used for all 
measurements.  The zoom function of the microscope was used to reach a total 
magnification of 60x to 100x for all images.  Each final image was taken at a scan rate of 
40 μs/pixel at 1025 by 1025 pixels.  Images were acquired and contrast was adjusted 
using Fluoview Viewer software V. 3.1.2.2 (Olympus, Center Valley, PA).   
In vivo studies.  All animal studies were conducted in accordance to protocols 
approved by the Texas A&M University Institutional Animal Care and Use Committee. 
In vivo imaging studies were carried out on a Bruker In-Vivo Xtreme multimodal 
preclinical imaging system (Bruker BoiSpin Corp., Billerica, MA) outfitted with a back-
thinned, back-illuminated 4MP CCD detector and Bruker hard coated emission filters.  
In vivo images were acquired via a pre-established 3 step imaging protocol acquiring 
sequential X-ray, fluorescence and reflectance images.  X-rays were collected with a 
standard 0.4 mm aluminum x-ray filter and an exposure time of 20 s using an X-ray 
energy of 35 KVP (f-stop = 2.80, FOV = 100 mm, vertical and horizontal resolution = 
520 ppi).  Fluorescence images were collected at ex 760 nm and em 830 nm with a 20 s 
exposure (binning = 44, f-stop = 1.10, FOV = 100 mm, vertical and horizontal 
resolution = 130 ppi).  The background was subtracted automatically using an 
illumination correction reference obtained under the same conditions.  Reflectance 
images were obtained using a standard 3 second exposure and the same parameters as 
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per the X-ray image.  All Images were evaluated using Bruker molecular imaging 
software.   
Intratracheal (IT) administration of NIR contrast agents and in vivo imaging.  
Mice were anesthetized by Ketamine/Xylazine cocktail at 87 mg/kg and 13 mg/kg 
respectively, whereby each mouse is given 0.1 cc/10 g body weight IP, and imaged.  
Mice were then intubated orally with a 20 gauge flexible catheter by direct visualization 
of the vocal chords.  Assurance of successful intubation was assessed visually and by 
monitoring breathing sounds.  Following successful intubation IT injection was carried 
out by attaching a pre-loaded syringe to the catheter, such that 50 μL of the appropriate 
solution (33 μM free NIR Dye or micelles or SCKS containing 33 μM IR800CW in 
sterile water (approximately 0.5 mg of polymer) was administered.  Mice were 
extubated, upon re-establishment of normal breathing in vivo imaging was carried out at 
t = 0, 2, 6, 12 & 24 h, and then daily for 7 – 14 days.  For imaging post-injection (PI) 
mice were lightly anesthetized by administration of Isoflurane (1.5 – 2% v/v in 100% 
oxygen), using a precision vaporizer, via chamber or nose cone.  Analysis of all in vivo 
images was carried out using Bruker Molecular Imaging Software. 
Ex vivo biodistribution analysis.  At all study end points animals were euthanized by 
CO2 asphyxiation and relevant organs were plated for fluorescence imaging (liver, 
kidney, spleen, skin, muscle, heart, lung, blood and brain).  Ex vivo images were then 
obtained using a pre-established 2-step imaging protocol acquiring sequential X-ray and 
fluorescence images.  X-rays were collected with a standard 0.2 mm aluminum x-ray 
filter and an exposure time of 3.5 s using an X-ray energy of 30 KVP (f-stop = 2.00, 
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FOV = 175 mm, vertical and horizontal resolution = 300 ppi).  Fluorescence images 
were collected at λex = 760 nm and λem = 830 nm with an 8 s exposure (binning = 44, f-
stop = 2.00, FOV = 175 mm, vertical and horizontal resolution = 75 ppi).  The 
background was subtracted automatically using an illumination correction reference 
obtained under the same conditions.  All Images were evaluated using Bruker molecular 
imaging software.  To quantify the fluorescence intensity for each organ a rectangular 
region of interest (ROI) was created surrounding the organ.  For each ROI the net 
intensity minus the background was determined by the Molecular Imaging software, 
along with the area (cm2) of the ROI.  The net intensity was normalized by both organ 
weight (g) and ROI area.  The standard deviation was calculated for each organ based 
upon a population of n = 3. 
Pharmacokinetic (PK) calculations.  Analysis of all in vivo images was carried out 
using Bruker Molecular Imaging Software.  A ROI was created utilizing 1 mouse over 
the entire lung region, and saved as a template.  This template was then applied to 
images of each mouse obtained pre-injection and at 0, 3, 6, 12 and 24 h PI, and then 
daily for up to 14 days.  For each ROI the location was adjusted to cover the entire lung 
region of the animal, but the total area was not changed.  For each time point, for each 
mouse, the mean intensity minus the background was determined by the Molecular 
Imaging software and the pre-injection mean intensity was subtracted such that the 
intensity before injection of the contrast agent equals zero.  The fluorescence intensities 
were then normalized from 0 – 100 creating the PK profile for each material (IR800CW 
Azide, Micelles and SCKs).  Utilizing Origin 9.1 the rate of extravasation and half-life 
    59 
of each material was determined by obtaining a non-linear curve fit of the appropriate 
PK profile.  The standard deviation, at each time point, and for each material, was 
calculated based upon a population of n = 3. 
Ex vivo tissue collection for confocal imaging.  At all study end points animals were 
euthanized by CO2 asphyxiation.  For cryosectioning the lungs were filled with a 50/50 
solution of sterile water and optimum cutting temperature compound (OCT) utilizing a 
20 gauge syringe bent at a 45º angle.  All tissues were provided to the Veterinary 
Integrative Biosciences (VIBS) histology lab, sectioned to a thickness of 20 μm with a 
cryostat and stored on plus coated slides (Mercedes Medical, Sarasota, FL) at -80 C.  
Before confocal fluorescence imaging slides were warmed to room temperature, 1 drop 
of VECTASHIELD® mounting media containing DAPI (Vector Laboratories, 
Berlingame, CA) was applied and the tissue was covered with #1 cover glass.  Confocal 
images were acquired on a FV1000 confocal microscope with an IX-81 inverted base 
and PMT detectors was used for all confocal microscopy.  The DAPI nuclear stain was 
excited with a 405 nm diode laser, and emission was collected from 420-450 nm.  The 
NIR dye IT800CW (conjugated to the nanomaterials) was excited using a 635 nm solid-
state laser, and a 775 nm long-pass emission filter.  Tissue from untreated mice were 
used as a control to confirm the lack of autofluorescence.  A 10 or 20X UPlanSApo lens 
(na 0.75 infinity corrected) was used for all measurements.  Each final image was taken 
at a scan rate of 12.5 or 20 μs/pixel at 1025 by 1025 pixels at a final magnification of 10 
or 160x.  Images were acquired and contrast was adjusted using Fluoview Viewer 
software V. 3.1.2.2. 
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3.3 Results and discussion 
In order to construct high capacity and scalable polymer-based nanotherapeutics, we 
designed supramolecular and covalently-stabilized nanoparticles, formed from 
biocompatible, degradable and structurally-versatile amphiphilic block terpolymers that 
were prepared by efficient “click-type” chemistries, including rapid ring-opening 
polymerizations (ROPs) and azide-alkyne Huisgen cycloaddition reactions (Figure 3.1).  
The block copolymer consists of a degradable and water-soluble polyphosphoester 
backbone, for which the first block contains alkyl side chains for creating a hydrophobic 
Figure 3.1.  Design of the amphiphilic block terpolymer for therapeutic delivery. 
environment and the second block is comprised of alkynyl side chains for post-
polymerization modifications.  The alkynes in the second block were used to graft PEG 
chains onto the block copolymer through CuAAC, to increase the polymer 
hydrophilicity, and also the conjugation of near infrared fluorescent dyes (IRDye® 
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800CW), to facilitate imaging in vivo and determination of particle pharmacokinetics 
(PK).   
The amphiphilic nature of the resulting copolymers allowed for the formation of 
micelles in aqueous solution, which are capable of encapsulating PTX through 
hydrophobic interactions within the core.  Crucial to biomedical applications is that PEG 
is a well-known and non- to minimally-toxic coating for nanoparticles that imparts 
“stealth” effects.  PEGylation often results in minimal protein adsorption and 
mononuclear phagocyte system (MPS) clearance, and leads to prolonged blood 
circulation times and an increase in mucosal transport.15,16,163-167  Mucosal transport, in 
particular, is key to the development of inhalation-based chemotherapeutics in the 
treatment of lung metastasis of osteosarcoma.  Important for tailoring this platform is the 
presence of remaining unreacted alkynes, which were utilized for post-graft crosslinking 
and could be adapted for further modification. 
 
 
Figure 3.2.  (A) Synthesis of PEBP-b-PBYP-g-PEG via sequential ring-opening 
polymerization of EBP and BYP, followed by PEGylation via CuAAC.  (B) GPC traces 
of PEBP homo-polymer (black line), PEBP-b-PBYP diblock copolymer (red line) and 
PEBP-b-PBYP-g-PEG terpolymer (blue line). 
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The amphiphilic block terpolymer PEBP-b-PBYP-g-PEG was synthesized utilizing 
click-type chemistries, which are attractive as they occur rapidly, involve (near) 
quantitative conversions of reagents, high functional group tolerance and minimal side 
reactions (Figure 3.2A).  A hydrophobic-functional AB diblock polyphosphoester was 
synthesized via sequential ROPs, a well-established approach to synthesize degradable 
polymers such as polyesters,15,54,55 polypeptides,56,57 polycarbonates,58-60 and 
polyphosphoesters.61-63  Briefly, the diblock copolymer poly(2-ethylbutoxy 
phospholane)-block-poly(2-butynyl phospholane) (PEBP-b-PBYP) was synthesized via 
sequential ROPs of 2-ethylbutoxy phospholane (EBP) and 2-butynyl phospholane 
(BYP), catalyzed by organocatalyst 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) at 0 °C 
and -10 °C, respectively, in dichloromethane, with benzyl alcohol as an initiator (Figure 
3.2A).  Phosphorus-31 nuclear magnetic resonance (31P NMR) spectroscopy was used to 
monitor monomer conversion.  It was found that over 99% conversion was reached after 
3 min for the alkyl monomer, while the second alkyne monomer required less than 3 min 
to reach 99% conversion, even at lower monomer concentration and temperature.  The 
reaction was quenched by the addition of acetic acid, and purified by precipitation from 
dichloromethane into pentane and diethyl ether (3:1) mixture, followed by 
centrifugation.  Gel permeation chromatographic (GPC) analysis showed that both PEBP 
and PEBP-b-PBYP exhibited monomodal molecular weight distributions with relatively 
low polydispersity indices (PDIs) of 1.14 and 1.24, respectively (Figure 3.2B).  The 
decreased retention time of PEBP-b-PBYP, relative to PEBP, demonstrated successful 
chain extension.  PEGylation was achieved in N,N-dimethylformamide (DMF) via 
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CuAAC quantitatively for CH3O-PEG2k-azido-functionalized PEG grafts, as confirmed 
by proton NMR (1H NMR) spectroscopy and GPC (Figure 3.2).  To remove copper ions, 
the reaction mixture was passed through a neutral alumina column and dialyzed against 
nanopure water suspended with Chelex for 2 d in a cold room at ca. 4 °C.  A white 
powder-like product was obtained after lyophilization.  The residual copper 
concentration was analyzed by ICP-MS, revealing a mass fraction of less than 10 ppm, 
which is acceptable for drug delivery applications. 
 
 
Figure 3.3.  Schematic representation of the formation of micelles and SCKs physically 
loaded with PTX. 
 
With an average of only four PEG grafts per polyphosphoester block terpolymer 
backbone, PEBP-b-PBYP-g-PEG was found to be highly water soluble and PTX-loaded 
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micelles and SCKs could be prepared in a facile manner (Figure 3.3).  PTX-loaded 
micelles were formed by dissolving the polymer and PTX in ethanol, followed by the 
removal of ethanol in vacuo and resuspension in nanopure water, with 5 min sonication 
to allow for the formation of well-dispersed micelles. 
The SCKs were prepared by supramolecular assembly of PEBP-b-PBYP-g-PEG into 
micelles, followed by shell crosslinking via thiol-yne click chemistry.  The block graft 
terpolymer was first dissolved in methanol; subsequent addition of water directed the 
hydrophobic PEBP segments to aggregate and form the core domains of the micelles, 
while the hydrophilic PEG formed the shell domains.  The formed micelles were then 
shell crosslinked with hexa(ethylene glycol) dithiol (0.2 equivalents to alkyne groups) in 
the presence of 2,2-dimethoxy-2-phenylacetophenone (DMPA) and UV irradiation at 
365 nm.  The resulting SCKs were dialyzed for 2 d to remove organic solvent and other 
small molecules and subsequently lyophilized to yield a yellowish powder.  Upon 
dissolution in ethanol, the SCK suspension displayed strong light scattering when a laser 
light was passed through the solution indicating successful crosslinking, with a number-
averaged diameter of ca. 33 nm as measured by dynamic light scattering (DLS) (Figure 
3.4).  PTX was loaded into SCKs utilizing the procedure for the PTX-loaded micelles, 
using SCKs in place of the polymer PEBP-b-PBYP-g-PEG (Figure 2).  Importantly, long 
term storage (> 6 months) of lyophilized PTX-loaded micelles and SCKs did not affect 
their properties upon re-suspension in aqueous solution. 
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Figure 3.4.  DLS histograms of Dh(intensity), Dh(volume),, Dh(number) hydrodynamic 
diameters of empty SCKs in ethanol. 
The PTX concentration and loading capacity were optimized, for both the micelles and 
SCKs, by tuning PTX loading percentages and polymer or SCK concentrations (Table 
3.1).  The actual PTX concentrations were determined by HPLC at a flow rate of 1 
mL/min using a mixture of CH3CN and 20 mM aqueous NH4OAc at a ratio of 45:55 as 
the eluent.  At 10 wt% loading, the PTX concentrations increased from 1.0 mg/mL to 4.8 
mg/mL with increasing polymer concentration for both micelles and SCKs (Table 3.1, 
entries 1-4 and 7-9, respectively).  These nanoparticles were visually stable in nanopure 
water, without any precipitation and could be stored for more than 1 month at 4 °C.  
However, when the loading percentage increased to 15 or 20 wt% (Table 3.1, entries 5 
and 6, respectively), the obtained nanoparticles were only stable in nanopure water for 
ca. 2 d, at which time significant quantities of white precipitates were visualized.  
Incorporation of PTX into micelles or SCKs appeared to be highly effective, as all 
initially added PTX was visibly dispersed within the transparent particle solutions at 
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high concentrations of 10 wt% (entry 4 for micelles, entry 9 for SCKs).  At such 
concentrations, both micelles and SCKs demonstrated homogeneous light scattering 
when a red laser was passed through the solutions, suggesting that well-dispersed 
nanoparticles encapsulating PTX were prepared (Figure 3.5).  Compared with our 
previous SCK formulations, the PTX concentration in aqueous solution achieved in this 
study was increased approximately 160 times to 4.8 mg/mL, which is equal to 
benchmarking systems such as Abraxane® and NK105, as well as many of the high 
loading polymeric micellar delivery systems reported in the literature.54,66,142,147 
Table 3.1  Loading capacity of micelles and SCKs and their apparent solution-state 
stability 
Entry Sample 
Polymer 
(mg/mL) 
PTXa 
(g/mL) 
PTXb 
(µg/mL) 
Stabilityc 
1 micelles-10%-A 9.0 1000 1040 > 1 month 
2 micelles-10%-B 13.5 1500 1510 > 1 month 
3 micelles-10%-C 18.0 2000 2040 > 1 month 
4 micelles-10%-D 45.0 5000 4820 > 1 month 
5 micelles-15% 8.5 1500 1490 2 dd 
6 micelles-20% 32.0 800 - 2 dd 
7 SCKs-10%-A 9.0 1000 980 > 1 month 
8 SCKs-10%-B 18.0 2000 1960 > 1 month 
9 SCKs-10%-C 45.0 5000 4950 > 1 month 
aTheoretical concentration  
bConcentration measured by HPLC 
cStability when stored at 4 °C unless otherwise noted 
dSample precipitated when stored at room temperature. 
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Figure 3.5.  Photos of (A) PTX-loaded micelles in nanopure water and (B) PTX-loaded 
SCKs in nanopure water both at a PTX concentration of 4.8 mg/mL, with a red laser 
passing through. 
The sizes of the micelles and SCKs physically loaded with PTX were characterized 
both by DLS and transmission electron microscopy (TEM).  DLS analysis indicated that 
the number-averaged hydrodynamic diameters (Dh(number)) of the particles were 14 ± 4 
nm and 24 ± 6 nm (Figure 3.6 A, D), respectively, with negative zeta potentials of -40 
mV.  TEM images demonstrated that both micelles and SCKs were well-dispersed and 
had relatively uniform dry-state substrate-adsorbed diameters of ca. 42 ± 5 nm and 24 ± 
4 nm, respectively (Figure 3.6 B, E).  As PPEs are soft materials (Tg = - 51 °C), the 
micellar structures could not maintain their spherical shapes in the dry state on TEM 
grids, tending to become flattened, leading to an observed diameter larger than their Dh.  
Crosslinking to create SCKs limited the extent of deformation of the nanostructures.  In 
an effort to more accurately determine the dry state diameters, cryo-TEM measurements 
were performed on both PTX-loaded micelles and SCKs, where specimens were 
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prepared in vitreous ice to view the unaltered macromolecular co–assembly, without 
shape deformation or staining perturbation (Figure 3.6 C, F).  It was confirmed that both 
micelles and SCKs had diameters of ca. 17 nm with narrow size distributions, which was 
in agreement with data obtained from DLS measurements.  
Figure 3.6.  Characterization of nanoparticle sizes for PTX loaded micelles (A-C) and 
SCKs (D-F).  Displayed from left to right respectively: DLS histograms displaying their 
hydrodynamic diameters in nanopure water, TEM sample negatively stained by uranyl 
acetate, and cryo-TEM images without staining. 
The release of PTX from micelles or SCKs was evaluated by monitoring the 
decreasing concentration of PTX from a solution of loaded micelles or SCKs dialyzed 
(MWCO 10 kDa) against PBS at 37 °C over 3 days (Figure 3.7).  It was found that both 
micelles and SCKs released PTX at a slow and sustained rate.  As expected, shell 
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crosslinking created an additional physicochemical layer that retarded drug transport 
through the shell, providing a decreased rate of release for PTX from SCKs, as 
compared to the corresponding micelle precursors.  The apparent PTX release half-life 
(t1/2) from micelles and SCKs were determined to be 6.5 and 12 h, respectively.  
Therefore, the release profiles can be potentially tuned simply by altering the degree of 
crosslinking.41 
Figure 3.7.  Release of paclitaxel that was either loaded into micelles or SCKs and 
studied by a dialysis method over 3 days at 37 °C in PBS, measured in triplicate.  
The in vitro hydrolytic degradation of the PEBP-b-PBYP-g-PEG micelles was 
evaluated at different pH values utilizing 31P NMR spectroscopy to monitor the cleavage 
of their phosphodiester backbones and phosphoester side chains (Figure 3.8).67,168  At 
neutral pH = 7.4, the nanoparticles displayed high stability, observing only a small 
degradation peak (<10%) at 0.35 ppm by 31P NMR after incubation in PBS for 103 days 
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(Figure 3.8 A).  Generally, it has been shown that the hydrolytic degradation rate is 
greatly influenced by side-chain functionalities, for example, amino group-containing 
cationic nanoparticles degraded much faster compared to anionic, non-ionic and 
zwitterionic nanoparticles.67,100,169-171  We hypothesize that the increased stability of 
PEBP-b-PBYP-g-PEG arises from not only a lack of nucleophiles in the neutral PBS, 
but also the densely-packed mPEG2k grafted surface, which leads to limited exposure of 
the polymer to nucleophiles within the surrounding environment.  As expected, the 
extent of hydrolysis increased significantly under both acidic (pH = 1, Figure 3.8 B) and 
basic conditions (pH = 10, Figure 3.8 C).168  For example, at pH = 10 the 31P NMR 
signal from PBYP decreased by more than 70% after 115 d. 
Figure 3.8.  Changes in 31P NMR for micelles as a function of hydrolytic degradation 
times in (A) PBS (pH = 7.4), (B) HCl/H2O (pH = 1) and (C) Na2CO3/ NaHCO3 (pH = 
10). 
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To investigate the in vitro cellular uptake and in vivo biodistribution and PK of the 
PEBP-b-PBYP-g-PEG micelles and SCKs, a hydrophilic near-infrared (NIR) fluorescent 
dye IR800CW azide was grafted to the polymer via CuAAC in nanopure water (Figure 
3.9).  The unreacted dye was removed using a Sephadex G-25 column followed by 
dialysis for 2 d (MWCO 12-14 kDa).  Removal of the unconjugated IR800CW dye was 
confirmed by the disappearance of the free dye peak in DMF GPC (Figure 3.10).  
Confirmation of covalent dye conjugation for the purified polymer-dye conjugate was 
also examined by fluorescence spectroscopy.  As previously reported for PPE block 
copolymers, the PPE is capable of undergoing degradation during gel electrophoresis 
and, thus, alternative spectroscopic techniques (fluorescence anisotropy (r) and intensity 
averaged fluorescence lifetime (τi)) were utilized to confirm successful conjugation 
(Table 3.2).172 
Figure 3.9.  Schematic representation of NIR labeling of PEBP-b-PBYP-g-PEG 
micelles with IRDye 800CW azide (0.5 eq. to polymer precursor). 
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Figure 3.10.  The DMF gel permeation chromatography (GPC) traces of free dye (red 
line), polymer (dark cyan), dye-labeled polymer (blue line), and mixture of free dye and 
dye-labeled polymer (black line).  The values in parentheses correspond to the 
polymer/dye concentrations (mg/mL) injected into the DMF GPC.  
The use of spectroscopic techniques to evaluate dye-nanoparticle conjugation is 
advantageous, as the results can provide valuable information on the dynamic behavior 
of the fluorophores within their supramolecular and external environments.172  In the 
case of evaluating dye-macromolecule conjugation of NIR cyanine dyes, such as 
IR800CW, the use of r and τi measurements is often considered difficult.  The trouble 
with measuring changes in these spectroscopic properties following conjugation of NIR 
dyes lies with their short fluorescence lifetimes in aqueous solvents (< 1.0 ns), 
traditionally elongated structures that lead to high r measurements for the unconjugated 
dyes (> 0.2) and reliance upon extended linkers utilized for conjugation resulting in 
higher local mobility or “wobbling” of NIR dyes upon coupling.173  Therefore, when 
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utilizing such techniques, small changes that may not be considered of interest in the 
case of longer-lived and more compact visible-emitting dyes take on increased 
significance when evaluating conjugation of NIR cyanine-based dyes. 
Table 3.2.  Fluorescence properties of IR800CW nanoparticle conjugates 
Solvent Sample 
λabs 
(nm) 
λem 
(nm) 
r i (ns) ΦFL 
Nanopure 
H2O 
IRDye 800 CW 774 788 0.218 ± 0.006 0.500 ± 0.011 0.086 
Micelles + IR800CWa 774 787 0.221 ± 0.006 0.493 ± 0.012 - 
SCKs + IR800CWa 774 789 0.216 ± 0.005 0.492 ± 0.012 - 
IR800CW Micelles 778 792 0.239 ± 0.005 0.668 ± 0.015 0.071 
IR800CW SCKs 778 792 0.241 ± 0.007 0.703 ± 0.017 0.074 
PBS pH 
7.4 
IRDye 800 CW 774 789 0.221 ± 0.006 0.501 ± 0.017 - 
Micelles and Dyea 774 789 0.219 ± 0.003 0.489 ± 0.012 - 
SCKs and Dyea 774 790 0.220 ± 0.006 0.495 ± 0.012 - 
Dye labeled-micelles 778 792 0.247 ± 0.004 0.678 ± 0.016 - 
Dye labeled-SCKs 778 792 0.240 ± 0.006 0.708 ± 0.016 - 
aPhysical mixtures of polymeric nanomaterial with IR800CW, r = steady-state 
anisotropy, λex = 700 nm, and λem = 820 nm, i = intensity-weighted lifetime, 
ΦFL = fluorescence quantum yield (relative to ICG = 0.027 in water174) 172 
Following grafting of the dye IR800CW to PEBP-b-PBYP-g-PEG micelles and SCKs, 
both r and τi, were evaluated, and changes in both spectroscopic properties were 
observed (Table 3.2).  The r and τi of both the free dye and physical mixtures of the free 
dye with polymeric nanomaterials resulted in starting anisotropy values ca. 0.220 and τi 
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near 0.500 ns.  Upon grafting of the dye to both micelles and SCKs, statistically 
significant increases in r and τi were observed in both water and pH 7.4 PBS, indicating 
that the dye was covalently attached to, rather than physically associated with, the 
polymeric nanomaterials.  By utilizing both aqueous solvents (water and PBS), the effect 
of crosslinking on the ability of the polymeric materials to interact with the surrounding 
solvated environment could be probed.  In this case, the SCK displayed no change in 
either the r or τi measurements, while the micellar particles displayed small changes that 
are not statistically different.  Given the noted nature of such measurements with NIR 
cyanine dyes, these changes cannot be entirely discounted to lack meaning, but rather 
may be considered indicative that crosslinking does have an effect upon the ability of 
these polymeric materials to freely interact with their surrounding environment, which is 
also supported by previous findings.16,41,162 
Table 3.3.  Comparison of the IC50 values of PTX (as a Taxol-mimicking formulation), 
physically-loaded PTX micelles (both with and without the NIR label IR800CW) and 
SCKs in both control (OVCAR-3) and osteosarcoma (CCH-OS-O and SJSA) cell lines. 
Formulation 
IC50 (µM) 
OVCAR-3 RAW 264.7 CCH-OS-O SJSA 
Taxola 0.005 ± 0.002 0.040 ± 0.010 0.019 ± 0.001 0.047 ± 0.006 
PTX Micelles 0.015 ± 0.010 0.100 ± 0.040 0.028 ± 0.001 
IR800CW PTX 
Micelles 
0.016 ± 0.009 0.028 ± 0.001 0.068 ± 0.007 
PTX SCKs 0.010 ± 0.008 0.080 ± 0.020 0.014 ± 0.001 
aTaxol-mimicking formulation: Cremophor-EL and ethanol, 1:1 v/v 
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The in vitro cytotoxic effects of the physically PTX-loaded micelles and SCKs were 
measured against human ovarian adenocarcinoma cells (OVCAR-3), RAW 264.7 mouse 
macrophages (RAW 264.7), CCH-OS-O and SJSA cell lines to establish their IC50 
values at 72 h incubation time, as compared to that of PTX (as a Taxol-mimicking 
formulation; Cremophor-EL and ethanol, 1:1 v/v) (Table 3.3).  OVCAR-3 cells serve as 
a control for comparability to previously-studied polymeric chemotherapeutic delivery 
vehicles,66,142,175 while the osteosarcoma cell lines CCH-OS-O and SJSA demonstrate 
the effective toxicity of the PTX-loaded materials towards the targeted disease, lung 
metastasis of osteosarcoma.  Polymeric micelles and SCKs physically-loaded with 10 
wt% PTX displayed in vitro cytotoxicities comparable to those of the Taxol-mimicking 
formulation.  Despite the slower PTX release, PTX-loaded SCKs exhibited only slightly 
higher cytotoxicity compared to PTX-loaded micelles.  As a result of their greater 
sensitivity to PTX, the difference was more significant on OVCAR-3 cells, in 
comparison to the other cell lines.  The reduced cytotoxic effects of these nanoscopic 
carriers may be, in part, due to the fast release of lipophilic PTX from the small 
molecular Cremophor-EL surfactants, which can diffuse passively through cell 
membranes and cause cytotoxicity.  Grafting of IR800CW to the micellar polymer 
structures had no effect on nanoparticle cytotoxicity in OVCAR-3 or CCH-OS-O cell 
lines and, thus, is not expected to change the outcomes in RAW 264.7 and SJSA cell 
lines or as regards the cytotoxicity of the SCKs.  As a control, the cytotoxicity of the 
corresponding nanoparticles without PTX was evaluated, and they were found to be non-
toxic at the tested concentrations. 
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Figure 3.11.  Confocal microscopy images demonstrating cellular internalization of both 
unloaded micelles (A, B) and micelles physically loaded with PTX (C, D) into CCH-OS-
O  cells (A, magnification = 60x, scale bars = 30 m; C, magnification = 40x, scale bars 
= 50 m; B, D, magnification = 100x, scale bars = 20 m; blue = DAPI (nuclear stain) 
and red = IR800CW from NIR labeled micelles).  Images to the right overlay 
fluorescence on the DIC. 
After establishing that the IC50 values for the PTX-loaded micelles and SCKs in 
osteosarcoma cell lines were comparable to the pharmaceutical Taxol-mimicking 
formulation, a cell uptake study by confocal microscopy was conducted, using CCH-OS-
O osteosarcoma cells.  The resulting images support cellular internalization of both the 
micellar (Figure 3.11) and SCK (Figure 3.12) nanostructures, whereby nuclear 
degradation appeared to occur, presumably, upon PTX release within the cellular 
environment following internalization of PTX-loaded nanoparticles (Figure 3.11 C-D, 
micelles).  When the unloaded micelles and SCKs were taken up by the CCH-OS-O cells 
(Figure 3.11 A-B, micelles), there appeared to be no effect, which reflected the reported 
lack of cytotoxicity.  These studies further demonstrate the cytotoxicity of these PTX-
    77 
loaded materials and highlight their ability to deliver PTX and effectively disrupt the 
growth of osteosarcoma cells. 
 
 
Figure 3.12.  Confocal microscopy images demonstrating cellular internalization of both 
unloaded SCKs (A, B) and SCKs physically loaded with PTX (C, D) into CCH-OS-O 
cells (A, C, magnification = 60x, scale bars = 50 µm; B, D, magnification = 100x, scale 
bars = 20 µm; blue = DAPI (nuclear stain) and red = IR800CW from NIR labeled 
SCKs).  Images to the right overlay fluorescence on the DIC. 
 
Previous research utilizing liposomal95-97 and nanoparticle176,177 drug formulations has 
demonstrated that drugs delivered directly to the respiratory tract can result in high 
pulmonary drug concentration, reduced systemic toxicity, and reduced dosage 
requirements vs. parenteral or oral administration.95-97  Additionally, these studies 
revealed that delivery of therapeutics by inhalation-based methods shows great promise 
towards increased efficacy of treatment, relative to systemic delivery.  However, unlike 
in the case of systemic delivery, these studies have largely avoided evaluating the overall 
behavior of the nanoparticles themselves as regards lung extravasation and whole body 
biodistribution.  Studies addressing nanoparticle disposition and biokinetics from 
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aerosol-based treatments have focused on non-degradable and/or inorganic nanoparticles 
evaluated by ex vivo tissue analysis, or concentrated on specific interactions, such as 
translocation of particles from the lungs to lymph nodes.97,176-178  While these studies 
provide valuable information as to nanoparticle location and toxicology, initial screening 
via optical imaging in vivo would allow for monitoring of real time trafficking, from 
which PK data and routes of excretion can be evaluated.  Of significant interest was 
evaluation of the PK of the degradable PEBP-b-PBYP-g-PEG micelles and SCKs, and 
determination of whether crosslinking would affect the rate of extravasation (kex), with 
correlation to the in vitro findings. 
In the case of the PEBP-b-PBYP-g-PEG micelles and SCKs presented herein, it was 
hypothesized that the degradable polymer-based nanoparticles themselves would be 
capable of extravasation from the lungs and secondary organs on a timeline compatible 
with repeated dosing of PTX, but that the rate of lung extravasation for micelles vs. 
SCKs would be different, due to the increased stability imparted to SCKs through 
crosslinking.  The hypothesis, as regards extravasation of micelles vs. SCKs, was 
supported by previously reported findings where crosslinked SCKs were shown to have 
higher morphological stability, undergo slower disintegration, and elicit lower immuno-
toxicity than their non-crosslinked micellar analogs.100  Nanoparticle PK were indirectly 
evaluated by NIR optical imaging, following intratracheal administration to ensure that 
extravasation of the majority of the delivery vehicle largely occurred within the 1-2 
week time frame largely considered appropriate for repeated dosing.179 
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IR800CW Azide, PEBP-b-PBYP-g-PEG-g-IR800CW micelles or SCKs (λex = 778 
nm, λem = 792 nm) were administered intratracheally to six mice each.  All mice were 
monitored over 7 to 14 days by whole body optical imaging on a Bruker Xtreme™ in 
vivo preclinical imaging system.  The biodistribution of each dye/nanoparticle was 
imaged at regular intervals, directly post injection (PI), at 2, 6, 12 and 24 h PI and then 
daily until the appropriate endpoint of either 7 or 14 d PI (n = 3 mice at each endpoint 
per injected dye/nanoparticle to reach statistical significance) (Figure 3.13 A).  For all 
images, normalized fluorescence intensities over the lung region were obtained through 
image analysis and plotted vs. time to generate PK profiles (Figure 3.13 B) for each 
experimental group (IR800CW azide, micelles or SCKs).  The rate of extravasation from 
the lungs (kex) and t1/2 were obtained by fitting the PK profile with a non-linear curve fit 
(Table 3.4).  At the study endpoint, tissue and organs were harvested (liver, kidney, 
spleen, skin, muscle, brain, lung, heart, blood and the GI tract (stomach, intestines, 
cecum, etc.)) and imaged ex vivo to obtain endpoint biodistribution data (Figure 3.13 C).  
PK analysis established the lung extravasation t1/2 for the PEBP-b-PBYP-g-PEG-g-
IR800CW micelles to be ca. 4 d (Table 3.4), whereas the small molecule NIR probe 
exhibited a t1/2 of 4 h, with > 85% cleared from the lungs within 12 h and the entire body 
within 1-2 d (Figure 3.13 A, B).  The micellar t1/2 was supported by the imaging results, 
suggesting that micelles exhibit extended lung retention of >14 d, at which time the t1/2 
indicates ca. 7 - 10% of the original micelle dose should remain present.  Alternatively, 
the polymeric SCKs display a t1/2 of ca. 8 d, twice that of their micellar counterparts.  
The difference in extravasation rates is most likely due to a change in the structure-
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function relationship, whereby crosslinking leads to added structural stability and 
decreased interactions with the surrounding biological environment, as compared to the 
micellar structures, supporting the findings of the NIR spectroscopy study above.  We 
hypothesize that the resulting decrease in external interactions with fluids and other 
biological elements (proteins, enzymes, etc.) would decrease opportunities for externally 
induced degradation (e.g. enzymatic) resulting in the observed longer t1/2.  These studies 
and findings may be complicated by the indirect detection method, whereby the dye is 
being tracked independent of whether it is bound to the original nanoparticle, 
disassembled polymer chains, or partial fragments due to cleavage of the dye from the 
polymer backbone or polymer backbone degradation.  However, the significantly faster 
biological clearance of the small molecule dye suggests that the micelle and SCK studies 
were, in fact, measurements predominantly of nanoparticle/polymer clearance rates. 
Table 3.4.  Pharmacokinetics of the dye IR800CW azide and its micellar and SCK 
conjugates. 
Agent Latency (d) kex (d
-1) t1/2
* (d)
IR800CW Azide 0.08 9.29 0.16 
Micelles 0.08 0.17 4.18 
SCKs 2.00 0.11 8.28 
Kex = rate of extravasation from the lungs 
*t1/2 = t1/2 + Latency
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Figure 3.13.  (A) The overlaid optical on X-ray images of the small molecule dye 
IR800CW Azide (top) vs. PEBP-b-PBYP-g-PEG-g-IR800CW micelles (middle) and 
SCKs (bottom) collected as a function of time.  (B) PK profiles of normalized mean 
fluorescence intensity as a function of time for the free dye (IR800CW azide) and 
IR800CW labeled micelles and SCKs.  (C) The quantified biodistribution data collected 
ex vivo on harvested organs at 7 and 14 days PI for IR800CW azide vs. IR800CW 
labeled micelles and SCKs.  
 
Ex vivo fluorescence imaging of the collected tissue and organs was evaluated to 
confirm that the nanomaterials remained largely in the lungs, and to identify secondary 
organ systems that may have accumulated small quantities of nanomaterials or potential 
degradation products.  Semi-quantitative analysis (Figure 3.13 C) reveals that the major 
site of nanoparticle accumulation, for both micelles and SCKs, was in the lungs (the site 
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of administration) at both 7 and 14 days PI.  The clearly observed difference between 
retention of nanoparticle formulations and unconjugated IR800CW azide over 7 days is 
statistically significant based upon a student’s t-test (n = 3), and supports the reported in 
vivo PK studies.  Evaluation of both the in vivo and ex vivo findings suggests that at least 
two routes of extravasation from the lungs and excretion from the body may have taken 
place concurrently.  In vivo studies revealed both early clearance to the bloodstream and 
through the mucociliary tract, due to repeated coughing up and swallowing of the 
micelles or SCKs.  Over time, extravasation from the lungs via the mucociliary tract was 
observed to become negligible, as later images revealed accumulation largely within the 
kidney and liver, indicating the primary route of extravasation was into the blood.  Ex 
vivo findings indicated limited accumulation of both nanomaterials in the kidney and 
liver, demonstrating that both micelles and SCKs were excreted concomitantly via both 
the renal and hepatobiliary pathways.  When considering the degradable nature of these 
materials, the findings were not unexpected, as degradation by-products could be of a 
multitude of sizes (from partly intact polymers or nanoparticle pieces to small 
molecules) that are capable of undergoing excretion from the body via either pathway, 
depending on size.16  Overall, the t1/2 and biodistribution results support the ability of 
both the micelles and SCKs to undergo extravasation from the lungs and whole body 
excretion within a timeline reasonable for repeated dosing on a weekly or biweekly 
basis. 
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Figure 3.14.  Representative ex vivo confocal microscopy z-stack of 20 μm lung sections 
7 days PI of IR800CW labeled (A) micelles and (B) SCKs (10x, scale bar = 100 m) 
supporting distribution of the nanoparticles throughout the lungs of healthy mice (blue = 
DAPI (nuclear stain) and red = IR800CW NIR labeled nanoparticles).  Images to the 
right overlay fluorescence on the DIC. 
To confirm that intratracheal delivery did not solely deliver the PEBP-b-PBYP-g-
PEG-g-IR800CW micelles and SCKs to the location of deposition within the lungs, but 
rather that the nanoparticles are capable of distributing throughout the lung tissue, the 
general location of the particles was evaluated by confocal microscopy on frozen lung 
sections.  The lungs of mice treated with IR800CW micelles and SCKs (n = 3 for each 
particle) were filled with a 50/50 solution of sterile water/OCT, frozen and sliced at a 
thickness of 20 μm in a cross-sectional manner from the distal to proximal end, such that 
both the left and right lobes were included in each section.  Fluorescence images of lung 
sections (Figures 3.14 and 3.15 display representative images) were obtained after 
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applying mounting media containing DAPI for nuclear staining.  NIR signal from 
IR800CW-labeled nanoparticles was observed throughout both the left and right lobes at 
distal, medial and proximal locations for all treated mice, while untreated controls lacked 
fluorescence signal in the NIR region.  Such outcomes indicated that the nanomaterials 
were capable of migrating from the point of administration throughout the lung, which 
would be vital in the treatment of widespread metastatic disease. 
Figure 3.15.  Representative ex vivo confocal microscopy images of a 3D reconstruction 
of 20 μm lung sections (From left to right: 0º, 45º, 90º, 135º, 180º) 7 days PI of 
IR800CW labeled (A) Micelles and (B) SCKs (160x, scale bar = 10 mm) indicating the 
nanomaterials are able to enter the cellular microenvironment surrounding the nucleus in 
vivo. (blue = DAPI (nuclear stain) and red = IR800CW NIR labeled nanoparticles). 
3.4 Conclusions 
Polyphosphoester-based amphiphilic block graft terpolymers have been prepared by 
efficient “click-type” reactions, and were able to undergo co-assembly with PTX to form 
well-defined nanoparticles, as supramolecular micelles and covalently-stabilized SCKs.  
Characterization of the resulting nanotherapeutics demonstrated that they exhibited 
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desirable physiochemical properties when loaded with up to 10 wt% of PTX, a 
concentration of 4.8 mg/mL in aqueous solution that was a 160-fold increase over our 
previous SCK formulations.50  During subsequent drug release studies, it was observed 
that the t1/2 of PTX release for SCKs is nearly double that of their micellar counterparts 
(12 vs. 6.5 h respectively).  These results demonstrated that crosslinking was capable of 
mediating PTX release by forming an additional physicochemical layer through the 
shell, the tuning of which could be utilized to further tune the performance of these 
nanoscopic containers.  Residual alkynyl groups along the backbones were modified by 
attaching the NIR dye IR800CW, enabling their use in vivo and ex vivo imaging-based 
studies.   
The promising features displayed by these PTX-loaded nanoparticles led to further 
investigation of their in vitro and in vivo characteristics to evaluate potential efficacy 
against known metastatic osteosarcoma cell lines and the potential of the particles 
towards direct administration to the lung for the treatment of metastatic osteosarcoma 
tumors.  In vitro, these micellar formulations had comparable cytotoxicities with the 
commercially available Taxol®- mimicking formulation, further validating them as 
excellent candidates for translational studies.  In vivo evaluation of the pharmacokinetics 
and biodistribution, following intratracheal delivery, revealed that crosslinking has the 
ability to control the rate of nanoparticle extravasation from the lungs.  SCKs were 
observed to be retained for almost twice the time of their micellar equivalents, ca. 8 d vs. 
4 d respectively.  These extravasation timelines appear to be reasonable for translational 
development when considering the repeating dosing schedules already in place for PTX 
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chemotherapeutics.  Interestingly, we have shown that the structure-function relationship 
of nanomaterials not only affects in vitro outcomes, but also has implications on in vivo 
performance and pharmacokinetics following intratracheal delivery to the lungs.   
Given the findings presented herein, these new PEBP-b-PBYP-g-PEG 
chemotherapeutic delivery vehicles have great potential as nanocarriers, providing 
sustained release treatments via administration directly to the site of lung metastasis of 
osteosarcoma.  This initial work has established the ability to load drugs into well-
designed polymer nanoparticle frameworks, achieve in vitro efficacy against relevant 
cancer cells, and probe the in vivo biodistribution of the non-loaded nanoparticles in 
healthy animals to understand their trafficking behaviors.  Important for tailoring this 
platform is the presence of remaining unreacted alkynes, which could be adapted for 
further modification, such as attachment of targeting ligands and grafting of imaging 
agents to evaluate biodistribution and nanoparticle location within tissues.  However, 
key issues remain to be investigated, including the relationships between in vitro vs. in 
vivo rates of degradation of the particles and release of drug molecules, the independent 
trafficking globally and at the cellular level in diseased vs. healthy tissues, and the 
behaviors for each of the drug and carrier components, whether intact or in a fragmented 
form.  Clearly, there is much chemistry and biology remaining to be understood, with 
this work being an important first step, for continuing ongoing studies. 
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CHAPTER IV 
 DEGRADABLE POLYPHOSPHOESTER-BASED SILVER-LOADED 
NANOPARTICLES AS THERAPEUTICS FOR BACTERIAL LUNG 
INFECTIONS * 
 
4.1 Introduction 
 Despite current advancements in modern medicine, infectious diseases, especially 
pulmonary infections, continue to pose great clinical challenges to successful 
medical treatment.86,180  In 2012, lower respiratory infections were reported as the 
second leading cause of years-of-life lost (YLL) worldwide.181  One of the 
contributing factors is widespread antibiotic resistance, which enables antibiotic-
resistant bacteria, such as Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter 
species (ESKAPE), to survive despite treatment with existing antibacterial drugs.86-88  
The growing number of multi-drug resistant strains has made imperative the 
development of new antibiotics and novel approaches to deliver existing agents.86,89-
91  
 Silver has been used as an antimicrobial agent for centuries, especially in the 
                                                 
* Reprinted (adapted) with permission from “Degradable polyphosphoester-based silver-loaded 
nanoparticles as therapeutics for bacterial lung infections” by Zhang, F.; Smolen, J. A.; Zhang, 
S.; Li, R.; Shah, P. N.; Cho, S.; Wang, H.; Raymond, J. E.; Cannon, C. L.; Wooley, K. L., 
Nanoscale, 2015, 7, 2265-2270.  http://pubs.rsc.org/en/content/articlehtml/2015/nr/c4nr07103d.  
Copyright 2015 The Royal Society of Chemistry (RSC). 
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topical treatment of wounds and burns.182  Silver cations are well known to be highly 
toxic against a broad spectrum of microorganisms, while metallic silver has minimal 
antimicrobial activity.183-185  Although their biocidal mechanisms are not fully 
understood, silver cations have been reported to cause bacterial protein denaturation, 
enzyme oxidation, and interference with DNA replication.186,187  Furthermore, unlike 
traditional antibiotics, silver cations exhibit low toxicity to human tissues and 
documented instances of bacterial resistance are rare.180,188,189  Therefore, various 
silver-based antimicrobials have been developed.  For example, silver sulfadiazine 
(AgSD) cream, which was introduced in the 1960s, has become a routine remedy in 
the treatment of burns over the last few decades.182,190  However, silver cation-based 
small molecules are often not practical in vivo, because free Ag+ will interact with 
anions and other biological compounds in the human body, decreasing the 
bioavailability of free Ag+.180,185,191  Therefore, there is a remaining need to develop 
a drug-delivery system that can effectively carry the silver-based antimicrobials to 
the infected tissues with minimal inactivation of these drugs. 
 Recently, several nanosized systems for the delivery of silver-based small 
molecules have been developed to improve bioavailability and efficacy.35,191-194  Our 
group has investigated shell crosslinked knedel-like (SCK) nanoparticles, comprised 
of poly(acrylic acid)-block-polystyrene (PAA-b-PS) block copolymers, for the 
packaging and delivery of both silver cation and hydrophobic 1-hexyl-3-methyl-4,5-
dichloro-imidazole-2-ylidene silver(I) acetate (silver carbene complex, SCC10).  
Although these PAA-b-PS based SCKs displayed lower antimicrobial activities 
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compared to AgNO3 in vitro, they exhibited remarkably-enhanced therapeutic 
efficacy in vivo.35,193  A key drawback to these materials, however, is their stable, 
non-degradable structure, which raises concerns about their clearance from the body, 
possible side effects from their extended retention, and also their environmental 
persistence.  Moreover, the electrostatic interaction between silver cations and the 
carboxylates of the acrylic acid residues is weak, leading to instability, formation of 
AgCl precipitates when challenged by saline solution, and relative ineffectiveness in 
vivo for the SCKs loaded only with Ag cations.35,193   
  To address these problems, we have designed and synthesized an amphiphilic 
block terpolymer with a hydrolytically-degradable polyphosphoester-based backbone 
and side chain functionalities that allow for stronger binding of silver 
cations.61,74,99,100,195  The alkyne side chains are designed to incorporate silver via 
reversible interactions between silver cations and alkynes, which has been 
traditionally employed in various catalytic processes.196-199  A portion of the alkynes 
was consumed for the installation of methoxypolyethylene glycol (mPEG), which 
was grafted onto the backbone via copper(I)-catalyzed alkyne-azide cycloaddition 
(CuAAC) reactions to increase hydrophilicity and enhance mucosal transport.15,163-
165,200  These alkyne groups also offer opportunities for further modifications, such as 
crosslinking to increase nanoparticle stability and addition of fluorescent probes or 
radiolabeling sites for investigation of trafficking in vitro and in vivo.15,36,100,117,201  
Finally, the alkyl side chains impart hydrophobicity, allowing the formation of 
micelles with core-shell morphology, as well as providing avenues to load potential 
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hydrophobic drugs, for example hydrophobic silver carbene complexes including 
SCC10,192 for combination drug delivery. 
4.2 Materials and methods 
4.2.1 Materials 
2-Chloro-2-oxo-1,3,2-dioxaphospholane (95%) was used as received from Thermo 
Fisher Scientific, Inc. (Pittsburgh, PA).  Chelex 100 resin was used as received from 
Bio-Rad Laboratories (Hercules, CA).  Tetrahydrofuran (THF) and dichloromethane 
(DCM) were dried through a purification column system (J. C. Meyer Solvent Systems, 
Inc., Laguna Beach, CA).  ɑ-Methoxy-ω-azido PEG2k (Mn = 1,950 kDa, Mw/Mn = 1.03) 
was purchased from RAPP POLYMERE (Tuebingen, Germany).  All other chemicals 
were purchased from Sigma-Aldrich (St. Louis, MO) and used without further 
purification, unless otherwise noted.  Slide-A-Lyzer dialysis cassettes (10 kDa molecular 
weight cut-off, MWCO) were purchased from Pierce Biotech. (Rockford, IL).  The 
Spectra/Por dialysis membranes (MWCO 12-14 kDa) were purchased from Spectrum 
Laboratories, Inc. (Rancho Dominguez, CA).  Nanopure water (18 MΩ·cm) was 
acquired by means of a Milli-Q water filtration system, Millipore Corp. (Bedford, MA).  
Dr. Maynard Olson (University of Washington, Seattle, WA) provided the laboratory 
strain PAO1-V, and Dr. Thomas Ferkol (Washington University, St. Louis, MO) 
provided the mucoid, cystic fibrosis clinical isolate PAM57-15.  PAHP3, BG80, BM54, 
SALL06, and SAEH05 were cultured and isolated from cystic fibrosis patient sputum at 
St. Louis Children’s Hospital (St. Louis, MO).  The USA300 strain of methicillin-
resistant S. aureus, TCH1516, was acquired from ATCC (BAA-1717). 
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4.2.2. Instrumentation   
1H NMR and 13C NMR spectra were recorded on a Varian Inova 300 spectrometer 
interfaced to a UNIX computer using VnmrJ software.  Chemical shifts were referenced 
to the solvent residual signals. 
FTIR spectra were recorded on an IR Prestige 21 system using a diamond ATR lens 
(Shimadzu Corp., Japan) and analyzed using IRsolution v. 1.40 software. 
The DMF gel permeation chromatography (GPC) was conducted on a Waters 
Chromatography, Inc. (Milford, MA) system equipped with an isocratic pump model 
1515, a differential refractometer model 2414, and a three-column set of Styragel HR 4 5 
μm DMF (300 × 7.5 mm), Styragel HR 4E 5 μm DMF (300 × 7.5 mm), and Styragel HR 
2 5 μm DMF (300 × 7.5 mm).  The system was equilibrated at 70 °C in pre-filtered DMF 
containing 0.05 M LiBr, which served as polymer solvent and eluent (flow rate set to 
1.00 mL/min).  Polymer solutions were prepared at a concentration of ca. 3 mg/mL and 
an injection volume of 200 μL was used.  Data collection and analysis were performed 
with Empower 2 v. 6.10.01.00 software (Waters, Inc.).  The system was calibrated with 
polystyrene standards (Polymer Laboratories, Amherst, MA) ranging from 615 to 
442,800 Da.   
Dynamic light scattering (DLS) measurements were conducted using a Delsa Nano C 
(Beckman Coulter, Inc., Fullerton, CA) instrument equipped with a laser diode operating 
at 658 nm.  Size measurements were made in nanopure water (n = 1.3329, η = 0.890 cP 
at 25 ± 1 °C).  Scattered light was detected at a 165° angle and analyzed using a log 
correlator over 70 accumulations for a 3.0 mL sample in a glass sizing cell (4.0 mL 
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capacity).  The photomultiplier aperture and the attenuator were automatically adjusted 
to obtain a photon counting rate of ca. 8 kcps.  Calculations of the particle size 
distribution and distribution averages were performed using CONTIN particle size 
distribution analysis routines.  The peak averages of histograms from number 
distributions out of 70 accumulations were reported as the average diameters of the 
particles.  The particle ζ-potential values were determined by a Delsa Nano C particle 
analyzer (Beckman Coulter, Fullerton, CA) equipped with a 30 mW dual laser diode 
(658 nm).  The ζ-potential of the particles in suspension was obtained by measuring the 
electrophoretic movement of charged particles under an applied electric field.  Scattered 
light was detected at a 15° angle at 25 °C.  The ζ-potential was measured at five regions 
in the flow cell, and a weighted mean was calculated.  These five measurements were 
used to correct for electro-osmotic flow that was induced in the cell due to the surface 
charge of the cell wall.  All determinations were repeated five times. 
Glass transition temperatures (Tg) were measured by differential scanning calorimetry 
on a Mettler-Toledo DSC822® (Mettler-Toledo, Inc., Columbus, OH), with a heating 
rate of 10 °C/min.  Measurements were analyzed using Mettler-Toledo Stare v. 7.01 
software.  The Tg was taken as the midpoint of the inflection tangent, upon the third 
heating scan.  Thermogravimetric analysis was performed under N2 atmosphere using a 
Mettler-Toledo model TGA/SDTA851e, with a heating rate of 10 °C /min.  
Measurements were analyzed by using Mettler-Toledo Stare v. 7.01 software. 
Transmission electron microscopy (TEM) images were collected on a JEOL 1200EX 
operating at 100 kV and micrographs were recorded at calibrated magnifications using a 
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SIA-15C CCD camera.  The samples as aqueous solutions (4 μL) were deposited onto 
carbon-coated copper grids, and after 1 min, the excess of the solution was quickly 
wicked away by a piece of filter paper.  A drop of 1 wt% uranyl acetate was then added, 
and allowed to stand for 30 seconds before excess stain was wicked away.  The grids 
were allowed to dry in air overnight.  High-resolution scanning transmission electron 
microscopy (STEM) and elemental mapping were conducted on a FEI Tecnai G2 F20 
FE-TEM coupled with energy-dispersive X-ray (EDX), operating at a voltage of 200 kV 
with a Gatan CCD camera.  
The atomic force microscopy (AFM) imaging was performed on a MFP-3D system 
(Asylum Research) in tapping mode using standard silicon tips (VISTAprobes, CSR-25, 
resonance constant: 28 kHz, tip radius: <10 nm, spring constant: 0.1 N/m).  For AFM 
sample preparation, nanoparticles were dissolved in nanopure water at 0.025 mg/mL, 
and 10 μL of the sample was spin-coated onto a mica surface and allowed to dry in air 
overnight. 
A B&W Tek iRaman system (785 nm, 300 mW max) was used to assess the 
polyphosphoester system upon association with silver.  Measurements were obtained 
through a 20x objective (PLL, Olympus) at 30 mW with 1 s integration averaged over 10 
spectra.  Relative populations for the species in the acetylide fingerprint region were 
assessed by peak deconvolution using Origin 9.0 Pro software package. 
The concentration of silver was measured by inductively coupled plasma-mass 
spectrometry (ICP-MS) on Perkin Elmer DRCII ICP-MS.  The element/mass detected 
was 107Ag and the internal standard used was 103Rh. 
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4.2.3. Experimental procedures 
Synthesis of EBP and BYP monomers.  2-(But-3-yn-1-yloxy)-2-oxo-1,3,2-
dioxaphospholane (BYP) and 2-(2-ethylbutoxy)-1,3,2-dioxaphospholane (EBP) were 
synthesized as previously described.61 
Synthesis of PEBP-b-PBYP diblock copolymer.  A solution of EBP (1.5 g, 7.2 
mmol) and benzyl alcohol (15.6 mg, 0.14 mmol) in 2.1 mL anhydrous dichloromethane 
was transferred via syringe into a flame-dried vial equipped with a stir bar and rubber 
septum, under N2, in an water/ice bath.  A solution of 1,5,7-triazabicyclo[4.4.0]dec-5-
ene (TBD) (40.2 mg, 0.29 mmol) in 0.3 mL anhydrous dichloromethane was injected 
quickly into the vial.  After being stirred for 2 min, another 2.4 mL of anhydrous 
dichloromethane was injected into the vial to dilute the reaction mixture, and the vial 
was transferred to a cooling bath composed of equal amounts of ice/water and sodium 
chloride at -10 °C.  Less than 0.1 mL of the reaction mixture was withdrawn and diluted 
with CDCl3 to determine the EBP conversion by 
31P NMR.  After stirring for another 2 
min, the reaction mixture was augmented with a solution of BYP (1.27 g, 7.2 mmol) in 
2.4 mL anhydrous dichloromethane via syringe.  The reaction was quenched by adding 
an excess amount of acetic acid dissolved in DCM after another 3 min, and an aliquot of 
the mixture was used to determine the conversion of BYP by 31P NMR.  The PEBP-b-
PBYP was purified by precipitation from acetone into a pentane/diethyl ether mixture 
(3:1 volume ratio) three times and then dried under vacuum.  .  1H NMR (300 MHz, 
CDCl3, ppm):  δ 0.89 (t, J = 7.2 Hz, POCH2CH(CH2CH3)2), 1.37 (m, 
POCH2CH(CH2CH3)2), 1.50 (m, POCH2CH), 2.11 (s, POCH2CH2C≡CH), 2.62 (m, 
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POCH2CH2C≡CH), 4.00 (m, POCH2CH), 4.12–4.39 (m, POCH2CH2OP, POCH2CH2), 
5.08 (d, J = 8.3 Hz OCH2Ar), 7.32–7.41 (m, Ar-H);  13C NMR (75 MHz, CDCl3, ppm):  
10.99, 20.69, 22.75, 41.55, 65.52-67.11, 70.08, 70.88, 79.59;  31P NMR (121 MHz, 
CDCl3, ppm):  δ -1.25, -1.81.  GPC:  Mn = 25200 g/mol, PDI = 1.25.  DSC:  Tg = -59°C, 
- 45 °C.  TGA in N2:  180-365 °C, 58% mass loss;  365–500 °C, 6.1% mass loss, 35% 
mass remaining above 500 °C.  IR (cm-1):  3700-3150, 3000-2800, 1645, 1464, 1379, 
1267, 1009, 966, 868, 806. 
Azide-alkyne Huisgen cycloaddition of PEBP-b-PBYP with ɑ-methoxy-ω-azido 
PEG (CH3O-PEG2k-azido).  In a typical experiment, a dried vial containing a magnetic 
stir bar was charged with PEBP-b-PBYP (0.83 g, 43 µmol, 1 eq.), ɑ-methoxy-ω-azido 
PEG (0.33 g, 0.17 mmol, 4 eq.), N,N,N′,N′,N′′-pentamethyldiethylenetriamine 
(PMDETA, 12 mg, 69 µmol, 1.6 eq.) and 7 mL of DMF.  The reaction mixture was 
degassed by several freeze-pump-thaw cycles (N>3), during which copper(I) bromide 
(4.9 mg, 34 mmol, 0.8 eq.) was added.  The flask was allowed to return to room 
temperature after the final cycle and stirred for another 4 h.  The solution was 
subsequently filtered through a neutral alumina column and dialyzed against Chelex 100 
resin in nanopure water in presoaked dialysis tubing (MWCO.ca. 6–8 kDa) for 2 d to 
remove copper ions, followed by lyophilization to yield white powder with a 70 % yield.  
Inductively coupled plasma-mass spectrometry (ICP-MS) confirmed that less than 10 
ppm of copper was present in the polymer.  1H NMR (300 Hz, CDCl3, ppm):  δ 0.90 (t, J 
= 7.5 Hz, POCH2CH(CH2CH3)2), 1.37 (m, POCH2CH(CH2CH3)2), 1.50 (m, POCH2CH), 
2.11 (s, POCH2CH2C≡CH), 2.56-2.65 (m, POCH2CH2C≡CH), 3.12 (m, NCH2CH2), 3.38 
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(s, OCH3), 3.64 (s, OCH2CH2), 4.00 (m, POCH2CH), 4.14-4.39 (m, POCH2CH2, 
POCH2CH2OP), 5.08 (d, J = 8.4 Hz, OCH2Ar), 7.31-7.41 (m, Ar-H), 7.60-7.66 (m, 
CH2CH2CCHNCH2).  
13C NMR (75 MHz, CDCl3, ppm):  δ 11.03, 20.72, 22.79, 41.60, 
65.52-67.15, 70.13, 70.68, 70.95, 79.72, 128.06, 128.73.  31P NMR (121 MHz, CDCl3, 
ppm): δ -0.99, -1.64.  GPC: Mn = 31300 g/mol, PDI = 1.26.  DSC:  Tg = - 52 °C; Tm = 42 
°C.  TGA in N2:  180–265 °C, 41% mass loss; 265–380 °C, 32% mass loss, 360–600 °C, 
1% mass loss, 26 % mass remaining above 600 °C.  IR (cm-1): 3800-3050, 3050-2700, 
1651, 1460, 1348, 1271, 1016, 964, 866, 803. 
Silver loading into micelles.  In a typical experiment, PEBP-b-PBYP-g-PEG (32.0 
mg, 1.0 eq.) was dissolved in 3.2 mL of nanopure water and sonicated for 3 min.  Silver 
acetate (9.0 mg, 46 eq.) in 2.0 mL of nanopure water was added, and the mixture 
solution was shaded with aluminum foils and stirred overnight.  The solution was 
transferred to a centrifugal filter device (100 kDa MWCO), and washed extensively for 
several cycles (N>3) with nanopure water to remove free small molecules.  The amount 
of silver loaded into the micelles was quantified by ICP-MS using rhodium as an internal 
standard. 
Release of silver from silver-loaded micelles.  The release profiles of the silver-
loaded micelles were studied by monitoring the decrease of silver concentration over 
time in dialysis cassettes by ICP-MS.  In a typical procedure, 3.0 mL of silver-loaded 
micelles was transferred into a presoaked dialysis cassette.  The cassette was allowed to 
stir in a beaker containing 3000 mL nanopure water or phosphate buffer (10 mM 
phosphate, 10 mM NaCl, pH 7.4) at 37 °C.  Aliquots (ca. 0.05 mL) were taken at pre-
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determined time and silver concentrations were determined by ICP-MS.  The release 
experiments were conducted in a triplicate manner. 
Determination of Minimum Inhibitory Concentrations (MICs) and Minimum 
Bactericidal Concentrations (MBCs).  The bacterial strains were streaked from frozen 
stocks onto tryptic soy agar (TSA) plates and incubated at 37°C for 24-48 h, depending 
on the growth rate of the strain.  Single colonies were then inoculated into Mueller 
Hinton broth (MHB) and incubated at 37 °C with 200 rpm shaking until they reached an 
optical density of 0.4 at 650 nm (OD650), corresponding to approximately 5 × 10
8 
CFU/mL.  The silver-loaded micelles and silver acetate were suspended/dissolved and 
diluted in molecular-grade water and added to a 96-well plate (100 µL/well).  The 
bacteria suspensions were diluted 1:500 in double-strength (2X) MHB and added 1:1 by 
volume to the diluted silver acetate or nanoparticles (105 CFU/well).  The plates were 
then sealed with gas-permeable membranes (Breathe-Easy®) and incubated for 18-24 h 
at 37 °C.  MICs were recorded as the lowest concentration of silver that yielded clear 
replicate wells.  To determine MBCs, 100 µL of the contents of each clear well was 
dispensed onto TSA plates supplemented with 5% sheep blood.  The plates were 
incubated 24-48 h at 37 °C, depending on the strain, and the MBCs were recorded as the 
lowest concentration of silver that yielded no growth.  MIC/MBCs were all performed 
three times and the results with the highest MIC or MBC amongst the replicates were 
reported. 
Cytotoxicity with AlamarBlue®.  16HBEs, provided by Dr. D. Gruenert (University 
of California, San Fransisco, CA), are a human bronchial epithelial cell line that were 
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transformed with SV40 large T-antigen using the replication-defective pSVori plasmid.  
16HBEs between passage 20 to 40 were cultured in Minimum Essential Medium with 
Earle's Balanced Salts with non-essential amino acids and supplemented with penicillin-
streptomycin (1%), l-glutamine (1%), and fetal bovine serum (10%).  Prior to 
cytotoxicity studies, the cells were lifted with trypsin, seeded in a 96-well plate (25,000 
cells/well), and incubated overnight at 37°C, 5% CO2, and 100% RH.  The silver-loaded 
micelles and silver acetate were suspended/dissolved and diluted in the same feeding 
media and added fresh to the cells.  After a 24 h incubation, the media with silver was 
removed and replaced with OPTI-MEM containing 10% AlamarBlue® (Life 
Technologies Inc.) and the plates were incubated for an additional 6 h.  To determine 
cytotoxicity, the plates were read with a plate-reading spectrophotometer (BMG 
Labtech) at 570 nm and 600 nm and cell viability was calculated according to 
manufacturer’s instructions.  IC50 values, based on molar concentration of silver, were 
calculated by generating a non-linear curve fit and interpolating the concentration 
yielding 50% inhibition (Graphpad Prism®).  Viability assays were performed three 
times and averaged.  Significant difference between the silver-loaded micelles and silver 
acetate was performed using non-parametric Student’s t-test (Graphpad Prism®). 
4.3 Results and discussion 
 The amphiphilic block terpolymer PEBP-b-PBYP-g-PEG was synthesized by 
utilizing click-type chemistries (Figure 4.1).61  Hydrophobic-functional AB diblock 
polyphosphoesters PEBP-b-PBYP were synthesized by one-pot sequential ring-
opening polymerizations (ROP) of hydrophobic monomer 2-ethylbutoxy 
    99 
phospholane (EBP) and alkyne-functionalized 2-butynyl phospholane (BYP) in 
dichloromethane, with benzyl alcohol as the initiator.  PEGylation was achieved via 
CuAAC of PEBP-b-PBYP by reaction with azido-terminated mPEG of 2 kDa 
molecular weight in N,N-dimethylformamide (DMF), followed by purification using 
Sephadex G-25 size exclusion chromatography and extensive dialysis against 
nanopure water to remove copper and other impurities.  The gel permeation 
chromatographic (GPC) analysis (Figure 4.2) demonstrated the successful chain 
extension from homopolymer PEBP, with a peak maximum retention time at 24.5 
min, to obtain the diblock copolymer PEBP-b-PBYP, having a peak maximum at 
22.7 min.  GPC also allowed for confirmation of grafting by PEG, with an 
observed >98% reduction in the intensity of the non-grafted PEG signal (25.6 min) 
and a shift of the grafted polymer product to shorter retention time (22.0 min) (Figure 
4.2). 
 
Figure 4.1.  Synthesis of PEBP-b-PBYP-g-PEG via sequential ring-opening 
polymerizations of EBP and BYP, followed by PEGylation via CuAAC 
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Figure 4.2.  GPC traces of PEBP homopolymer (black line, PDI = 1.20), PEBP-b-PBYP 
diblock copolymer (red line, PDI = 1.25) and PEBP-b-PBYP-g-PEG terpolymer (blue 
line, PDI = 1.26). 
 
 Due to the water-soluble polyphosphoester backbone and densely-grafted mPEG, 
the amphiphilic block terpolymers could be directly dissolved in nanopure water at 
concentrations up to 120 mg/mL after 3 min sonication, during which they 
spontaneously formed micellar nanoparticles (Figure 4.3).  These micelles were 
found to have a number-averaged hydrodynamic diameter of 11 ± 3 nm with 
monomodal size distribution and a low polymer dispersity of 0.25, as measured by 
dynamic light scattering (DLS) (Figure 4.4 a).  The circular images observed by 
transmission electron microscopy (TEM) suggested that these nanoparticles were 
spherical with uniform sizes of 35 ± 4 nm (Figure 4.4 c).  The significantly greater 
diameter by TEM vs. DLS also suggested that the particles deformed and flattened to 
a great extent upon deposition from solution and drying onto the carbon-coated 
copper grids for TEM imaging.  Atomic force microscopy (AFM) was, therefore,  
conducted, and found to give an average height value measured as 0.82 nm, 
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confirming that deformation occurred upon deposition onto a mica substrate (Figure. 
4.5 a, b).  The flattening phenomenon observed by TEM and AFM could be 
attributed to the intrinsic low glass transition temperature (-52 ºC) of the 
polyphosphoester backbone. 
 
 
Figure 4.3.  Schematic representation of micelle construction via self-assembly of the 
amphiphilic terpolymers in water, followed by loading with silver acetate (AgOAc). 
 
 Silver loading was subsequently performed after successful micellization, using 
silver acetate as the Ag+ source to avoid potential inflammatory response from 
AgNO3, which was used in the previous study (Figure 4.3).
193  The reaction mixture 
of micelles and silver acetate was stirred overnight to ensure maximum loading 
efficiency, followed by purification by passing through centrifugal filter devices 
(MWCO 100 kDa) several times (N>3) to remove unreacted silver acetate.  The 
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actual loading was measured by inductively coupled plasma mass spectrometry (ICP-
MS), using Rh as an internal standard.  Different Ag feeding ratios were tested to 
optimize conditions with appropriate loading efficiency and loading amount (Figure 
4.6).  At feeding ratios below 1 (Ag+ : alkyne), the loading amount increased 
approximately linearly, with only a slight drop in the loading efficiency, indicating 
reliability of the chemistry.  A higher amount of silver loading was achieved with a 
maximum 15% loading (w/w), though much lower loading efficiency was observed 
as the feeding ratio continued to rise above 1.  The feeding ratio of 1 was chosen for 
further characterization and biological evaluation, as it provided a good balance 
between loading amount and efficiency. 
 
 
Figure 4.4.  Characterization of nanoparticles.  DLS histograms of intensity-averaged 
(Dh(intensity)), volume-averaged (Dh(volume)), number-averaged (Dh(number)) 
hydrodynamic diameters of (a) micelles, and (b) Ag-loaded micelles.  Bright-field TEM 
images of (c) micelles, stained by uranyl acetate, and (d) Ag-loaded micelles.  Dark-field 
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STEM image (e), and elemental mapping (f) of Ag-loaded micelles.  The silver-loaded 
micelles were not stained in all samples. 
Figure 4.5.  (a) Tapping mode AFM height image of empty micelles, and (b) height 
profile along the red line drawn in (a), (c) Tapping mode AFM height image of silver-
loaded nanoparticles and (d) height profile along the red line drawn in (c). 
The sizes and size distributions of these Ag-loaded micelles were also 
characterized by DLS and TEM.  These data suggest that silver loading had minimal 
effect on the number-averaged hydrodynamic diameter of the micelles, with an 
average diameter remaining at ca. 11 nm.  No staining of the Ag-loaded micelles is 
needed, since Ag is of high atomic number, which provides sufficient image contrast. 
Both bright-field TEM and high-angle annular dark-field imaging in the scanning 
TEM mode (HAADF-STEM) confirmed that well-defined silver-loaded nanoparticles 
were prepared, with relatively uniform dry-state substrate-adsorbed diameters of ca. 
30 nm (Figure  4.4 d, e).  As observed for the non-loaded micelles, comparisons of 
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TEM and AFM images indicated that these silver-loaded nanoparticles underwent 
severe deformation upon deposition and drying, giving AFM-measured height and 
diameter values of ca. 1.0 nm and ca. 30 nm, respectively, on a mica substrate 
(Figure 4.5 c, d).  Elemental mapping was performed on the Ag-loaded nanoparticles 
using an energy-dispersive X-ray spectroscopy (EDS) detector in the STEM mode.  
The co-localization of silver, oxygen and phosphorous further demonstrated that 
silver was loaded into the polymeric matrix (Figure 4.4 f). 
 
 
Figure 4.6.  Optimization of loading efficiency (left, blue line) and loading amount 
(right, black hashed bars).  The experiment was done in triplicate. 
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Figure 4.7.  Raman spectroscopy of PEBP-b-PBYP (blue line), PEBP-b-PBYP-g-PEG 
(green line), and Ag-loaded micelles (PEBP-b-PBYP-Ag-g-PEG, feeding ratio = 1, red 
line). 
 
 The 1:1 silver-incubated sample was assessed by Raman spectroscopy to determine 
the extent and nature of silver-yne interactions (Fig. 5).  Both the block copolymer 
PEBP-b-PBYP and block terpolymer PEBP-b-PBYP-g-PEG displayed only one peak 
in the region of 1900-2300 cm-1, corresponding to the terminal alkyne groups present 
as side chain functionalities along one block of the polymer backbone.198  In the case 
of silver-loaded nanoparticles, two additional peaks at 1982 and 2209 cm -1 were 
observed and were assigned to silver acetylide and Ag-alkyne complex, 
respectively.198,202,203  An integrated signal intensity assessment of the number of 
subunits in each state, presuming comparable scattering cross-sections for each 
species, was performed, and revealed that ca. half of the alkyne functionalities were 
covalently bound to silver, with a third π-associated to silver, and that the remainder 
did not react. 
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Figure 4.8.  Release of Ag that was loaded into micelles at 37 ºC in nanopure water 
(black line) and 10 mM phosphate buffer with 10 mM NaCl, as measured by ICP-MS of 
aliquots collected from the cassettes over five days. 
 
 Release of silver from the nanoparticles was evaluated by monitoring the decrease 
of silver concentration inside dialysis cassettes at 37 ºC, analysed by ICP-MS (Fig. 6).  
It was found that silver was released in a sustained and controlled manner in 
nanopure water, with a release half-life t1/2 of 28 h.  The release was also conducted 
in 10 mM phosphate buffer containing 10 mM NaCl, to mimic the in vivo 
environment in patients with lung infection.  As expected, the presence of NaCl 
significantly accelerated silver release due to the formation of AgCl, where the t1/2 
decreased from 28 h to 16 h.  The sustained and controlled release of therapeutics 
may improve efficacy and reduce side effects.  In addition, slow release kinetics 
allow a lower dosing frequency, which offers convenience to enhance patient 
adherence, as well as potential cost reduction.  Furthermore, the silver-loaded 
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nanoparticles were stable in PBS for more than 2 days without visible precipitation, 
thus displaying the superior stability needed for in vitro and in vivo applications. 
 
Table 4.1.  MICs and MBCs of silver acetate and the silver-loaded micelles against 
cystic fibrosis pathogens.  The MIC/MBCs were performed three times and the 
values reported represent the highest MIC/MBCs amongst the replicates.  
Concentration of silver-loaded micelles based on mass of silver. 
Strains 
MIC (µg/mL) MBC (µg/mL) 
AgOAc Ag-NP AgOAc Ag-NP 
P. aeruginosa 
   PAO1 8 4 16 16 
   PAM57-15 8 4 16 16 
   PAHP3 8 4 16 16 
S. aureus 
   TCH1516 32 16 >256 >256 
   SALL06 32 16 >256 >256 
   SAEH05 16 8 64 16 
Burkholderia 
sp. 
   BG80 8 4 8 8 
   BM54 8 4 16 8 
 
 The antimicrobial potency of the silver-loaded nanoparticles was examined by 
broth micro dilution to determine the minimum inhibitory concentrations (MICs) and 
minimum bactericidal concentrations (MBCs) against cystic fibrosis-associated 
pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia sp. 
(Table 4.1).  Strains tested included a laboratory strain of P. aeruginosa (PAO1), 
USA300 S. aureus (TCH1516), and strains isolated from cystic fibrosis patients 
(PAM57-15, PAHP3, SALL06, SAEH05, BG80, and BM54).  The MICs and MBCs 
of the silver nanoparticles were compared with silver acetate and generally showed 
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enhanced antimicrobial potency against these pathogens, with a reduction of MICs 
by 50% and similar MBCs.  P. aeruginosa and Burkholderia sp. were more 
susceptible to silver than S. aureus, which was resistant to complete killing by silver 
in the case of TCH1516 and SALL06.  The silver-loaded nanoparticles did show a 
remarkably higher potency against S. aureus strain SAEH05, which was not resistant 
to killing by silver.  The increased antibacterial activities of silver-loaded 
nanoparticles over silver acetate might be ascribed to their increased stability in the 
aqueous environment and possibly superior association and/or uptake by the 
bacteria.204  Furthermore, the silver-loaded nanoparticles displayed decreased 
toxicity compared with silver acetate, towards a cell line derived from human 
bronchial epithelial cells (16HBE), though it was not significantly different, as 
determined by nonparametric Student’s t-test (Fig. S3).  The increased antibacterial 
activities and decreased cytotoxicities towards human healthy cells demonstrated the 
advantages of using nanosized delivery systems for silver-based therapeutics in vitro, 
and suggest their great potential in vivo. 
4.4 Conclusions 
 In summary, we have developed novel biocompatible and degradable 
polyphosphoester-based polymeric nanoparticles, which are capable of carrying 
silver cations via formation of silver acetylides with different coordination 
geometries, towards the treatment of lung infections associated with cystic fibrosis.  
The amphiphilic block terpolymer PEBP-b-PBYP-g-PEG was synthesized by “click-
type” reactions, which are rapid, reliable and scalable.  The amount of silver loaded 
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into the micelles was quantified by inductively coupled plasma-mass spectrometry 
(ICP-MS) using rhodium as an internal standard.  It was found that up to 15% (w/w) 
loading could be achieved, consuming most of the pendant alkyne groups along the 
backbone.  Raman spectroscopy of Ag-loaded micelles revealed that silver was 
loaded into the nanoparticles mainly by two coordination geometries at a molar feed 
ratio of 1:1 (alkyne : silver acetate).  A combination of DLS, TEM and AFM 
indicated that the nanoscopic polymer assemblies were well-defined, having a 
hydrodynamic diameter of ca. 11 nm, and that they underwent significant flattening 
upon adsorption onto substrates.  The co-localization of silver, oxygen and 
phosphorous, visualized by EDS elemental mapping, further confirmed that silver 
was loaded into the polymeric matrices.  It was found that silver was released in a 
sustained and controlled manner over 5 days, with release half-life values of 28 h in 
nanopure water and 16 h in 10 mM phosphate buffer containing 10 mM NaCl.  The 
superior stability of silver cations when loaded into the micelles has the potential to 
avoid the inactivation by anions and other biological compounds in the human body.  
Furthermore, these silver-loaded nanoparticles were measured to have higher 
antimicrobial activities with much lower MICs and similar MBCs against a series of 
cystic fibrosis pathogens and lower toxicities to human bronchial epithelial cells in 
vitro, as compared to the free drug (silver acetate), demonstrating advantageous 
features of this nanoscopic silver delivery platform.  Evaluation of these silver-
loaded nanoparticles as antimicrobial agents for lung infections  in vivo, as well as 
determination of their in vitro and in vivo degradation profiles, are currently under 
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investigation. 
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CHAPTER V 
 CONCLUSIONS 
 
Polymeric micelles are one of the most promising nanoscopic drug delivery platforms 
for the treatment of a wide range of diseases, including cancer and infectious diseases.  
Their characteristic core-shell morphology makes them especially suitable for packaging 
and protection of hydrophobic drugs in the core, while the hydrophilic shells provide 
water solubility and functionality for modifications, such as crosslinking, attachment of 
imaging agents and targeting ligands.  The incorporation of crosslinks within the shells 
of polymeric micelles, to produce shell crosslinked knedel-like nanoparticles (SCKs), 
has been shown to provide for enhanced structural stability, better control with 
therapeutics release and alteration of their biological properties, while retaining the 
tunability of size and shape, and enhancing the ability to perform chemical modifications 
throughout the shell of the nanosized scaffold.  In this dissertation, polymeric 
nanoparticles were designed and synthesized for the delivery of various therapeutic 
agents, including cisplatin & PTX for cancer therapy, and silver-based small molecules 
& other antibiotics for pulmonary infections, with a special attention on the effects of 
crosslinking on their in vitro and in vivo performance. 
We first demonstrated the feasibility of incorporating CDDP into the shells of 
micelles and SCKs, which were self-assembled from non-degradable poly(acrylic acid)-
b-polystyrene as a model system, by forming polymer-metal complexes.  The drug 
loading decreased upon increasing the degree of crosslinking, with the micelles having 
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the highest drug loading percentage (48%, w/w).  Nanosized particles with unimodal 
size distribution and low polydispersity indices were observed in all cases.  The 
nanoparticles imparted significant physical stability to the incorporated drug and allowed 
control over its release from the polymeric particles.  These CDDP-loaded nanoparticles 
exhibited cell-killing abilities in vitro that are comparable with reported micellar 
formulations.  Crosslinking of polymeric micelles is often considered beneficial for 
improving stability against dilution.  Here, Pt provides complexation-based crosslinks, 
and additional covalent crosslinks diminish sites for Pt complexation, giving lower 
cisplatin loading.  Although cytotoxicity increased with covalent crosslinking, the lower 
drug loading counterbalanced the overall effect.  In addition, upon incubating the 
micellar and crosslinked nanoparticles with the mouse macrophages, the crosslinked 
nanoparticles resulted in higher in vitro immunotoxicity.  Therefore, any covalent 
crosslinking within future nanoparticle designs should be incorporated into an alternate 
region within the nanoparticle framework, to avoid consuming functionalities required 
for the drug complexation.  Recently, we learnt the lessons above, and designed 
nanoscopic delivery vehicles comprised of degradable polyphosphoester-based 
polymers, where cisplatin was loaded into the core of these nanoparticles without 
additional covalent crosslinking (Appendix A). 
Nanomaterials have great potential to offer effective treatment against devastating 
diseases by providing sustained release of high concentrations of therapeutic agents 
locally, especially when the route of administration allows for direct access to the 
diseased tissues.  In Chapter III, we further investigated the effects of crosslinking of 
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polymeric micelles on their in vitro and in vivo performance, exploiting the 
biodegradable polyphosphoester-based polymeric micelles and SCKs, each derived from 
amphiphilic block-graft terpolymers, poly(2-ethylbutoxy phospholane)-block-poly(2-
butynyl phospholane)-graft-poly(ethylene glycol) (PEBP-b-PBYP-g-PEG).  It was found 
that high concentrations of PTX could be loaded into both micelles and SCKs, with well-
defined morphology and uniform sizes.  Encapsulation of 10 wt% PTX, into either 
micelles or SCKs, allowed for aqueous suspension of PTX at concentrations up to 4.8 
mg/mL, as compared to < 2.0 µg/mL for the aqueous solubility of the drug alone.  Drug 
release studies indicated that PTX release from these nanostructures was defined through 
a structure-function relationship, whereby the half-life of sustained PTX release was 
doubled through crosslinking of the micellar structure to form SCKs.  These results 
demonstrated that crosslinking was capable of mediating PTX release by forming an 
additional physicochemical layer through the shell, the tuning of which could be utilized 
to further adjust the performance of these nanoscopic containers.  Residual alkynyl 
groups along the backbones were modified by attaching the NIR dye IR800CW, 
enabling their use for in vitro, in vivo and ex vivo imaging-based studies.   
We further investigated the in vitro and in vivo characteristics of both micelles and 
SCKs.  In vitro, these micellar formulations had comparable cytotoxicities with the 
commercially available Taxol® mimicking formulation, further validating them as 
excellent candidates for translational studies.  In vivo evaluation of the pharmacokinetics 
and biodistribution, following intratracheal delivery, revealed that crosslinking had the 
ability to control the rate of nanoparticle extravasation from the lungs.  SCKs were 
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observed to be retained for almost twice the time of their micellar equivalents, ca. 8 days 
vs. 4 days respectively.  These extravasation timelines appear to be reasonable for 
translational development when considering the repeating dosing schedules already in 
place for PTX chemotherapeutics.  Interestingly, we have shown that the structure-
function relationship of nanomaterials not only affects in vitro outcomes, but also has 
implications on in vivo performance and pharmacokinetics following intratracheal 
delivery to the lungs.  More recently, we further optimized the formulation by PTX dual 
loading, where PTX was both chemically conjugated and physically loaded.  The dual- 
loaded formulation could achieve a >15 mg/mL PTX total concentration in water 
(Appendix B). 
In Chapter IV, we extended our degradable polyphosphoester-based nanoparticles, 
constructed from PEBP-b-PBYP-g-PEG, to deliver silver cations for the treatment of 
pulmonary infections.  Silver cations were loaded to polymeric micelles via formation of 
silver acetylides with different coordination geometries.  The amount of silver loaded 
into the micelles was quantified by inductively coupled plasma-mass spectrometry (ICP-
MS) using rhodium as an internal standard.  These systems displayed up to 15% (w/w) 
silver loading, consuming most of the pendant alkyne groups along the backbone.  
Raman spectroscopy of Ag-loaded micelles revealed that silver was loaded into the 
nanoparticles mainly by two coordination geometries at a molar feed ratio of 1:1 (alkyne 
: silver acetate).  A combination of DLS, TEM and AFM characterization indicated that 
the nanoscopic polymer assemblies were well-defined, having a hydrodynamic diameter 
of ca. 11 nm, and that they underwent significant flattening upon adsorption onto 
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substrates.  The co-localization of silver, oxygen and phosphorous, visualized by EDS 
elemental mapping, further confirmed the silver loading into the polymeric matrices.  
Silver-loaded nanoparticles was found to release their payload in a sustained and 
controlled manner over 5 days, with release half-life values of 28 h in nanopure water 
and 16 h in 10 mM phosphate buffer containing 10 mM NaCl.  The superior stability of 
silver cations when loaded into the micelles has the potential to avoid the inactivation by 
anions and other biological compounds in the human body.  Furthermore, these silver-
loaded nanoparticles were measured to have higher antimicrobial activities against a 
series of cystic fibrosis pathogens and lower toxicities to human bronchial epithelial 
cells in vitro, as compared to the free drug (silver acetate), demonstrating advantageous 
features of this nanoscopic silver delivery platform.  Evaluation of these silver-loaded 
nanoparticles as antimicrobial agents for lung infections in vivo in mice is currently 
under investigation.  Combination delivery of silver and other antibiotics is also 
currently under investigation (Appendix C). 
In summary, nanoscale drug delivery is a relative new, but fast growing field, which 
holds great promise for increased efficacy and reduced side effects of the incorporated 
therapeutic agents.  In this dissertation, we have successfully loaded either hydrophilic 
drugs, such as silver cations and cisplatin, or hydrophobic paclitaxel into well-defined 
nanoparticles towards different lung diseases.  These drugs were either physically 
entrapped or chemically conjugated to the nanocarriers.  We have tested these 
formulations in vitro against relevant cancer cells or bacteria, and probed the in vivo 
biodistribution of the non-loaded nanoparticles in healthy animals to understand their 
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trafficking behaviors.  However, some key issues remain to be investigated, for example 
the in vivo efficacy of the drug-loaded formulations, the relationships between in vitro 
vs. in vivo rates of degradation of the particles and release of their payloads, the 
independent trafficking globally and at the cellular level in diseased vs. healthy tissues, 
and the behaviors for each of the drug and carrier components, whether intact or in a 
fragmented form.  Clearly, there is much chemistry and biology remaining to be 
understood, with this work being an important first step, providing initial information on 
the in vivo fate of polyphosphoester-based degradable nanoparticles. 
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APPENDIX A 
CORE-CROSSLINKED DEGRADABLE POLYPHOSPHOESTER-BASED 
MICELLES FOR CISPLATIN DELIVERY* 
 
In Chapter II, the cisplatin was incorporated into the shell of non-degradable 
polymeric micelles via the formation of polymer-metal complexes with high drug 
loading.  We found that increased shell crosslinking led to decreased cisplatin loading, 
and increased immunotoxicities due to the incomplete crosslinking by amidation 
chemistry.  In this study, we designed and synthesized nanoscopic delivery vehicles, 
comprised of degradable polyphosphoester-based polymers.  The core of these 
nanoparticles was loaded with cisplatin without additional covalent crosslinking. 
The block copolymer PEG-b-PBYPA was synthesized via “click-type” reactions as 
illustrated in Figure A1.  Briefly, poly(ethylene glycol)-b-poly(2-butynyl phospholane) 
(PEG-PBYP) was synthesized by ring-opening polymerization of butynyl phospholane 
(BYP), with PEG (Mn ~ 2000 Da) as the initiator and 1,8-diazabicycloundec-7-ene 
(DBU) as the catalyst.  Within 4 min, a well-defined block copolymer was obtained with 
relatively low polydispersity index of 1.12, as determined by gel permeation 
chromatography (GPC).  Subsequently, the pendant alkynes along the PBYP block were 
completely transformed into carboxyl acid groups by copper(I)-catalyzed azide-alkyne 
                                                 
* In collaboration with Sarosh Khan, Richen Li, Shiyi Zhang, Mahmoud Elsabahy, Karen L. 
Wooley, Department of Chemistry, Texas A&M University. 
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cycloaddition (CuAAC) in dimethylformamide (DMF).  The polymer was purified by 
dialysis against nanopure water containing Chelex 100 resin for three days, to remove 
copper and other potential contaminants.  A white powder was obtained after 
lyophilization. 
 
 
 
Figure A1.  Synthesis of PEG-b-PBYPA copolymer via ring-opening polymerization, 
followed by addition of 2-azidoacetic acid by click chemistry.  Cisplatin induced the 
formation of nanoparticle by forming polymer-metal complex. 
 
Cisplatin loading was then performed by incubating the PEG-b-PBYPA and cisplatin 
in water for three days.  The coordination bonds between chloride ligands and platinum 
were labile, and underwent ligand substitution reactions with the pendant carboxylates 
from the polymer.  Since cisplatin has two chloride ligands for substitution, it can 
crosslink two polymer chains or form an intramolecular loop, leading to decreased water 
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solubility.  The crosslinking of the two polymer chains, together with their decreased 
water solubility, induced the formation of core-crosslinked micelles.  As reported in 
CHAPTER II, the platinum concentration was quantified by inductively coupled plasma 
mass spectrometry (ICP-MS).  The amount of cisplatin loaded into the nanoparticles was 
found to increase, with the increasing feed ratio of cisplatin over polymer, but with 
lower loading efficiencies. 
 
 
Figure A2.  Characterization of Pt-loaded nanoparticles.  (A) DLS histograms of 
intensity-averaged (Dh(intensity)), volume-averaged (Dh(volume)), number-averaged 
(Dh(number)) hydrodynamic diameters; (B) bright-field TEM; (C) dark-field STEM; (D) 
EDS elemental mapping. 
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The cisplatin-loaded nanoparticles were characterized by dynamic light scattering 
(DLS), transmission electron microscopy (TEM), scanning TEM (STEM), and energy-
dispersive X-ray spectroscopy (EDS) elemental mapping (Figure A2).  These 
nanoparticles were shown to have a number-averaged hydrodynamic diameter of 67 nm 
with a narrow polydispersity index of 0.236, as measured by DLS (Figure A2, A).  
Samples for TEM were not stained, since Pt itself provided enough contrast for imaging.  
The platinum core was measured to have a diameter of ca. 35 nm by TEM (Figure A2-
B).  The co-localization of platinum and phosphorous demonstrated that platinum was 
loaded into the polymeric matrix (Figure A2, C, D). 
 Moreover, platinum was released in a controlled and sustained manner over 7 days, 
whereas ca. 95% platinum was released in 2 h for cisplatin placed in dialysis cassettes.   
In summary, this work demonstrated cisplatin could be loaded into the core of 
polyphosphoester-based degradable nanoparticles, as an extension of the research in 
Chapter II.  In addition, the in vitro cytotoxicities of Pt-loaded nanoparticles and their 
hydrolytic and enzymatic degradations are under investigation. 
Experimental procedures 
Synthesis of PEG-b-PBYP.  In a typical experiment, a solution of poly(ethylene 
glycol) methyl ether (mPEG45, 195 mg, 0.098 mmol, 1.0 eq) in 0.3 mL of anhydrous 
dichloromethane and a solution of butynyl phospholane (BYP, 515 mg, 2.93 mmol, 30 
eq) in 0.2 mL of anhydrous dichloromethane were transferred into a flame-dried 5 mL 
vial equipped with a rubber stopper and a stir bar.  At room temperature, a solution of 
1,8-diazabicycloundec-7-ene (DBU, 31 mg, 0.20 mmol, 2.0 eq) in 0.2 mL of anhydrous 
    139 
dichloromethane was injected into the vial under a nitrogen gas atmosphere.  After 4 
min, a solution of excessive acetic acid in dichloromethane was added into reaction 
mixture to quench the reaction.  The monomer conversion was measured to be 86% by 
31P NMR.  The PEG-b-PBEP was purified by precipitation into anhydrous diethyl ether 
three times and dried under vacuum, with a yield of 83%.  1H NMR (CDCl3, ppm): δ 
2.05-2.15 (br, POCH2CH2C≡CH), 2.55-2.67 (m, POCH2CH2C≡CH), 3.41 (s, 
CH2CH2OCH3), 3.67 (s, CH2OCH2CH2OCH2), 4.25-4.28 (m, POCH2CH2C), 4.29-4.41 
(POCH2CH2OP).  
13C NMR (CDCl3, ppm):  20.8, 65.9, 66.6, 70.7, 71.0, 79.7.  
31P NMR 
(CDCl3, ppm ): δ -1.61.  GPC:  Mn = 15900 g/mol, PDI = 1.12.  DSC:  Tg = -39 °C.  
TGA in N2:  170-278 °C, 37% mass loss; 278–310 °C, 34% mass loss; 310–500 °C, 4% 
mass loss; 25% mass remaining above 500 °C.  IR (cm-1):  3700-3080, 3080-2600, 1648, 
1460, 1342, 1274, 1009, 956, 843, 802. 
Synthesis of anionic polymer.  In a 10-mL Schlenk flask equipped with a magnetic 
stir bar, PEBP-b-PBYP (200.0 mg, 0.029 mmol), 2-azidoacetic acid (96 mg, 0.95 mmol), 
and PMDETA (55 mg, 0.32 mmol) were added and dissolved in DMF (4 mL).  The 
reaction mixture was deoxygenated by freeze-pump-thaw (3x), during which copper(I) 
bromide (23 mg, 0.16 mmol) was added.  The flask was allowed to return to room 
temperature after the final cycle and stir overnight.  The resulting mixture was dissolved 
in nanopure water and purified by dialysis against nanopure water for 2 days with 
Chelex resin.  The polymer solution was lyophilized to give a white powder.  1H NMR 
(D2O, ppm): δ 3.04-3.20 (br, POCH2CH2C=CH), 3.39 (s, CH2CH2OCH3), 3.71 (s, 
CH2OCH2CH2OCH2), 4.11-4.45 (m, POCH2CH2C, POCH2CH2OP), 4.96-5.03 (br, 
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NCH2COOH), 7.78-7.87 (br, POCH2CH2C=CHN ).  
13C NMR (CDCl3, ppm ):  25.9, 
45.0, 66.9, 67.3, 69.5, 124.6, 125.3, 165.0.  31P NMR (CDCl3, ppm ): δ -1.70.  DSC:  Tg 
= -53 °C, Tm = -38 °C.  TGA in N2:  160-310 °C, 23% mass loss; 310–420 °C, 28% mass 
loss; 420–500 °C, 4% mass loss, 45% mass remaining above 500 °C.  IR (cm-1):  3700-
3030, 3030-2650, 1615, 1465, 1389, 1341, 1249, 1102, 1059, 1013, 979, 961, 956, 842, 
808. 
Cisplatin loading.  In a typical experiment, to a vial containing a magnetic stir bar and 
polymer solution (10 mg/mL in water, pH was adjusted to 5.5), a solution of cisplatin 
(0.5 mg/mL in water, 0.5 molar ratio with respect to the carboxylate groups) was added 
dropwise.  The solution was stirred for three days and then dialyzed against nanopure 
water at room temperature for 36 h to remove free cisplatin.  The purified Pt-loaded 
nanoparticles were lyophilized to obtain white powder and stored in freezer for further 
use.  Dynamic light scattering (DLS), transmission electron microscopy and inductively 
coupled plasma mass spectrometry (ICP-MS) were used to measure the particle 
dimensions and platinum concentrations, respectively. 
Platinum release.  In a typical procedure, a solution of CDDP-loaded nanoparticles 
or CDDP (1.0 mL) was transferred into a presoaked dialysis cassette (Slide-A-Lyzer, 10 
kDa MWCO, Pierce Biotechnology, Rockford IL).  The cassette was allowed to stir in a 
beaker containing PBS (180 mL, 10 mM phosphate, 137 mM NaCl, pH 7.4 at 37 °C), 
and 1 mL of samples were collected from the dialysate at pre-determined times and 
analyzed by ICP-MS, with fresh PBS (2 mL) added back into the beaker.  The release 
experiments were conducted in a triplicate manner. 
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APPENDIX B 
DESIGN AND DEVELOPMENT OF MULTIFUNCTIONAL 
POLYPHOSPHOESTER-BASED NANOPARTICLES FOR ULTRAHIGH 
PACLITAXEL DUAL LOADING* 
 
In Chapter III, paclitaxel (PTX) was physically loaded into the PEBP-b-PBYP-g-PEG 
micelles, which were highly water-soluble and stable in aqueous solution.  The micelles 
were able to be cleared from the lung relatively fast with a t1/2 of 4 days, though they 
degraded very slowly in vitro.  In this study, we designed and synthesized nanoscopic 
multifunctional polyphosphoester-based nanoparticles for ultrahigh paclitaxel dual 
loading, where PTX was both chemically conjugated and physically loaded.  The PTX 
conjugates could be dissolved in nanopure water with a solubility as high as 110 mg/mL, 
 
 
Figure B1.  Overall design of multifunctional polyphosphoester-based nanoparticles for 
ultrahigh paclitaxel dual loading. 
                                                 
* In collaboration with Sarosh Khan, Richen Li, Ashlee Jahnke, Mahmoud Elsabahy, Karen L. 
Wooley, Department of Chemistry, Texas A&M University. 
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 corresponding to a PTX concentration of 25 mg/mL (PTX loading: 23.0 wt%); whereas 
dual loaded micelles could dissolve in nanopure water with a solubility of 50 mg/mL, 
where 10 wt% was physically loaded PTX and 21 wt% was chemically conjugated PTX. 
 
 
Figure B2.  Characterization of nanoparticles.  DLS histograms of (A) PTX-conjugated 
micelles, and (B) PTX dual loaded micelles; TEM images of (C) PTX-conjugated 
micelles, and (D) PTX dual loaded micelles.  Samples were negatively stained by uranyl 
acetate. 
 
 The sizes and size distributions of PTX-conjugated micelles and PTX dual loaded 
micelles were characterized by dynamic light scattering (DLS) and transmission electron 
microscopy (TEM) (Figure B2).  The PTX-conjugated micelles were measured to have a 
number-averaged hydrodynamic diameter (Dh(number))of 8 nm, with polydispersity 
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index of 0.329, as measured by DLS (Figure B2, A).  PTX dual loaded micelles 
displayed a Dh(number) of 9 nm, with slightly lower polydispersity index of 0.267 
(Figure B2, B).  By TEM, PTX-conjugated micelles were determined to have dry-state 
diameter of 18 nm, compared to 25 nm of that of PTX dual loaded micelles, both of 
which had relatively uniform sizes (Figure B2, C, D).  
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Figure B3.  In vitro cell viability data in OVCAR-3 with Taxol (IC50 = 0.0044 µM), 
PTX physical loading (IC50 = 0.0045 µM), PTX chemical conjugation (IC50 = 0.46 µM), 
and PTX dual loading (IC50 = 0.0040 µM, calculated based on the concentration of 
physically-loaded PTX). 
 
 The cytotoxicities of these nanoparticles were studied against OVCAR-3 cancer cell 
lines (Figure B3).  PTX-conjugates were found to be much less cytotoxic compared to 
Taxol, while PTX physically-loaded and PTX dual loaded micelles demonstrated similar 
cytotoxicities to Taxol.  The lower cytotoxicity of PTX-conjugates was partly due to the 
relative stable linkages, where nearly no drugs were released in PBS in several days. 
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Figure B4.  Confocal microscopy images demonstrating cellular internalization of PTX-
conjugated micelles (A-C) and PTX dual loaded-micelles (D-F) in RAW 264.7 cells.  
Green = Alexa Fluor 488 (dye-labelled nanoparticle) and blue = DRAQ5 (nuclear stain).  
Images to the right overlay fluorescence on the DIC. 
 
To investigate the cell internalization of PTX chemically conjugated and PTX dual 
loaded nanoparticles, an Alexa Fluor 488 azide was conjugated to the polymer pendant 
residual alkynes via CuAAC in nanopure water.  Both fluorescein-labeled nanoparticles 
were readily internalized, after incubation with RAW 264.7 mouse macrophages for 2 
hours (Figure B4). 
In summary, nanoscopic multifunctional polyphosphoester-based nanoparticles were 
prepared, where PTX was both chemically conjugated and physically loaded.  These 
nanoparticles were cytotoxic against cancer cells, and could be easily modified with 
functional moieties, herein, a fluorescent dye as an example.   
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Experimental procedures 
Synthesis of PEBP-b-PBYP-g-PEG/PTX.  In a 10-mL Schlenk flask equipped with a 
magnetic stir bar, PEBP-b-PBYP-g-PEG (300.0 mg, 0.0110 mmol), azido-PTX (109.1 
mg, 0.110 mmol), and PMDETA (19.0 mg, 0.0110 mmol) were added and dissolved in 
DMF (6 mL).  The reaction mixture was deoxygenated by freeze-pump-thaw (3x), 
during which copper(I) bromide (7.9 mg, 0.0550 mmol) was added.  The flask was 
allowed to return to room temperature after the final cycle and stir overnight in a 
preheated reaction bath at 37 oC.  The resulting mixture was precipitated from acetone 
into ethyl ether (3x) to remove unreacted azido-PTX.  The crude product was collected 
and dissolved in 5 mL nanopure water and purified by Sephadex G-25 column to remove 
copper ions.  The solution was transferred to dialysis tubing (MWCO: 12-14 kDa) and 
dialyzed against nanopure water for 2 days.  The micelle solution was then lyophilized to 
give a white powder (271.3 mg, 66.3 %).  1H NMR (CDCl3, ppm):  δ 0.89 (t, J = 7.4 Hz, 
POCH2CH(CH2CH3)2), 1.08-1.31 (broad multiple peaks, protons from PTX), 1.37 (m, 
POCH2CH(CH2CH3)2), 1.52 (m, POCH2CH), 1.56-2.80 (broad multiple peaks, protons 
from PTX, POCH2CH2C≡CH), POCH2CH2C≡CH), 3.00-3.18 (brs, NCH2CH2), 3.38 (s, 
OCH3), 3.64 (s, OCH2CH2 from PEG), 3.78 (m, CH from PTX(C-3)-CH), 3.96-4.02 (t, J 
= 5.5 Hz, POCH2CH), 4.02-4.56 (br, POCH2CH2, POCH2CH2OP, and protons from 
PTX), 4.90-5.00 (br, CH from PTX(C-5)-CH), 5.07 (d, J = 8.0 Hz, OCH2Ar), 5.48 (br, 
CH from PTX(C-2’)-CH), 5.65 (br, CH from PTX(C-2)-CH), 5.90 (br, CH from PTX(C-
3’)-CH), 6.15 (br, CH from PTX(C-13)-CH), 6.30 (br, CH from PTX(C-10)-CH), 7.28-
7.70 (broad multiple peaks, PhH from PTX, CH2CH2CCHNCH2), 7.75 (br, PhH from 
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PTX), 8.11 (br, PhH from PTX).  13C NMR (CDCl3, ppm): δ 9.9, 11.1, 15.0, 20.8, 21.1, 
21.53, 22.2, 22.9, 24.2, 25.8, 26.9, 27.2, 29.9, 33.5, 35.6, 36.0,41.9, 43.4, 45.2,46.0, 
50.0, 50.3, 53.5, 58.6,59.3, 65.8-67.3 (multiple overlapping br), 70.2, 70.8, 71.5-72.5 
(multiple overlapping br), 74.4, 75.2, 75.8, 79.1, 81.2, 84.6,122.5, 127.2-129.8 (multiple 
overlapping br), 130.4, 132.1, 132.8, 133.0, 133.9, 134.0, 137.3, 142.1-144.0 (multiple 
overlapping br), 167.1, 167.5, 170.1, 171.2, 172.7, 204.0.  31P NMR (CDCl3, ppm):  δ -
0.98 and -1.70.  DSC:  Tg = -15 °C.  TGA in N2:  200-270 °C, 33% mass loss; 270–330 
°C, 29% mass loss; 420–500 °C, 6% mass loss, 32% mass remaining above 500 °C.   
Self-assembly of PEBP-b-PBYP-g-PEG/PTX.  The polymer was directly dissolved 
in water and sonicated for 5 min and micelles formed spontaneously.  The solubility 
could be as high as 110 mg/mL, with a PTX concentration of 25 mg/mL (PTX loading: 
23.0 wt%).  Hydrodynamic diameters of SCKs in nanopure water as measured by DLS:  
Dh(intensity) = 22 ± 12 nm, Dh(volume) = 11 ± 5 nm, Dh(number) = 8 ± 2 nm;  ζ-
potential in nanopure water:  - 43 ± 3 mV 
PTX loading into PEBP-b-PBYP-g-PEG/PTX.  In a typical experiment, to a 20-mL 
vial containing 50.0 mg of polymer in ethanol (50.0 mg/mL), a solution of PTX (5.56 
mg, 2.0 mg/mL in ethanol, 10 wt%) was added.  The flask was shaken robustly to mix 
the solution, and then ethanol was completely removed in vacuo.  Subsequently, 1.0 mL 
of nanopure water was added to the vial to resuspend the polymer and PTX mixture.  
After sonication for 5 min, a well dispersed nanoparticle suspension was obtained.  The 
resuspension was centrifuged at 4000 rpm for 5 minutes to remove possible large 
aggregates.  PTX concentration in the upper clear supernatant was determined by HPLC 
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with acetonitrile and 20 mM ammonium acetate (45/55) as the eluent.  Final PTX 
loading: 10 wt% was physically loaded and 21 wt% was chemically conjugated.  DLS, 
AFM and TEM were used to characterize these PTX-loaded nanoparticles, and HPLC 
was used to confirm the actual loading amount of PTX.  Hydrodynamic diameters of 
SCKs in nanopure water as measured by DLS:  Dh(intensity) = 26 ± 15 nm, Dh(volume) 
= 12 ± 6 nm, Dh(number) = 9 ± 3 nm;  ζ-potential in nanopure water:  - 40 ± 4 mV. 
Dye-labeling of PEBP-b-PBYP-g-PEG/PTX.  In a typical experiment, an oven-dried 
vial containing a magnetic stir bar was charged with PEBP-b-PBYP-g-PEG/PTX, 10.0 
mg, 0.268 µmol), Alexa Fluor 488 azide (0.116 mg from a 1.0 mg/mL stock solution in 
DMSO, 0.134 µmol), copper (II) sulfate pentahydrate (0.0672 mg, from 1.0 mg/mL 
stock solution in water, 0.268 µmol), sodium ascorbate (0.532 mg, 2.68 µmol) and 2.0 
mL nanopure water.  The reaction mixture was degassed for 10 min via nitrogen 
bubbling, wrapped with aluminum foil and stirred for another 12 h at 37 °C.  The 
solution was subsequently passed through a Sephadex G-25 desalting column and 
dialyzed against Chelex® 100 resin in nanopure water in presoaked dialysis tubing 
(MWCO ca. 12–14 kDa) for 2 days, to remove copper ions and unreacted dye, 
followed by lyophilization to yield green to yellow powder with a 92% yield and a 75% 
conjugation efficiency. 
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APPENDIX C 
PREPARATION AND IN VITRO ANTIMICROBIAL ACTIVITIES OF 
DEGRADABLE NANOPARTICLES CAPABLE OF DUAL LOADING OF 
SILVER CATIONS AND MINOCYCLINE FOR BACTERIAL LUNG 
INFECTIONS* 
 
Pulmonary infections are becoming difficult to treat, partly due to the widespread 
bacterial resistance.  Combinational delivery of antimicrobials, which have different 
killing mechanisms, has the potential to overcome bacterial resistance.  In this project, 
we designed and synthesized anionic shell crosslinked knedel-like nanoparticle (aSCKs), 
which could carry both silver cations via Ag-S interaction, and minocycline via 
electrostatic interaction.   
 
 
Figure C1.  Chemical structures for aSCK polymer precursor, minocycline, and silver 
acetate. 
                                                 
* In collaboration with Parth N. Shah,† Justin A. Smolen,†,§ Richen Li,§ Carolyn L. Cannon,† 
Karen L. Wooley,§ †Department of Microbial Pathogenesis and Immunology, College of 
Medicine, Texas A&M Health Science Center, §Department of Chemistry, Texas A&M 
University.   
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The anionic polymer was synthesized via thiol-yne reaction between 3-
mercaptopropionic acid and diblock copolymer poly(2-ethylbutoxy phospholane)-block-
poly(2-butynyl phospholane) (PEBP-b-PBYP).  Then, aSCKs were prepared by self-
assembly of the anionic polymer, followed by crosslinking using a diamine as a 
crosslinker.  Silver cations and minocycline were loaded into the aSCKs by mixing them 
together for 3 h, and purified by centrifugal filter devices.  The dual loaded aSCKs were 
obtained by stirring silver-loaded aSCKs with minocycline for 3 h, followed by 
purification.  Both silver cations and minocycline could be loaded into the same aSCKs 
with ca. 10% loading (Table C1).  Dual loaded aSCKs had a slightly higher minocycline 
loading, which might be due to some potential interaction between the two drugs.  
Dynamic light scattering (DLS) suggested that dual loaded aSCKs had a largest number-
averaged hydrodynamic diameter (Dh(number)) of 22 nm, whereas the Dh(number) of 
minocycline-loaded aSCKs was measured to be smallest of 12 nm (Figure C2).  
Transmission electron microscopy (TEM) indicated that these nanoparticles were 
spherical (Figure C2).  
 
Table C1.  Silver and minocycline loading into aSCKs. 
 Ag (mg) 
Minocycline 
hydrochloride (mg) 
SCKs 
(mg) 
Drug loading 
Ag-SCKs 0.464 0 4.6 10.1% 
Mino-SCKs 0 0.175 1.63 10.8% 
Dual-SCKs 0.161 0.217 1.62 
Ag: 9.9%;  
Minocycline 
hydrochloride: 13.4% 
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Figure C2.  DLS (top) and TEM (bottom) of drug-loaded aSCKs.  From left to right: 
Dual loaded aSCKs, Ag-loaded aSCKs, and minocycline-loaded aSCKs.  Samples D and 
E were not stained, and sample F was stained by uranyl acetate. 
 
 
 
Figure C3.  Drugs releases from aSCKs in nanopure water at 37 °C. 
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 The in vitro drug release experiments were investigated in nanopure water (Figure 
C3).  Rapid drug releases were observed for all drug-loaded aSCKs.  The release half-
life of minocycline from either minocycline-loaded nanoparticles or dual loaded 
nanoparticles was ca. 1.1 h.  Interestingly, the release of silver was slower in the dual 
loaded nanoparticles compared to the Ag-loaded nanoparticles. 
 In conclusion, we were able to load both silver cations and minocycline into the same 
nanoparticle with relatively high loading.  Both drugs could be released from the dual 
loaded nanoparticles.  Their in vitro antimicrobial activities and in vivo performance are 
currently under investigation. 
Experimental procedures 
Preparation of aSCKs.  The anionic diblock copolymers (623 mg, 2.08 mmol of 
acrylic acid) were suspended into nanopure water (60.0 mL) and sonicated for 10 min.  
The clear solution was stirred for another 1 hour to obtain well dispersed micelles, 
followed by the addition of a solution of 2,2’-(ethylenedioxy)bis(ethylamine) (EDDA, 
46.1 mg, 0.311 mmol) dropwisely in nanopure water (10.0 mL).  The solution was 
allowed to stir for 1 h at room temperature.  To this reaction mixture was added 
dropwise a solution of 1-[3’-(Dimethylamino)propyl]-3-ethylcarbodiimide methiodide 
(EDCI, 204 mg, 0.687 mmol) in nanopure water (10.0 mL) via a syringe pump over 1 
hour.  The reaction mixture was allowed to stir overnight at room temperature and was 
then transferred to presoaked dialysis membrane tubes(MWCO ca. 12–14 kDa), and 
dialyzed against nanopure water for 36 h in the cold room (4–8 ºC) to remove small 
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molecules.  The purified anionic SCKs solution was lyophilized into powder and kept in 
the freezer at -20 ºC. 
Silver loading into aSCKs.  In a typical experiment, aSCKs (250 mg) were dissolved 
in 25.0 mL of nanopure water and sonicated for 5 min.  Silver acetate (100 mg) in 20.0 
mL of nanopure water was added, and the mixture solution was shaded with aluminum 
foils and stirred overnight.  The solution was transferred to a centrifugal filter device 
(100 kDa MWCO), and washed extensively for several cycles (N>3) with nanopure 
water to remove free small molecules.  The amount of silver loaded into the micelles 
was quantified by ICP-MS using rhodium as an internal standard. 
Minocycline loading into aSCKs.  In a typical experiment, aSCKs (5.0 mg) were 
dissolved in 3.0 mL of nanopure water and sonicated for 5 min.  Minocycline 
hydrochloride (1.5 mg) in 1.0 mL of nanopure water was added, and the mixture solution 
was shaded with aluminum foils and stirred overnight.  The solution was transferred to a 
centrifugal filter device (100 kDa MWCO), and washed extensively for several cycles 
(N>3) with nanopure water to remove free small molecules.  The amount of minocycline 
hydrochloride loaded into the micelles was quantified by UV-Vis using absorbance at 
345nm. 
Dual loading into aSCKs.  In a typical experiment, Ag-loaded aSCKs (9.2 mg, 
containing 0.92 mg silver) were dissolved in 5.0 mL of nanopure water and sonicated for 
5 min.  Minocycline hydrochloride (2.8 mg) in 1.8 mL of nanopure water was added, 
and the mixture solution was shaded with aluminum foils and stirred overnight.  The 
solution was transferred to a centrifugal filter device (100 kDa MWCO), and washed 
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extensively for several cycles (N>3) with nanopure water to remove free small 
molecules.  The amount of minocycline hydrochloride loaded into the micelles was 
quantified by UV-Vis using absorbance at 345nm, while the amount of silver loaded into 
the micelles was quantified by ICP-MS using rhodium as an internal standard. 
Release of drugs from nanoparticles.  The release profiles of the drug-loaded aSCKs 
were studied by monitoring the decrease of drug concentration over time in dialysis 
cassettes by ICP-MS or UV-Vis.  In a typical procedure, drug-loaded aSCKs (3.0 mL) 
were transferred into a presoaked dialysis cassette.  The cassette was allowed to stir in a 
beaker containing 3000 mL nanopure water at 37 °C.  Aliquots (ca. 0.05 mL) were taken 
at pre-determined time. Silver and minocycline hydrochloride concentrations were 
determined by ICP-MS and UV-Vis, respectively.  The release experiments were 
conducted in a triplicate manner. 
    154 
APPENDIX D 
OTHER JOINT WORK AND LIST OF PUBLICATIONS IN GRADUATE 
STUDY 
 
Besides the three chapters and three appendices above, other joint research was also 
conducted (Table D1).  Polyphosphoester-based materials were extensively investigated, 
which laid the foundation of this dissertation.  Their design, syntheses, properties, and 
various biomedical applications were discussed in details in publications listed in Table 
D1 under entry 1-3, 7, 9. 10, 12, 16.  Another important class of degradable materials is 
polypeptides, which were facilely synthesized by ring-opening polymerization of N-
carboxyanhydrides (NCAs) and exploited as both organogelators and hydrogelators 
because of their ability to form secondary structures (Table D1, entry 4-6, 14).  
Furthermore, poly(carboxybetaine) was prepared and evaluated against poly(ethylene 
glycol) both in vitro and in vivo as nanoparticle coating material (Table D1, entry 8, 17).  
In addition, poly(acrylic acid)-based block copolymers were also utilized as nanocarriers 
of cisplatin by forming polymer-metal complex and silver-based antimicrobials through 
electrostatic interactions, as well as building blocks in the hierarchical assembly of 
multicompartment superstructures (Table D1, entry 11, 13, 15). 
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Table D1.  List of co-authored publications in graduate study. 
Entry Authors 
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